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There are some oddities in the perspective with which we see the world.
The fact that we live at the bottom of a deep gravity well, on the surface of a
gas covered planet going around a nuclear ﬁreball 90 million miles away
and think this to be normal is obviously some indication of how skewed
our perspective tends to be, but we have done various things over
intellectual history to slowly correct some of our misapprehensions.
Douglas N. Adams
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InTroduCTIon
avian Influenza
Avian influenza (AI) is a contagious disease of birds that is caused by viruses be-
longing to the influenza A genus within the family Orthomyxoviridae (15, 112).
Influenza A viruses are antigenically divided into 16 hemagglutinin (HA; H1-H16)
and 9 neuraminidase (NA; N1-N9) subtypes. The primary hosts of AI viruses are
wild aquatic birds, in which the virus replicates asymptomatically in the intestinal
tract and to a lesser extent in the respiratory tract. All known influenza A virus
subtypes have been isolated from birds. Only certain subtypes infect humans and
other mammals such as horses, pigs and dogs, in which they cause acute respira-
tory disease and are efficiently transmitted within the host population (183). Every
year, seasonal human influenza causes severe illness in three to five million indi-
viduals and can cause up to half a million deaths worldwide (185). These numbers
can dramatically increase during occasional pandemic outbreaks. 
AI can be transmitted to domesticated birds, such as chickens, ducks and turkeys,
through fecal contamination of water. Based on the severity of the disease in poul-
try, AI can be classified into two clinical forms: a low pathogenic (LPAI) form that
causes mucosal infections with variable morbidity and decreased egg production,
and a high pathogenic (HPAI) form, which causes high morbidity and mortality
in poultry with devastating economic effects (159). HPAI, also known as fowl
plague, arises from LPAI subtypes H5 and H7, and it is generally assumed to occur
in domestic birds that become infected with LPAI H5 and H7 strains from the wild-
bird reservoir (5)
As a zoonosis, influenza A virus can be transmitted between species from animals
to humans. Recent outbreaks of HPAI H5N1 and H7N7 strains in poultry resulted
in transmission to humans with high fatality among hospitalized individuals (23,
42). Until now, such viruses have yet shown difficult to transmit between humans,
although recent studies suggest that they are able to do so (65). Control of out-
breaks of AI is therefore not only necessary to prevent economical losses in poultry
farming, but also to protect global public health. Migratory behavior of aquatic
birds allows the AI virus to spread fast and widely, making outbreaks difficult to
prevent or control. Although HPAI outbreaks are generally controlled by culling
of the infected flocks, vaccination has been shown to be an effective, additional
tool (160).
Influenza a virus anatomy and replication cycle
The influenza A virus (Fig. 1) is characterized by a lipid envelope of spherical or
filamentous shape, that contains the negative sense single-stranded RNA genome,
divided into eight linear segments (15, 112). These eight segments can encode at
least twelve viral proteins, including the three RNA polymerase subunits PB1, PB2
and PA, the nucleocapsid protein NP, the matrix protein M1, the ion channel-like
protein M2, the non-structural protein NS1, the nuclear export protein NEP (pre-
viously known as NS2) and the earlier mentioned glycoproteins HA and NA. A
small, pro-apoptotic protein called PB1-F2 may be expressed from an alternative
reading frame by the PB1 gene segment. Furthermore, recent studies revealed an
open reading frame in the PA gene that encodes the PA-X protein, which represses
cellular gene expression and modulates the host response to infection (71). The
host cell derived lipid envelope of the virion is studded with HA trimers and NA
tetramers, which form the main influenza virus antigens. In addition to HA and
NA, a small number of M2 proteins are present in the viral envelope. Beneath the
viral envelope lays a matrix of M1 proteins, which enclose the virion core contain-
ing the 8 ribonucleoprotein complexes (vRNP). Each vRNP contains one RNA seg-
ment, coated with NP protein and includes the heterotrimeric RNA-dependent
RNA polymerase. Furthermore NEP, but not NS1 is present in the virion.
Infection of a cell starts by attachment of the virion to receptors on the cell mem-
brane (Fig. 2). Human influenza viruses prefer binding to receptors containing
sialic acid (SA) with α-2,6 linkage, that are commonly found on human tracheal
epithelial cells, whereas avian influenza strains prefer receptors with α-2,3 linkage,
that are more common in avian gut epithelium. The HA protein is therefore a de-
terminant for host specificity. Furthermore, HA is also the major virulence factor
fig. 1. Schematic overview of the inﬂuenza A virus particle.
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associated with the HPAI phenotype. HA is build up out of three monomers, each
consisting of two disulphide-linked polypeptides, HA1 and HA2, which result
from proteolytic cleavage of the precursor HA0 (15). Cleavage is required for the
virus to be infectious. HPAI viruses contain multiple basic amino acids at the cleav-
age site and can therefore be cleaved by a wider range of proteases, thereby allow-
ing the virus to replicate systemically resulting in high pathogenicity. After cellular
fig. 2. Schematic overview of the infection of a cell by inﬂuenza A virus. Infection starts with binding HA on the
virus membrane to sialic acid receptors on the cell membrane (1). Then, the virus particles is internalized by en-
docytosis (2). Acidiﬁcation of the endosome results in fusion of the virus membrane with that of the endosome,
and release of the viral genome into the cytoplasm (3). The vRNPs are then imported into the nucleus where it
is replicated into more vRNA copies, and transcribed into vmRNAs (4). The vmRNAs are exported to the cytoplasm
where they are translated (5). PB1, PB2, PA, NP, NS1, M1 and NEP proteins are then imported into the nucleus
(6A), whereas HA, NA and M2 are transported to the cell membrane (6B). In the nucleus, progeny vRNPs are
formed after binding of NP and polymerase proteins to the new vRNAs. Binding of M1 and NEP to the vRNPs re-
sults in export of the viral genome to the cytoplasm, where virus assembly occurs at the cell membrane (7).
When  a new virus particles is formed, the NA cleaves the cellular sialic acid receptors, thereby facilitating the
release of progeny virions from the cell (8).
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attachment, influenza virus particles are internalized by endocytosis. Acidification
of the endosome then leads to two essential steps. A pH reduction inside the virion,
enabled by the M2 ion-channels, depolymerizes the M1 matrix layer and dissoci-
ates M1 from the RNPs (99, 197). Simultaneously, a pH-induced conformational
change of HA allows fusion between the viral and the endosomal membrane and
release of the viral content in the cytoplasm. The vRNPs are then imported into
the nucleus by the host nuclear import machinery. Unlike most other RNA viruses,
the influenza virus replicates inside the nucleus of host cells. Each vRNP acts as
an independent functional unit that directs the synthesis of two positive-sense
RNAs, the viral mRNA (vmRNA) and the complementary RNA (cRNA), by using
the negative sense viral RNA (vRNA) as a template. The vmRNAs are exported to
the cytoplasm where they are translated. PB1, PB2, PA, NP and NS1 are expressed
early in the infection, whereas HA, NA, M1, M2 and NEP are expressed later (112).
PB1, PB2, PA, NP, NS1, M1 and NEP are imported into the nucleus, either by the
host import machinery, or by diffusion through the nuclear pores (14). The viral
polymerase uses the cRNA as an intermediate for the synthesis of more vRNAs,
which form the basis of new vRNPs. By associating with M1 and NEP, the vRNPs
obtain a nuclear export signal (NES), which leads to transport to the cytoplasm.
In the meantime, viral envelope proteins HA, NA and M2 accumulate at the cell
surface, whereas M1 accumulates just underneath the cell membrane. Progeny
viruses are assembled at the cell surface and bud outward through the cell mem-
brane. Finally, NA cleaves the sialic acid receptors from the cell surface, thereby
facilitating the release of progeny virions from the cell.
The NS1 protein does not have a structural function in the virus particle, but in-
stead facilitates virus replication. Cytoplasmic dsRNA and 5’-triphosphate-con-
taining RNA are produced during influenza infection and both are recognized as
pathogenic patterns by antiviral proteins such as retinoic-acid inducible gene I
(RIG-I), dsRNA-dependent protein kinase R (PKR) and 2’-5’-oligoadenylatesyn-
thetase (OAS). NS1 prevents the initiation of the host antiviral response by binding
dsRNA and RIG-I (107), and blocks the activation of PKR and OAS, which could
otherwise induce several pathways that lead to type I interferon (IFN) production
(132). The IFN response protects cells against invading viral pathogens. The cellu-
lar factors that mediate this defense are the products of interferon-stimulated genes
(ISGs). Apart from its role as IFN antagonist, NS1 also acts directly to modulate
other important aspects of the virus replication cycle, including viral RNA repli-
cation, viral protein synthesis (26, 34), and general host-cell physiology. NS1 in-
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hibits cellular pre-mRNA processing (including IFN pre-mRNA) and mRNA nu-
clear export (59). Furthermore, NS1 regulates splicing of M segment mRNA (134),
nuclear export of viral mRNA (144) and viral ribonucleoprotein (vRNP) (180).
The influenza RNA polymerase has a high mutation rate of 1.5 x 10-5 mutations
per nucleotide (124) or 0.2 mutations per influenza virus genome per replication
cycle (129). In theory, a population of 2 x 105 infectious influenza virus particles is
expected to possess all possible single amino acid substitutions (129). Such an
amount of virus is easily present in 2 µl of the allantoic fluid of embryonated
chicken eggs infected with a high yielding influenza strain. The high mutation rate
allows the virus to quickly adapt to new environments. The seasonal changes in
the antibody binding sites of the viral hemagglutinin protein (antigenic drift) and
the occurrence of antiviral resistant virus strains are examples of the adaptability
of influenza virus. Because of the high mutation rate, a viral population should be
considered as a quasispecies, a dynamic equilibrium of non-identical but related
mutants arising from the high mutation rate on the one hand, and a strong selec-
tive pressure on the other (28), rather than a multiplicity of viral particles with a
defined nucleic acid sequence. The phenotypic plasticity of the influenza virus is
further facilitated by the segmented genome. Although it may occur rarely, simul-
taneous infection of a cell by different influenza subtypes can result in an antigenic
shift, when the progeny virus contains a mixture of gene segments from the dif-
ferent virus strains. An influenza pandemic can occur when a reassortant virus
arises to which humans are susceptible but immunologically naïve. Examples of
such pandemics as a result of antigenic shift are the Spanish flu of 1918-1919 and
the recent Mexican/swine flu of 2009. The Spanish flu was infamously lethal as a
results of the unique combination of genes, with the HA, NA and PB1 gene con-
tributing to the high pathogenicity (123, 166).
avian influenza vaccines
Vaccination protects birds against AI by stimulating host immunity, which is
largely based on antibodies against the HA protein. These neutralizing antibodies
bind to the HA and thereby prevent attachment of the virus to the cell. Due to the
large number of HA subtypes, and the antigenic diversity within the subtypes, it
is important for the vaccine to immunologically resemble the field strain. The NA
protein contributes to a lesser degree to immunity. Moreover, certain vaccines de-
liberately contain a different NA subtype, allowing infected animals to be differ-
entiated from vaccinated animals (DIVA) (18). Such DIVA vaccines allow for better
surveillance of AI outbreaks and thus may improve worldwide acceptance of vac-
cination. Historically, vaccines are made of isolated strains that closely resemble
the field virus, and which are propagated in embryonated chicken eggs. The de-
velopment of reverse genetics techniques allowed the rescue of influenza virus
from plasmid DNA (40, 67). This has opened up the possibility of virus engineer-
ing, allowing the creation of viruses with enhanced productivity yield in eggs or
decreased safety concerns associated with HPAI.
Inactivated vaccines are the main type of AI vaccines approved for use and are
prepared by either chemical or physical inactivation of the produced virus (160).
Whereas influenza vaccines for humans are further purified to create a subunit
vaccine containing the HA and NA proteins, avian vaccines generally contain the
crude allantoic fluid of the harvested eggs, in order to keep production costs low
(73). An adjuvant is used to increase the immunogenicity, often in the form of a
water-in-oil emulsion. Live virus vaccines have not been approved yet for use in
poultry, although they have been experimentally tested. The main cause of the
low acceptance is the potential of such viruses to reassort with genes of other AI
viruses, resulting in a virus with increased pathogenicity (73). Infection with a live-
virus vaccine stimulates not only the humoral immune response, but also the mu-
cosal and cellular response and thereby gives a better protection against infection
with WT virus. Furthermore, they may be administered via aerosol spray or drink-
ing water, thereby reducing the costs of large scale vaccination of commercial poul-
try. Live influenza virus vaccines have been approved for use in humans and are
based on cold-adapted virus, or virus unable to express NS1 (20). Other types of
AI vaccines include DNA vaccines and recombinant virus-vectored vaccines (73).
The latter group also contains vaccines that have been approved for use in poultry
and are based on the in vivo expression of influenza genes through use of a non-
influenza virus vector, such as Newcastle disease virus (141). They induce protec-
tive immunity as would a live AI virus vaccine but without the risk of
reassortment. Both of these recombinant vaccine types do not require the produc-
tion of influenza virus and therefore fall outside the scope of this thesis.
Production of influenza vaccines
The ability to produce influenza virus in embryonated eggs allowed for large scale
production of influenza vaccines. Most influenza vaccines, both human and ani-
mal, are still propagated in these systems, which have changed very little since the
1940s (84). As one egg generally produces enough virus for 1 dose of human in-
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fluenza vaccine, the egg-based production process requires large quantities of high
quality fertilized eggs, which are acquired from specific pathogen-free laying
flocks. The supply of these eggs has a long lead time and needs to be planned
many months in advance. Furthermore, the egg supply is vulnerable to logistic
problems and the availability of eggs can become limiting during an outbreak,
when the demand for eggs for human and veterinary vaccines will rise, while lay-
ing flocks may be endangered by preventive measures including culling of birds.
In case of a pandemic, the egg-based production process is too slow to produce
enough vaccine in time. Therefore, animal cell culture has been suggested as an
alternative by regulatory agencies and industry for production of human influenza
vaccines (8). Cell culture based processes are more robust and flexible, and allow
virus to be grown in a closed system. Furthermore, optimization of process con-
ditions and cell line engineering can enhance virus yield and improve product
quality. 
The production of influenza virus in cell culture consists of two steps (50). First,
the cells need to be grown to high cell densities in a short time. A fast growing cell
line that has a doubling time of at least 20-30 h is therefore necessary (49). The use
of suspension cells simplifies the scale-up of the production process because roller
bottles or micro-carriers to provide attachment surface are no longer required and,
more importantly, detachment and reattachment is no longer needed between sub-
sequent cultivation steps upon scale-up (47). Furthermore, the ideal production
cell line is able to grow in serum-free (SF) media, since the usage of serum is not
preferred due to the high costs, lot-to-lot variation and risk of contamination with
viruses, mycoplasmas and prions. Additionally, growth on SF media simplifies
the production process as medium exchange before infection is no longer required
to counter the trypsin inhibition by serum (47). Trypsin is generally added at the
start of the virus propagation step, as it cleaves the precursor HA0 and thereby al-
lows multicyclic virus replication. Furthermore, trypsin can cleave extracellular
IFN, thereby limiting cellular antiviral defenses (149). Cells are infected at a low
multiplicity of infection (m.o.i.) and virus is generally harvested 2-3 days later for
further processing. To compete with egg-based processes, cell culture should be
able to propagate a wide variety of influenza strains to high virus titers (more than
1 x 108 TCID50/ml or more than 7.97 log2 HAU/100µl (49)). A wide variety of cell
lines have been assessed for their suitability for influenza virus production. Vac-
cines produced in three cell lines (MDCK, Vero and PER.C6®) are in clinical trials,
and the first licenses for seasonal and pandemic influenza vaccines produced in
MDCK and Vero cells have been given (49).
The process requirements for a veterinary vaccine differ from that of human vac-
cines. Lesser regulatory requirements on culture media, downstream processing
and purity (49) allow for a less stringent process. However, the low price of poultry
vaccines ($0.05–0.15 per dose) limit companies to invest in research and develop-
ment, licensing, and scaling-up manufacturing, especially when competition limits
the number of doses sold (160). Whereas several animal-cell derived human in-
fluenza vaccines are already on the market, veterinary vaccines are still commer-
cially produced in chicken eggs.
Contents of this thesis
In this thesis, the use of several animal cell culture systems as substrate for pro-
duction of AI vaccines for poultry was assessed and virus and cell line engineering
methods were developed, to further enhance virus yield. We started in Chapter 2
with a comparison of three continuous cell lines that are currently used to produce
different virus vaccines. The MDCK, VERO and BHK-21 cell lines were assessed
for their ability to replicate a selection of different AI strains to high titers. Fur-
thermore, we tried to adapt VERO and MDCK cells, which normally grow at-
tached, to suspension growth. MDCK-SFS cells, which were adapted to growth in
suspension, showed the highest, overall yield of influenza virus and were selected
for further studies.
During the comparison of virus replication in the different cell lines, we observed
that only a few influenza virus strains were able to replicate in BHK21 cells, a fast
growing and high cell density reaching suspension cell line. However, the virus
strains that were able to replicate in BHK21 cells, reached virus titers that exceeded
those of MDCK and Vero cells. Therefore, we focused in Chapter 3 on the factors
that limit replication in this cell line and suggest a method to use BHK21 cells for
the production of virus containing the antigenically important HA1 domain of
strains that normally not replicate in this cell line.
In Chapter 4, a vaccine candidate virus is introduced from which the gene for the
non-structural NS1 protein has been deleted (delNS1). NS1 is important for virus
replication in several different ways, including inhibition of the host innate im-
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mune response. Without NS1, influenza virus replicates poorly and is therefore
considered for use as a live-attenuated vaccine. Furthermore, a delNS1 virus can
be used as a DIVA vaccine. To develop a high yielding delNS1 virus production
system, we made two MDCK cell lines that are able to express NS1. We then as-
sessed the ability of these cell lines to enhance delNS1 virus replication by com-
plementing the lack of virus-expressed NS1. Furthermore, we assessed the impact
of the recombinant NS1 expression on IFN induction and apoptosis.
Whereas the approach used in Chapter 4 to increase delNS1 virus replication may
be described as “intelligent” design, in Chapter 5 the same goal was tackled by
using Darwinian evolution. The delNS1 virus was adapted to MDCK-SFS cells and
mutations responsible for the ability of the virus to efficiently replicate in the ab-
sence of NS1 were determined. Finally, Chapter 6 summarizes and discusses the
results of the work described in this thesis in relation to current and future in-
fluenza vaccine production.
Chapter 2
adaptation of a Madin-darby canine
kidney cell line to suspension growth in
serum-free media and comparison of its
ability to produce avian influenza virus to
Vero and bHK21 cell lines.
Rutger van Wielink
Jet Kant-Eenbergen
Michiel Harmsen
Dirk Martens
René Wijffels
Jose Coco-Martin
J. Virol. Methods. 2011. 171:53-60.
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absTraCT
Madin-Darby canine kidney (MDCK) cells are currently considered for influenza
vaccine manufacturing. A drawback of these cells is their anchorage dependent
growth, which greatly complicates process scale-up. In this paper a novel MDCK
cell line (MDCK-SFS) is described that grows efficiently in suspension and retained
high expression levels of both α-2,6 and α-2,3 sialic acid receptors, which bind
preferably to human and avian influenza viruses, respectively. The production of
avian influenza virus by BHK21, Vero and MDCK-SFS cell lines was compared.
Although BHK21 cells consisted of two populations, one of which lacks the α-2,3
receptor, they supported the replication of two influenza strains to high titers.
However, BHK21 cells are generally not applicable for influenza production since
they supported the replication of six further strains poorly. MDCK-SFS cells
yielded the highest infectious virus titers and virus genome equivalent concentra-
tion for five of the eight influenza strains analyzed and the highest hemagglutina-
tion activity for all eight virus strains. Taken together with their suitability for
suspension growth this makes the MDCK-SFS cell line potentially useful for large
scale influenza virus production.
Inﬂuenza virus production by suspension MDCK cell line.
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InTroduCTIon
Avian influenza (AI) virus is a zoonotic pathogen with a natural reservoir entirely
in birds. During the recent outbreaks of AI among poultry, transmission of H5,
H7, and H9 subtype viruses to humans have occurred, sometimes with fatal out-
come (155). Vaccination with inactivated AI vaccine protects chickens from disease
and is currently in use in some countries (32). Vaccination of poultry is not only
important to protect birds but also to prevent further transmission to humans.
Influenza vaccines are produced traditionally in embryonated eggs. However, the
supply of these eggs has a long lead time, is vulnerable to logistic problems and
the availability of eggs can become limiting during an outbreak, when the demand
for eggs for human and veterinary vaccines will rise, while laying flocks may be
endangered by preventive measures including culling of birds. The use of animal
cell cultures as an alternative to embryonated eggs is therefore recommended by
regulatory agencies and industry (8).
An ideal production cell line is able to grow in serum-free (SF) media as suspended
cells. The usage of serum is not preferred due to the high costs, lot-to-lot variation
and risk of contamination with viruses, mycoplasmas and prions. Additionally,
SF growth simplifies the production process as medium exchange before infection
is no longer required to counter the trypsin inhibition by serum (47). The use of
suspension cells simplifies the scale-up of the production process because roller
bottles or micro-carriers to provide attachment surface are no longer required and,
more importantly, detachment and reattachment is no longer needed between sub-
sequent cultivation steps upon scale-up (47). 
In the past, various cell lines have been evaluated for their suitability for influenza
virus production (49). Madin-Darby canine kidney (MDCK) and Vero cells are con-
sidered to be best suited for this purpose as they support the replication of a wide
variety of virus strains to high titers (49, 54, 89, 106). However, most of these stud-
ies were done with adherent cell lines, which have disadvantages in large scale
production processes. In a few studies suspension cell lines were used for in-
fluenza virus production. A MDCK cell line able to grow in suspension was gen-
erated by transfection with the human siat7e gene (21). Another MDCK cell line
was adapted to suspension growth by serial passaging (56) and is currently in use
by Novartis Vaccines. Furthermore, the PER.C6® (125), AGE1.CR® (91) and
EB14®/EB66® cell lines (104) produce influenza virus to high titers and grow in sus-
pension (49). These latter three continuous cell lines were especially designed for
vaccine production. Since they are only available under license, they were not con-
sidered for this study. These previous studies focus mainly on production of
human influenza viruses.
The aim of this study was to develop SF suspension cell lines that are able to pro-
duce a wide variety of AI virus strains, for veterinary vaccine production. For this
purpose BHK21, MDCK and Vero cells were used. BHK21 cells grow in suspension
and are already used to produce veterinary vaccines against foot-and-mouth dis-
ease and rabies. MDCK and Vero cells normally grow adherent and with serum.
Therefore, it was first attempted to adapt these cells to SF suspension growth, after
which these cell lines were assessed for their suitability for influenza A virus pro-
duction using seven low-pathogenic AI virus strains and the human PR8 reference
strain. 
MaTerIals and MeTHods
Cell lines
All parental and adapted cell lines used are shown in Table 1, together with their
origin, medium used and whether cells grow adherent or in suspension. Cell cul-
ture media were supplemented with 2 to 8 mM glutamine (depending on manu-
facturer’s instructions), 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco
Invitrogen). Adaptation of cell lines was attempted in four SF cell culture media:
Optipro, UltraMDCK, SFM4MegaVir (Hyclone) and SFM4BHK21. Cells were
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Table 1: Origin and culture conditions of cell lines used.
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grown at 37˚C and 5% CO2. Suspension cells were grown in shaker flasks at 100
rpm. Total and viable cell densities were determined with a Nucleocounter
(Chemometec A/S, Allerød, Denmark).
Virus strains and infection
Seven low pathogenic wild type AI virus strains and the A/Puerto Rico/8/34 (PR8)
human reference strain were used in this study (Table 2). The PR8 strain was ob-
tained from the ATCC (VR-95; Manassas, VA, US), whereas all other viruses were
kindly provided by Dr. G. Koch (CVI). All viruses were propagated in the allantoic
cavity of nine-day-old embryonated chicken eggs and the infectious virus titers
were between 7.8 and 8.8 log10 TCID50/ml. The viruses were not adapted to indi-
vidual cell lines prior to analysis of their propagation in cells. Apart from being
very laborious, since this should be done for each cell line virus combination, adap-
tation is also not desired in a vaccine production process because it takes time and
may alter the antigenicity of the vaccine. 
For the infection of adherent cells, the cells were allowed to attach to the surface
of 6-well plates (Greiner Bio-One) overnight. The next day, these cells were pro-
vided with 5 ml fresh medium without serum, even when cells were earlier grown
in serum containing medium (Table 1). Three wells of each adherent cell line were
used to count the amount of cells at the start of the infection (0.18 x 106 cells/ml for
serum dependent MDCK cells and 0.13 x 106 cells/ml for the other adherent cell
lines). The other wells were used to determine the virus titers 72 h post-infection
(p.i.). 
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Table 2: Characteristics of inﬂuenza virus strains used for propagation in cell lines.
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For the infection of suspension cells the cells were diluted to 0.3 x 106 cells/ml in
15 ml medium in 125-ml shaker flasks. Low cell densities were used to prevent de-
pletion of the media as a result of cell growth during slow proceeding infections,
and to be able to compare cells grown adherent and in suspension. Before infec-
tion, 3 µg/ml trypsin-EDTA (Gibco) was added to all cells. Because of their ability
to inactivate trypsin (74), Vero cells were supplied with additional trypsin-EDTA
(3 µg/ml), 24 h and 48 h p.i. All infections were performed in triplicate, with a mul-
tiplicity of infection (m.o.i.) of 0.01. After 72 h, samples were taken and stored at -
70˚C. The amount of virus produced was estimated by measuring the infectious
virus particle concentration, the virus genome equivalent concentration and the
hemagglutination activity.
flow cytometric analysis (fCa) of influenza binding sialic acid receptors
The abundance of α-2,3 sialic acid (SA 2,3) and α-2,6 sialic acid (SA 2,6) linkages
on the different cell lines was determined as described previously (55). This
method was modified by staining cells at the same time with SA 2,3 specific digox-
igenin (DIG)-labeled Maackia amurensis agglutinin (MAA) lectin and SA 2,6 specific
biotinylated Sambus nigra agglutinin (SNA) lectin, allowing simultaneous analysis
of both receptors. In short, cells were incubated with 10 µg/ml MAA (Roche Ap-
plied Science, Mannheim, Germany) and 10 µg/ml SNA (Vector Laboratories,
Burlingame, CA), followed by incubation with 5 µg/ml anti-DIG fluorescein (FITC)
labeled Fab Fragments (Roche Applied Science) and 0.5 µg/ml Streptavidin R-Phy-
coerythrin (R-PE) conjugate (Invitrogen, Carlsbad, CA). Cells were fixed in CellFIX
(Becton Dickinson, Franklin Lakes, NJ) and analyzed on a FACScan flow cytometer
(Becton Dickinson). The contribution of FITC fluorescence to the R-PE signal and
R-PE fluorescence to the FITC signal was compensated for. Incubations without
lectins and with single lectins were included as controls. Incubations with single
lectins gave similar results to incubations with two lectins.
Infectious virus titer assay 
The infectious virus titer was measured by determining the tissue culture infective
dose required to infect 50% (TCID50) of MDCK cells. Tenfold serial dilutions (10-
1 to 10-8) of the culture supernatant were prepared in medium containing 3 µg/ml
trypsin-EDTA and inoculated (six replicates per dilution) in 96-well plates (Greiner
Bio-One) grown to confluency with MDCK cells. Plates were incubated at 37˚C for
two days and then dried and stored at -20˚C. The end points were determined by
immunoperoxidase monolayer assay. Cells were fixed with cold 4% paraformalde-
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hyde, followed by a first incubation step with 0.78 µg/ml monoclonal anti-nucle-
oprotein (NP) antibody (HB65, ATCC) and a second incubation step with 2.6 µg/ml
peroxidase-conjugated rabbit anti-mouse immunoglobulins (Dako, Glostrup, Den-
mark). Cells were stained with 3-Amino-9-ethylcarbazole (AEC) and checked mi-
croscopically for viral presence. Virus titers, in log10 TCID50/ml were calculated
by the method of Reed and Muench (131).
Virus genome equivalent concentration measurement by quantitative
rT-PCr
The virus genome equivalent concentration was derived from the amount of viral
RNA copies determined by M-gene specific qRT-PCR, as described before (96).
RNA was isolated from each sample with a MagNAPure LC system with the Mag-
NAPure LC Total Nucleic Acid Isolation Kit (Roche Applied Science). For the PCR,
primers AI-M-F45 (5′-CTTCTAACCGAGGTCGAAACGTA-3′) and AI-M-R251 (5′-
CACTGGGCACGGTGAGC-3′) and Taqman probe AI-M-Tqmn1 (5′-6FAM-CT
CAAAGCCGAGA TCGCGCAGA-XT-PH) (TIBMolBiol, Berlin, Germany) were
used. A calibration curve was used for each virus strain, made by a 3-step serial
dilution of the egg-based seeding virus with known infectious virus titer. Titers
of the samples are expressed as log10 TCID50 equivalent/ml. 
Hemagglutination activity assay
A revised hemagglutination activity (HA) assay with improved accuracy was used
as described previously (72). This revised assay includes a regression procedure
to analyze the HA in a continuous manner. Furthermore, samples are serially di-
luted 1.5-fold rather than 2-fold for improved accuracy. Plates (Greiner Bio-One)
were analyzed at 820 nm and titers are expressed as log2 HAU/100 µl.
statistical analyses of virus productivity
An ANOVA general linear model was used to test for differences in average pro-
duction of the influenza strains by the different cell lines, using the Minitab soft-
ware package (Minitab Inc., Coventry, UK). Cell lines, virus strains and an
interaction term were included in the model. Pair-wise comparisons of the mean
were performed with Tukey’s simultaneous test. Differences in mean were as-
sumed significant if p<0.05. 
resulTs
adaptation of cell lines to serum free and suspension growth
MDCK, Vero and BHK21 cells were adapted to SF growth, by gradual replacement
of the serum containing (SC) medium with SF medium, in 7 to 12 passages (p.).
The resulting cell lines are indicated by the suffix –SF (Table 1). Subsequently, at-
tempts were made to adapt MDCK-SF and Vero-SF cells from adherent to suspen-
sion growth in shaker flasks. For this purpose, Optipro, UltraMDCK,
SFM4MegaVir and SFM4BHK21 cell culture media were used. MDCK-SF cells only
grew in suspension in SFM4BHK21 medium, a prototype medium designed specif-
ically for BHK21 cells (Fig. 1A). They grew as single cells in suspension (Fig. 1B).
The resulting cell line was named MDCK-SFS. In all other culture media, extensive
cellular aggregation was observed before cell growth and viability decreased (data
not shown). During the first month of suspended cultivation (12 p.) the growth
rate of MDCK-SFS cells increased. Thereafter the growth rate remained stable for
over 3.5 months of serial cultivation (43 p.). The cells grow to a maximum cell den-
sity of 2.2 x 106 cells/ml and have a maximum specific growth rate of 0.029 h-1.
MDCK-SFS cells that were cultured statically in SFM4BHK21 medium attached to
the surface of the culture flask. This enables comparison of adherent and suspen-
sion MDCK cells in the same culture media, as well as direct comparison of
MDCK-SFS cells with the adherent Vero-SF cells. To study whether the ability to
grow in suspension is connected to the cell line or to the SFM4BHK21 medium the
suspension cell line MDCK-SFS was cultured in UltraMDCK medium, which re-
sulted in aggregate formation and attachment to the surface of the shaker flask.
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fig. 1. Adaptation of MDCK-SF cells to suspension growth. Panel A shows the logarithmic cumulative number of
cells starting with 1 ml 2 x 105 cell/ml, during adaptation in diﬀerent types of SF cell culture media: SFM4BHK21
(open circle), SFM4MegaVir (+), UltraMDCK (open triangle), Optipro (closed square). Panel B shows a micrograph
of single cell suspension MDCK-SFS cells growing in SFM4BHK21 medium (size bar 20 µm).
A B
Chapter 2
- 26 -
Unlike MDCK-SF cells, adherent Vero-SF cells formed small aggregates when cul-
tured agitated in SFM4BHK21 medium. Furthermore, despite frequent medium
replacement during a period of 45 days, no cell growth was observed and a Vero
cell growing in suspension was not obtained. Therefore, adherent Vero-SF cells
were used in further studies.
expression of sa 2,3 and sa 2,6 receptors on cell lines
Influenza viruses enter the cell after recognition and binding to specific cell surface
receptors. Most AI virus strains prefer binding to receptors with sialic acid groups
having α-2,3 linkages, whereas human influenza strains prefer receptors with α-
2,6 sialic acid linkage (15). The availability of the appropriate receptor is therefore
in principal a prerequisite for efficient virus replication. The relative abundance
of these receptors on the selected cell lines was determined by combining specific
SA-2,3-binding MAA and SA-2,6-binding SNA lectins in a single FCA, each linked
to a different fluorescent marker. MDCK and Vero-SF cells express both receptors
(Fig. 2A and E). The adaptation of MDCK to MDCK-SFS resulted in a broader dis-
tribution of SA 2,3 receptors, due to an increase in number of cells with a higher
abundance of this receptor (cf. Fig. 2A and B). BHK21 cells consist of two popula-
tions of cells with different receptor expression. The majority (76%) of the parental,
serum-dependent BHK21 cells express low amounts of SA 2,3 and SA 2,6 recep-
tors, whereas only a few cells (8%) express high levels of SA 2,6 but no SA 2,3 re-
ceptors (Fig. 2C). BHK21-SFS cells, however, consist of a larger cell population
fig. 2. FCA of inﬂuenza binding sialic acid receptors on diﬀerent cell lines. Cells were incubated with MAA and
SNA lectins, binding speciﬁcally to SA 2,3 and SA 2,6 receptors, respectively. The diﬀerent panels represent MDCK
(A and F), MDCK-SFS (B and G), BHK21 (C and H), BHK21-SFS (D and I) and Vero-SF (E and J) cells. The control
cells (F, G, H, I and J), which were not incubated with the lectins, were for more than 85% within the lower left
quadrant of each plot. 
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(65%) with high levels of SA 2,6 receptors and no SA 2,3 receptors, and a smaller
cell population (30%) expressing both receptors at lower levels (Fig. 2D). The dif-
ference between BHK21 and BHK21-SFS cells was not caused by serum compo-
nents binding to the receptors and thereby blocking lectin binding to the receptors
during subsequent FCA, since incubation of BHK21-SFS cells for 2 h in SC medium
did not affect these results (data not shown).
Comparison of influenza virus production by different cell lines
Two experiments were performed to compare the production of eight influenza
virus strains by the different cell lines. Note that virus strains are referred to by
their subtype, which are all different (Table 2). In the first experiment MDCK,
MDCK-SF, MDCK-SFS and Vero-SF cells were all grown adherently (Fig. 3) in the
media as described in Table 1. This allows comparison of the effect of adaptation
of MDCK cells to MDCK-SFS cells on virus production without measuring effects
of suspension growth itself on virus yield. Virus yields were assessed by virus
genome equivalent concentration, infectious virus titers and HA titers, which often
gave similar results. However, the virus genome equivalent concentrations are
often higher than the infectious virus titers, especially using the three types of
MDCK cells, where the difference is 10- to 100-fold (cf. Fig. 3A and B). This prob-
ably results from harvesting relatively late in infection, at 72 h p.i., since the infec-
tious virus titer often decreases after reaching its maximum. In contrast, the total
viral titer, comprised of both infectious and non-infectious particles as estimated
by the hemagglutinin activity (48) and quantitative PCR (our data, not shown) re-
mains constant for a longer period and therefore more likely represents the total
amount of virus produced during the 72 h infection period. Furthermore, the virus
genome equivalent concentration (Fig. 3A) showed less variation within each trip-
licate assay as compared to infectious virus titers (Fig. 3B) and HA titers (Fig. 3C).
Therefore, virus yields were primarily evaluated based on the virus genome equiv-
alent concentration . 
The yields of the eight different viruses did not vary substantially when using the
three different MDCK cells (Fig. 3A). When compensated for the 40% higher initial
cell density of serum-dependent MDCK cells, this leads to the conclusion that the
adaptation to SF and suspension growth did not negatively affect virus yield. In
comparison to MDCK-SFS cells grown adherently Vero-SF cells yielded, on aver-
age, a 5.1 times lower virus genome equivalent concentration (p<0.0001; Fig. 3A)
and 3.6 times lower HA titer (p<0.0001; Fig. 3C) whereas the average yield of in-
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fig. 3. Yields of diﬀerent inﬂuenza viruses or their HA antigen after propagation in adherent MDCK, MDCK-SF,
MDCK-SFS or Vero-SF cell lines. Yields were determined by assessment of virus genome equivalent concentration
using M-gene speciﬁc quantitative RT-PCR (A), infectious virus concentration by virus titration on MDCK cells
(B), or HA titration (C). Geometric mean and 95% conﬁdence interval of virus infections performed in triplicate
are presented.
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fig. 4. Yields of diﬀerent inﬂuenza viruses or their HA antigen after propagation in MDCK-SFS or BHK21-SFS cell
lines, where the MDCK-SFS cell line was grown both adherent and in suspension. Yields were determined by as-
sessment of virus genome equivalent concentration using M-gene speciﬁc quantitative RT-PCR (A), infectious
virus concentration by virus titration on MDCK cells (B), or HA titration (C). Geometric mean and 95% conﬁdence
interval of virus infections performed in triplicate are presented. 
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fectious virus did not differ significantly (p=0.98; Fig. 3B). These lower average
virus yields by Vero-SF cells primarily reflect the lower yields of H1N1, H5N2 and
H5N9 viruses.
In a second experiment virus yields in BHK21-SFS and MDCK-SFS cells were de-
termined. MDCK-SFS cells were grown both in suspension and adherent in
SFM4BHK21 medium (Fig. 4). The density of both suspension cell lines at the mo-
ment of infection was 2.3 times higher than of the adherent cells, since further di-
lution of the suspension cells to the density used for the adherent cells seriously
hampers their growth. Between the first and second experiment, a significant dif-
ference in the virus genome equivalent concentration of the adherent MDCK-SFS
was observed (1.7 times, p<0.0001), which can be accounted for by a higher H5N9
titer in the second experiment (cf. Fig. 3A and 4A). There were no significant dif-
ferences between the infectious virus titers (p=0.19) and the HA titers (p=0.92). Ad-
herently grown MDCK-SFS cells yielded on average 3-fold higher virus genome
equivalent concentrations (p<0.0001) and an almost two times higher HA titer
(p<0.0001), whereas the yield of infectious virus did not differ significantly
(p=0.39). When corrected for the initial cell density, adherent MDCK-SFS cells
would have 7-fold higher virus genome equivalent concentrations and 4-fold
higher HA titers as compared to the same cells grown in suspension.
BHK21-SFS cells supported replication of the H5N7 and H7N1 strains to titers
comparable to those obtained with MDCK-SFS cells (Fig. 4). However, the six other
virus strains yielded virus genome equivalent concentrations between 3.9-5.1 log10
TCID50 equivalent/ml, which is only slightly higher than the virus genome equiv-
alent concentration that was initially used for infection (3.5 log10 TCID50 equiva-
lent/ml). These levels were below the detection limit of the HA assay. Thus, these
six strains replicate poorly or not at all on BHK21-SFS cells. Visual inspection
showed no lysis of BHK21-SFS cells infected with any of the eight viruses at 72 h
p.i. The increase in cell density between 0 and 72 h p.i. was approximately 10-fold
for uninfected BHK21-SFS cells, whereas cells infected with the two viruses that
replicated efficiently on BHK21-SFS cells, H5N7 and H7N1 virus, showed a lower
increase in cell density of 6- and 3-fold, respectively. The other six virus strains
that replicate poorly on BHK21-SFS cells did not affect cell growth as the cell den-
sity increased to a similar level (factor 10-11) as uninfected cells. 
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MDCK (163), Vero (75) and other epithelial cells require attachment to a surface
such as tissue culture flasks or micro-carriers for proliferation. It has been reported
that suspended growth of MDCK cells resulted in the formation of multicellular
cysts of cells, having a polarized apical outside in which the percentage of repli-
cating cells decreased to 1-4% (176). Others described loose aggregation followed
by a slow decrease in viability, caused by aggregation-induced apoptosis (33).
These last findings correlate with the aggregation and decreasing viability of
MDCK cells when grown in suspension in three of the four culture media used in
this study. However, using SFM4BHK21 medium it was possible to isolate a stable,
single-cell suspension cell line, called MDCK-SFS. 
The ability of MDCK-SFS cells to grow in suspension as single cells appears to be
related to the use of the SFM4BHK21 medium, because these cells do not aggregate
in this medium whereas the transfer of these cells into UltraMDCK medium re-
sulted in cellular aggregation and surface attachment. SFM4BHK21 medium is de-
signed for BHK21 cells that grow in suspension, whereas the other media are
designed for MDCK, Vero and other cell lines which normally grow adherently.
Therefore, SFM4BHK21 medium most probably differs from the other media in
components that facilitate or prevent attachment to a matrix and to other cells, and
which possibly contributed to the success of this medium in supporting suspen-
sion growth of MDCK cells. Several medium components are known to have this
effect, including calcium which affects the attachment of MDCK cells to micro-car-
riers (48) and the size and density of cell aggregates (128). However it is difficult
to speculate on the nature of the relevant component as the composition of this
medium is undisclosed. SFM4BHK21 medium did, however, not support single
cell growth in suspension of Vero cells.
Other methods to achieve stably growing suspension MDCK cells have been de-
scribed. This included adaptation of MDCK cells to culture media containing met-
alloendopeptidase (165) or by growing cells in selection media in faster than
normal rotating roller bottles, resulting in the MDCK 33016 cell line (56). Recently
a suspension MDCK cell line was developed through transfection with siat7e, a
human gene involved in cellular adhesion (21). These suspension MDCK cell lines
did support replication of influenza virus. Comparison of virus yield is, however,
difficult as different virus strains and assay methods were used. Interestingly,
Inﬂuenza virus production by suspension MDCK cell line.
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when infected with influenza B virus, the siat7e transfected cells produced 23-fold
higher hemagglutinin titers, but 3-fold lower infectious virus titers in comparison
to the parental, adherent MDCK cells. However, here an effect of the adaptation
to SF and suspension growth on virus yields obtained with MDCK-SFS cells was
not observed. The maximum specific growth rate of the MDCK-SFS cells (0.029 h-
1) and the MDCK 33016 cells (56) are comparable to those found for adherent
MDCK cells (108). The siat7e transfected cells, however, grow at an at least 2-fold
lower rate.
Avian and human influenza virus strains differ in their binding preference to cell
surface receptors. Therefore, a suitable cell line for AI virus production should ex-
press at least the avian strain preferred SA 2,3 receptors. MDCK (125) and Vero
(29) cells express both receptors and virus binding to these cells is therefore not
expected to limit replication. The adaptation of MDCK cells to SF and suspension
growth did not affect the expression of both receptors. Similar to the findings de-
scribed in this paper , others (55) observed low expression of SA 2,6 receptors on
serum dependent BHK21 cells and related it to the restricted replication of human
influenza virus on these cells and the selection of receptor binding variants of the
viruses that bind better to the SA 2,3 receptors. Adaptation to SF media caused a
shift in receptor expression towards higher SA 2,6 and lower SA 2,3 receptor levels.
This shift could be caused by the direct response of the cell to the absence of serum
or by selection of cells having altered receptor expression levels during the adap-
tation process. The lower SA 2,3 receptor expression levels could cause restricted
propagation of AI virus strains in BHK21-SFS cells. However, the H5N7 and H7N1
strains replicate to high titers. Influenza virus receptor expression levels are there-
fore not determinants for infection of BHK21-SFS cells with these two avian virus
strains.
Possibly the different virus titers obtained using BHK21 cells are caused by the
presence of different polymerase genes since reassortment studies revealed that
the ability of influenza virus to form plaques in BHK21 cell monolayers is depend-
ent on the nature of one of the polymerase genes (6).
Unlike BHK21-SFS cells, MDCK-SFS and Vero-SF cells support the replication of
most strains to high titers of about 8 log10 TCID50 equivalent/ml. The yields of
the eight viruses obtained using Vero-SF cells were on average 5-fold lower as
compared to MDCK-SFS cells grown adherently. Such a difference in virus yield
between Vero and MDCK cells has been reported earlier (53, 88, 103). However,
by adaptation of the virus to Vero cells the yield could be twofold increased after
one passage (103) and 26-fold after 20 passages (53). Thus MDCK-SFS cells appear
optimal for influenza virus production, since they propagate a wide variety of
strains to high titers without the need for virus adaptation.
The highest titers reached with MDCK-SFS cells already reach the minimum level
(> 8 log10 TCID50/ml, > 8 log2 HAU/100 µl) that has been defined for commercial
influenza production (49). Furthermore, for the purpose of evaluating the suitabil-
ity of MDCK-SFS cells for industrial vaccine production it should be noted that
many process parameters can still be improved. The cell density at the moment of
infection was at least 3-fold lower than generally used (49). This was done here to
allow comparison to adherently grown cells and prevent medium depletion. Using
higher initial cell densities could possibly increase virus yields. Furthermore, the
maximum MDCK-SFS cell density can probably be increased by medium opti-
mization since the medium used was designed specifically for BHK21 cells. The
viral yield could be further increased by optimizing process conditions such as
m.o.i., trypsin concentration and harvest time, as was shown previously for other
cells (91, 147). Alternatively viral yield could possibly be improved by allowing
the cells to attach to micro-carriers immediately before virus infection, after their
suspension culture during scale up, since it was observed that MDCK-SFS cells
produce 4- to 7-fold more virus per cell when grown adherently than when grown
in suspension. Finally, the performance of MDCK-SFS cell lines in bioreactor cul-
tures should be studied to evaluate the suitability of these cells for industrial vet-
erinary vaccine production.
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absTraCT
Baby hamster kidney (BHK21) cells are used to produce vaccines against various
viral veterinary diseases, including rabies and foot-and-mouth-disease. Previously
we showed that particular influenza virus strains replicate efficiently in BHK21
cells whereas most strains, including model strain A/PR/8/34 [H1N1] (PR8), repli-
cate poorly. This prohibits the general use of these cells for influenza vaccine pro-
duction. 
We now show that in contrast to PR8, the related strain A/WSN/33 [H1N1] (WSN)
replicates efficiently in BHK21 cells. This difference is determined by the hemag-
glutinin (HA) protein since reciprocal reassortant viruses with swapped HAs be-
have similarly with respect to growth on BHK21 cells as the parental virus from
which their HA gene is derived. The ability of several other influenza virus strains
to grow on BHK21 cells appears to be similarly dependent on the nature of the
HA gene, since reassortant PR8 viruses containing the HA of these strains often
show a similar growth on BHK21 cells as the parental virus from which the HA
gene was derived. High virus titers could be obtained with reassortant PR8 strains
that contained a chimeric HA consisting of the HA1 domain of PR8 and the HA2
domain of WSN. HA1 contains most antigenic sites and is therefore important for
vaccine efficacy. This method of producing the HA1 domain as fusion to a het-
erologous HA2 domain could possibly also be used for the production of HA1 do-
mains of other viruses to enable the use of BHK21 cells as a generic platform for
veterinary influenza vaccine production.
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Traditionally, human and veterinary influenza vaccines are produced in embry-
onated chicken eggs, using reassortant seed virus containing the hemagglutinin
(HA) and neuraminidase genes from the epidemic strain and six internal genes
from the egg-adapted high-growth A/PR/8/34 [H1N1] (PR8) virus (84). Egg-based
manufacturing processes are however logistically complex and vulnerable to
changes in egg supply during major influenza outbreaks. Cell culture based pro-
duction is more robust and flexible, and is therefore suggested as an alternative
way to produce influenza vaccines. Indeed, MDCK, Vero and PER.C6® cell lines
are nowadays also used for this purpose (49). Baby hamster kidney cells (BHK21)
are commonly used for large scale production of virus for veterinary vaccines
against foot-and-mouth-disease and rabies. They have favorable growth charac-
teristics as they are easily cultured in suspension (106, 127, 184), have a high spe-
cific growth rate of 0.05 h-1 and can reach cell concentrations in batch culture as
high as 8 x 106 cells/ml (105, 184). BHK21 cells appear less suitable for influenza
virus propagation as they show an overall low virus yield compared to MDCK
and Vero cells (106, 110). However, previously we showed that influenza virus
replication efficiency in BHK21 cells is strain dependent (171). Strains that were
able to replicate in this cell line did this very efficiently, resulting in virus titers
that exceeded those found for MDCK and Vero cells infected with the same strains.
Such selective replication in BHK21 cells has been observed previously with two
influenza strains and was caused by one of the polymerase genes (6). Based on
their favorable growth characteristics, we investigated whether BHK21 cells can
potentially be used as a high-yielding, alternative platform to produce a wide va-
riety of avian influenza virus strains for veterinary vaccine production.
Of the eight influenza virus strains used in our previous study (171), six strains
replicated poorly in BHK21 cells (titer <3 log10 TCID50) whereas two strains repli-
cated efficiently (>7 log10 TCID50; Table 1). Similar analysis of three further H1N1
strains revealed that strains A/WSN/1933 (WSN) and A/turkey/NL/543301/1999
replicated efficiently whereas strain A/duck/Alberta/35/1976 replicated poorly
(Table 1). Replication in BHK21 cells is not determined by the HA subtype, as both
efficient and poor replicating strains are found among the H1, H5 and H7 subtypes
(Table 1). Interestingly, a distinct difference in replication efficiency was observed
between the two related H1N1 strains PR8 and WSN. For both these strains plas-
mid-based reverse genetics systems exist that enable the production of reassortant
viruses. Reassortant H1(WSN):PR8 virus, containing the HA gene of WSN in a
PR8 backbone and H1(PR8):WSN, containing the HA of PR8 in a WSN backbone,
were successfully rescued and could be amplified to high titers in embryonated
chicken eggs (as was the case for all other reassortants generated in this study). In
BHK21 cells, H1(WSN):PR8 virus replicated efficiently but the reciprocal virus
H1(PR8):WSN replicated poorly (Fig. 1A). The inability of PR8 to replicate in
BHK21 cells is therefore determined by HA and not by any of the other 7 gene seg-
ments. 
To assess whether the replication of other strains shown in Table 1 is also deter-
mined by the nature of the HA gene segment, seven additional reassortant viruses
with the HA of these wild-type strains in the PR8 backbone were made (Table 1).
HA reassortants derived from wild-type viruses that replicated efficiently
[H1(Ty/NL):PR8 and H5(Mall/DM):PR8] were also able to replicate, although the
infectious virus titers were about 100-fold lower than the wild-type virus. Simi-
larly, HA reassortant viruses derived from four wild-type strains that replicated
poorly [H1(Duck/Alb):PR8, H5(Ty/Wisc):PR8, H7(Ch/NL):PR8 and H9(Duck/
Germ):PR8] also replicated poorly in BHK21 cells. This suggests that the HA of
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Table 1: Infection of BHK21 cells with wild-type inﬂuenza virus strains or PR8-based HA reassortant strains.
BHK21-SFS cells (171) were grown in suspension in serum-free SFM4BHK21 culture media (Hyclone, Waltham,
MA.) and infected (m.o.i. 0.01) in the presence of 2 μg/ml trypsin-TPCK (Sigma-Aldrich, St. Louis, MO). Infectious
virus titres were determined 3 days post infection by TCID50, as previously described (171). Wild-type strains
A/Duck/Alberta/35/1976 and A/turkey/NL/543301/1999 were a gift of Dr G. Koch (CVI). All other strains used
in the present study were made using reverse genetics. A pHW2000-derived plasmid encoding the PR8 HA ge-
nomic RNA (pHW194) was earlier published (66). The HA genomic RNAs of seven further strains were isolated
from wild-type virus and ampliﬁed by RT-PCR using primers Bm-HA-1 (or derivatives thereof) and Bm-NS-890R
(68). When the sequence of the HA gene was available, derivatives of primer Bm-HA-1 were used that contain
6 additional bases at their 3’ end to increase PCR speciﬁcity. PCR fragments were inserted into pHW2000 using
BsmBI restriction endonuclease or BsaI when internal BsmBI sites are present in the HA gene segment (plasmids
pROM37 and pROM43), resulting in pROM37-46. The HA genomic RNA of WSN which was available in a pPOL-
SAPRIB-derived plasmid (40) was similarly inserted into pHW2000, resulting in pROM1. HA gene sequences were
deposited under EMBL accession nrs HE802058 to HE802066. Reassortant viruses were made with PR8 (66) and
WSN (40) reverse genetics plasmids as previously described (170). Virus identity was conﬁrmed by sequence
analysis.
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fig. 1. Replication in BHK21 cells of PR8 and WSN based inﬂuenza strains and PR8 reassortants containing cHA.
(A) BHK21 cells were infected with recombinant PR8, WSN, or the HA reassortants H(PR8):WSN or H(WSN):PR8
as described in Table 1. Infectious virus titres were determined 3 days post infection by TCID50.Geometric mean
titres and 95% conﬁdence interval of the mean of virus infections performed in triplicate are presented. (B) In-
fection of BHK21 cells with cHA reassortant virus strains. Cells were infected as described in Table 1. The infec-
tious virus titre was determined daily by TCID50. (C) Schematic overview of WSN-PR8 cHA proteins used to make
reassortant virus strains. The locations of the signal peptide (SP), HA1, HA2, ectodomain, transmembrane domain
(TM), cytoplasmic tail (CT), globular head, fusion peptide (FP) and receptor binding domain are indicated. Amino
acid positions are numbered taking the start codon of the signal peptide as 1 and ends at residue 565, with the
H3 numbering between brackets (186).Vertical bars represent amino acid diﬀerences between PR8 and WSN
HA. Replication eﬃciency of reassortant virus (panel A and B) is indicated with – (no replication), + (delayed
replication) and ++ (high yield). Reassortant viruses were made as described in Table 1. PCR fragments encoding
chimeras of WSN and PR8 HA genes were created by splice overlap extension PCR, joining the two fragments
directly behind nucleotide 416 (amino acid 128), 905 (amino acid 291) or 1114 (amino acid 344). Nucleotide
numbering refers to the position in the vRNA template (EMBL accession no. HE802058). Chimeric HA genes were
inserted into pHW2000 as described in Table 1, resulting in pROM2-7.
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these four strains also limits replication of the wild-type virus in BHK21 cells, al-
though other gene segments may also negatively affect their replication. The im-
portance of the HA gene in determining replication in BHK21 cells has also been
illustrated by Govorkova et al, who isolated HA mutants upon serial passage of
three influenza strains on these cells (55). Reassortant H3(Duck/Ukr):PR8 reacted
differently from the other reassortants since it replicated efficiently whereas the
corresponding wild-type virus replicated poorly. This suggests that in this case
not the HA but one or several of the other 7 gene segments limits replication in
BHK21 cells, possibly one of the polymerase genes (6). 
HA is a homotrimeric surface glycoprotein with each monomer consisting of two
disulphide-linked polypeptides, HA1 and HA2, that result from proteolytic cleav-
age of the precursor HA0 (15). HA recognizes sialic acid-linked receptors on the
cell surface by the receptor binding domain (RBD), located on HA1 (Fig. 1C). The
RBD is also the major antigenic component of the virus as a majority of the anti-
bodies generated after infection with influenza virus is directed against this region.
Therefore, HA1 is of primary interest for vaccine production. Structurally, the RBD
is located on the globular head that comprises most of HA1 whereas HA2, together
with the remainder of HA1, comprises the stalk region. After internalization of the
virion in the endosome the fusion peptide, located in the HA2 region (Fig. 1C),
undergoes a pH-induced conformational change, resulting in fusion of the viral
envelope with the cellular endosomal membrane. The HA proteins of PR8 and
WSN share 90% amino acid sequence identity (54 different residues, Fig. 1C). To
elucidate which part of the HA protein determines virus replication in BHK21
cells, six plasmids encoding PR8-WSN chimeric HAs (cHAs; Fig. 1C) were gener-
ated. Exchanges were made at the start of the RBD (position 129), the end of the
globular head (position 291), or the end of the HA1 domain (position 344) (86). 
PR8 reassortant viruses encoding these six cHAs were again amplified to high
titers in embryonated chicken eggs. Strains H(PR8291-WSN):PR8, H(PR8344-
WSN):PR8 and H(WSN344-PR8):PR8 replicated in BHK21 cells to high virus titers
that were comparable to those obtained with H1(WSN):PR8 (Fig. 1B), although the
rise in virus titer of H(WSN344-PR8):PR8 was delayed. Infection with H(PR8128-
WSN):PR8 and H(WSN128-PR8):PR8 resulted in a slower increase in virus titer,
but eventually they also reached high virus titers at 4 dpi. H(WSN291-PR8):PR8,
together with PR8, did not replicate in BHK21 cells. Based on these results it is not
possible to identify a specific region of HA that determines the ability to replicate
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in BHK21 cells, as the virus containing WSN HA1 and PR8 HA2 replicated equally
well as the strain containing the reciprocal cHA. Also the two strains containing
reciprocal cHAs exchanged at amino acid 128 replicated equally well. Neverthe-
less, these studies show that it is possible to grow a virus encoding the PR8 HA1
domain to high titers by fusion to the WSN HA2 domain.
Others have successfully created reassortants encoding cHAs by either replacing
the ectodomain (60, 61), HA1 (178) or the globular head (58) (Fig. 1C) and showed
that such viruses behave antigenically similar to the parental strains and are able
to induce high levels of HA-specific antibodies. Furthermore, Hai et al. (2012)
showed that exchange of the globular head is possible between strains from dif-
ferent subtypes and HA phylogenetic groups. These studies show that HA
chimeras can also be produced between highly divergent HAs while retaining anti-
genicity. Thus, BHK21 cells could potentially provide a high-yielding production
platform for PR8-based veterinary influenza vaccines by fusing the HA2 of WSN
with the HA1 of strains that themselves do not replicate in BHK21 cells. Further
research is required to evaluate this approach and to assess the antigenic and im-
munological qualities of vaccines resulting from it.
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Influenza A viruses lacking the gene encoding the non-structural NS1 protein
(delNS1) have potential use as live attenuated vaccines. However, due to the lack
of NS1, virus replication in cell culture is considerably reduced, prohibiting com-
mercial vaccine production. We therefore established two stable MDCK cell lines
that show inducible expression of the allele B NS1 protein. Upon induction, both
cell lines expressed NS1 to about 1000-fold lower levels than influenza virus-in-
fected cells. Nevertheless, expression of NS1 increased delNS1 virus titers to levels
comparable to those obtained with an isogenic virus strain containing an intact
NS1 gene. Recombinant NS1 expression increased the infectious virus titers 244
to 544-fold and inhibited virus induced apoptosis. However, NS1 expression re-
sulted in only slight, statistically not significant, reduced levels of interferon-β pro-
duction. Thus, the low amount of recombinant NS1 is sufficient to restore delNS1
virus replication in MDCK cells, but it remains unclear whether this occurs in an
interferon dependent manner. In contrast to previous findings, recombinant NS1
expression did not induce apoptosis, nor did it affect cell growth. These cell lines
thus show potential to improve the yield of delNS1 virus for vaccine production.
Chapter 4
- 44 -
InTroduCTIon
Influenza A virus is the causative agent of a highly contagious disease that affects
both humans and animals. Outbreaks of highly-pathogenic avian influenza (AI)
strains among poultry have resulted in transmissions to humans, often with fatal
outcome. Vaccination of poultry is an important tool to control such outbreaks.
Traditional vaccines consist of inactivated viral particles which closely resemble
the circulating strain. Currently vaccine strains are being developed with improved
characteristics, which include live attenuation, and the ability to serologically dif-
ferentiate between naturally infected and vaccinated-only animals (DIVA). In-
fluenza strains lacking the gene encoding the non-structural NS1 protein (delNS1)
are able to replicate in a host, albeit with reduced efficiency, indicating that NS1
is dispensable for virus replication. DelNS1 viruses are therefore considered as
live-attenuated vaccines (132) for both animals (133, 177) and humans (189). Fur-
thermore, delNS1 virus could be used as DIVA vaccine in poultry, as the presence
of antibodies against NS1 in infected animals, but not in vaccinated animals, allows
for better surveillance of AI outbreaks and thus may improve worldwide accept-
ance of vaccination (17).
NS1 facilitates the infection of a cell in many different ways and the reduced repli-
cation efficiency of delNS1 virus is a direct effect of the absence of these functions.
In cells infected with intact influenza virus, NS1 is expressed at very high levels
shortly after infection (59, 148, 172) and it inhibits the cellular antiviral response
by reducing the type I interferon’s (IFN) expression (such as IFN-α or IFN-β) at
various levels. NS1 binds to retinoic-acid inducible gene I (RIG-I) that recognizes
both cytoplasmic dsRNA and 5’-triphosphate-containing RNA, products that are
generated during influenza infection (107). NS1 also binds directly to dsRNA (132).
By binding to these molecules, NS1 inhibits the activation of several pathways that
lead to IFN induction. Furthermore, NS1 also limits IFN expression by inhibiting
cellular pre-mRNA processing (including IFN pre-mRNA) and mRNA nuclear ex-
port (59). The efficiency and mechanism by which different influenza strains block
the IFN response is strain dependent (63, 76). NS1 can also block the function of
two antiviral proteins, dsRNA-dependent protein kinase R (PKR) and 2’-5’-
oligoadenylatesynthetase (OAS) (132), and regulate both viral genome replication
and translation (180) and protein synthesis (59).
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The NS1 gene is localized on the eighth vRNA segment and splicing of the primary
NS1 mRNA results in the generation of a mRNA that encodes the nuclear export
protein (NEP) (59), a protein that plays a role in the nucleocytoplasmic export of
viral RNP’s and regulation of viral genome transcription and replication (135).
During development of delNS1 strains it is therefore important to retain the es-
sential NEP protein. The NS1 protein is divided into two distinct functional do-
mains: an N-terminal RNA-binding domain (residues 1–73) and a C-terminal
effector domain (residues 74–230), which predominantly mediates interactions
with host-cell proteins (59). Phylogenetic analysis of NS1 amino acid sequences
indicated that NS1 proteins can be divided into two groups, termed allele A and
B (94, 111). The homology within each allele is 93-100%, whereas between the two
alleles it can be as little as 62%. Allele B NS1 is found, with a few exceptions, ex-
clusively in avian influenza virus strains, whereas allele A NS1 is found in all
human, swine and equine strains and some avian strains.
Infection of cells with delNS1 virus induces higher levels of IFN than infection
with a wild-type strain and results in a lower virus yield (45, 77). In cells and ani-
mals with a low or absent IFN response, such as Vero cells, STAT1 or PKR knock-
out mice, and embryonated eggs younger than 8 days, the virus replicates to high
titers (30, 45, 77, 161), which indicates that inhibition of the IFN response is the
main function of NS1 (132). Influenza strains with C-terminally truncated NS1
genes show intermediate effects on IFN inhibition and virus replication (77), which
correlates with the presence of the dsRNA binding protein domain.
In large-scale influenza vaccine production, a serum-free and suspension cell cul-
ture based process is preferred above the traditional production in embryonated
hen’s eggs (171). However, the yield of delNS1 virus, as reported by others (45) is
below the minimal yield that is required for commercial vaccine production (49),
even with IFN deficient Vero cells. Higher virus titers can be obtained by using a
high multiplicity of infection (m.o.i.) (154), but such large amounts of seeding virus
are not feasible in large scale production. Another approach to increase virus yield
is transient recombinant expression of NS1 in the production cell line before in-
fection (148). However, host-cell encoded NS1 expression induces apoptosis (25,
81, 145, 195). This makes development of stable NS1 expressing cell lines difficult,
whereas transient expression is not feasible in large scale production. 
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The aim of this paper is to develop a stable NS1 expressing Madin-Darby canine
kidney (MDCK) cell line for high-yielding delNS1 virus production. To overcome
apoptosis induction, an inducible NS1 expression system is used. A commonly
used inducible expression system is based on the prokaryotic Tet repressor protein
(TetR) which allows expression of a gene of interest (GOI) under control of a tetra-
cycline-response element (TRE) in a cell line that is stably transfected with a trans-
activator protein (52). Two variants of this transactivator exist that respond in an
opposite manner to the doxycycline (Dox) antibiotic used for GOI induction. Using
the Tet-off system Dox addition represses GOI expression, whereas in the Tet-on
Advanced system Dox addition induces GOI expression. An adherently growing,
serum dependent MDCK Tet-off cell line is commercially available. For construc-
tion of cell lines stably expressing NS1 with the Tet-on Advanced system, which
allows more tight regulation of gene expression, the previously generated MDCK-
SFS cell line growing serum-free and in suspension (171) was used. We obtained
two MDCK Tet-on Advanced cell lines that showed inducible production of allele
B NS1 protein. We subsequently determined whether upon NS1 induction these
two cell lines supported replication to high titers of an influenza virus that either
contained or lacked an intact NS1 gene. Furthermore, we determined the effect of
NS1 induction on IFN-β production and the apoptotic response.
MaTerIal and MeTHods
Cell lines and virus strains
MDCK-SFS and Vero-SF cells (171) were grown adherently in serum-free Ultra-
MDCK culture media (Lonza Biowhittaker, Basel, Switzerland) and Optipro (In-
vitrogen, Carlsbad, CA, USA) respectively. MDCK Tet-off cells, obtained from
Clontech (Mountain View, CA, USA), were grown in DMEM with 5% Tet-system
approved fetal bovine serum (FBS). All culture media were supplemented with 4
mM glutamine and 100 units/ml penicillin and 100 µg/ml streptomycin (Gibco).
Human embryo kidney (293T) and MDCK cells used for generation of reassortant
virus were cultured in Glutamax medium (Invitrogen) supplemented with 10%
FBS. Cells were grown at 37˚C and 5% CO2. Cell density and viability were deter-
mined with a Countess automated cell counter (Invitrogen).
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The influenza virus strains A/Puerto Rico/8/34 H1N1 (PR8; ATCC VR-95, Manassas
VA, USA), A/turkey/Wisconsin/68 H5N9 (kindly provided by Dr. G. Koch, CVI),
A/turkey/Turkey/1/05 H5N1 (Veterinary Laboratories Agency, Pirbright, UK) were
propagated in embryonated chicken eggs.
Generation of recombinant influenza viruses
Viral RNA of influenza virus strain A/turkey/Turkey/1/05 H5N1 was isolated from
allantoic fluid of infected eggs using a high pure viral RNA isolation kit (Roche
Applied Science, Penzberg, Germany). Universal influenza genome primer uni12
(66) was used for reverse transcriptase (RT) reactions with the Superscript first
strand synthesis system (Invitrogen). HA segment forward (5’-TATT GCTCTTCA
GCCAGCAAAAGCAGGGGTWYAATCTGTC-‘3) and reverse (5’-ATATGCTCTT
CGATTAGTAGAAACAAGGGTGTTTTTAAYTAC-‘3) primers and NA segment
forward (5’-TATTGCTCTTCAGCCAGCAAAAGCAGGAGTTCAAAATGAA
TCC-‘3) and reverse (5’-ATATGCTCTTCGATTAGTAGAAACAAGGAGTTTT
TTGAACAAAC-‘3) primers with Sap I restriction sites were used for PCR reac-
tions with the Expand high fidelity PCR system (Roche). The resulting cDNAs
were inserted in vector pPOLISAP1RIB (40). The sequence of each insert was ver-
ified (NA, Genbank Acc. nr. EF619973; HA, Genbank Acc. nr. EF619980) by se-
quence analysis using the BigDye terminator v1.1 cycle sequencing kit (Applied
Biosystems, Carlsbad, CA, USA).
The sequence of the HA gene encoding the multi basic cleavage site of
A/turkey/Turkey/1/05 H5N1 was replaced by the corresponding sequence encod-
ing the consensus cleavage site of a low pathogenic HA gene of subtype H6 by
means of PCR mutagenesis as described previously (126). Using this method, the
H5 gene sequence CCTCAAGGAGAGAGAAGAAGAAAAAAGAGAGGACTA
TTT encoding the multi basic cleavage site PQGERRRRKKRGLF was converted
into the sequence CCAGAGATTGAAACTAGAGGACTTTTT encoding the low
pathogenic H6 subtype cleavage site PQIETRGLF. The resulting gene is referred
to as H5(6).
In order to generate an NS segment that only encodes the NEP protein but not the
NS1 protein we used a synthetic gene segment (GenScript Corporation, Piscat-
away, NJ, USA) corresponding to the NS gene segment of influenza virus strain
PR8 (EMBL Acc. nr. AF389122) in which the nucleotide sequence spanning the
exact intron sequence (nt 57-528) was deleted. The NS1-deletion gene segment was
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inserted in pHW2000 using BsmBI restriction sites as described earlier (66). The
bi-directional 8-plasmid reverse genetics system of strain PR8 was a gift of Dr.
Hoffman and Dr. Webster (67). To rescue recombinant virus, a mixture of 15 x 105
293T and 5 x 105 MDCK cells was transfected with equal amounts of the eight plas-
mids containing the different gene segments, using Lipofectamine 2000 (Invitro-
gen). At 12 h post transfection (hpt) the transfection mixture was replaced by
Glutamax medium supplemented with 0.3 % bovine serum albumin (Chemie
Brunschwig AG, Basel, Switzerland) and 250 ng/ml TPCK-trypsin (Sigma-Aldrich,
St. Louis, MO, USA). Virus was harvested at 48 hpt and 96 hpt. Virus stocks were
generated in 7-9 day old embryonated eggs and virus identity was confirmed by
sequence analysis. Using this system we were able to rescue the PR8::H5(6)N1 and
PR8::H5(6)N1delNS1 viruses. These strains are referred to as H5(6)N1 and delNS1,
respectively. 
Generation of stable MdCK cells with inducible ns1 expression
The pTet-on Advanced expression system for inducible gene expression was ob-
tained from Clontech. It includes the improved pTET-on Advanced and pTRE-
tight vectors, that make the inducible system more sensitive to Dox while reducing
leaky gene expression (167). Synthetic DNA fragments (GenScript Corporation)
encoding the allele A NS1 from A/Puerto Rico/8/34 H1N1 (Genbank Acc. no.
V01104) and allele B NS1 from A/turkey/Wisconsin/68 H5N9 (Genbank Acc. no.
U85378) were inserted in the pTRE-tight vector after mutating the 3’-splice site for
generation of NEP mRNA, as described previously (7). Furthermore, a synthetic
DNA fragment encoding the N-terminal 99 amino acids of allele A NS1 was in-
serted into pTRE-tight. The resulting plasmids are pTRE-tight-NS1allA, pTRE-
tight-NS1allB and pTRE-tight-NS1allA1-99. 
After transfection of MDCK-SFS cells with the pTet-On Advanced vector using Fu-
gene HD (Roche) stably transformed cells were selected with 400 µg/ml G418
(Promega, Fitchburg, WI, USA). Functional expression of the rtTA-Advanced trans-
activator protein was assessed by transient cotransfection of the selected cell lines
with pTRE-tight-LUC, that encodes firefly luciferase, and a vector that constitu-
tively expresses Renilla luciferase as a transfection control, followed by induction
with different concentration of Dox (Clontech). Two days later both the Renilla
and firefly luciferase activity was measured using the Dual-Luciferase reporter
assay system (Promega). One MDCK Tet-on Advanced cell line that showed high
and inducible firefly luciferase activity was selected for further work. 
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Both the MDCK Tet-on Advanced and the MDCK Tet-off cell line (Clontech) were
cotransfected with either one of the three pTRE-tight derived plasmids and a linear
hygromycin marker in a ratio of 20:1. Stably transformed cells were selected with
200 µg/ml hygromycin B (Clontech) and either 300 µg/ml G418 (Tet-on Advanced
cells) or 1 µg/ml puromycin (Clontech; Tet-off cells). Cell propagation was per-
formed in the presence of 200 µg/ml G418, 1 µg/ml puromycin and/or 100 µg/ml
hygromycin. None of these antibiotics were used during virus infections and other
assays. 
ns1 mrna quantification by qrT-PCr
MDCK cells (4 x 105) were incubated in 0, 0.1 and 1 µg/ml Dox for 24, 48 and 72 h
in 6-well plates (Greiner Bio-One), after which RNA was isolated with the RNeasy
plus kit (Qiagen, Hilden, Germany). The NS1 mRNA concentration was then de-
termined by real-time RT-PCR using the QuantiTect SYBR Green RT-PCR kit
(Roche). A calibration curve was used for both allele A NS1 and allele B NS1 geno-
types, made by a serial dilution of RNA isolated from cells 24 h post infection (hpi)
with H1N1 or H5N9 influenza virus (m.o.i. 5). NS1 mRNA levels were corrected
for the amount of actin mRNA. Allele A NS1 forward (5’-CAAAACATGGATC-
CAAACACTG-3’) and reverse (5’-GAATCCGCTCCACTATCTGCT-3’) primers,
allele B NS1 forward (5’-ACAGGGGGTTTGATGGTGA-3’) and reverse (5’-
CTTTGGAGGGAGTGGAG GTC-3’) primers, and canine actin forward (5’-
GGCATCCTGACCCTGAAGTA-3’) reverse (5’-GGGGTGTTGAAAGTCTCGA
A-3’) primers were used. 
sds-PaGe and Western blot analysis
MDCK NS1allAoff, NS1allA1-99on, NS1allBon1, NS1allBon2 and Tet-on Advanced
cells were incubated for 24 h with or without 1 µg/ml Dox and then subjected to
reducing SDS-PAGE, using NuPAGE® Novex® 12% Bis-Tris precast gels (Invitro-
gen). MDCK-SFS cells taken 24 h after infection with either H1N1 or H5N9 virus
(m.o.i. 5) were used as a source of authentic NS1. As a positive control for the trun-
cated allele A NS1, MDCK Tet-on Advanced cells were incubated for 24 h with 1
µg/ml Dox, transiently transfected with pTRE-tight-NS1allA1-99, and subse-
quently incubated for another 24 h. Polypeptides were transferred to polyvinyli-
denedifluoride membranes. NS1 was detected by immunoblotting using a
monoclonal mouse antibody against a peptide near the N-terminus of allele A NS1
(SC130568, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a custom-prepared
rabbit antiserum (anti-NS1allB217-230) directed against a keyhole limpet hemo-
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cyanin conjugated peptide (CKQKRYMARRVESEV; N-terminal acetylation) en-
compassing the C-terminal 14 amino acids of allele B NS1 of H5N9 virus with an
additional N-terminal cysteine for conjugation purposes. The peptide-specific an-
tibodies from the anti-NS1allB217-230 antiserum were affinity purified using this
same (unconjugated) peptide (GenScript Corporation). After subsequent incuba-
tion with, respectively, peroxidase-conjugated rabbit anti-mouse or goat anti-rabbit
immunoglobulins (Dako, Glostrup, Denmark), protein levels were visualized with
ECL plus (GE Healthcare, Buckinghamshire, UK) and quantified with a Storm840
imaging system (Molecular Dynamics, GE Healthcare).
Virus infection
For analysis of delNS1 virus replication by all four NS1 expressing cell lines, the
two control cell lines and the Vero cells, cells were incubated in 96-well plates
(Greiner Bio-One) (3 x 104 cells/well), for 24 h with or without 1 µg/ml Dox. The
following day cells were infected in triplicate with delNS1 virus (m.o.i. 0.001) and
after one h, they were washed twice and provided with 120 µl medium with 2
µg/ml trypsin-TPCK, without Dox or selection antibiotics and without FBS for
MDCK Tet-off cell lines. Three day post infection (dpi), virus titers were deter-
mined by M-gene specific qRT-PCR.
To study the infection kinetics of delNS1 and H5(6)N1 in NS1allBon1 and NS1all-
Bon2, 1 x 106 cells per well were incubated in 6-well plates (Greiner Bio-One), with
or without 1 µg/ml Dox. After 24 h incubation, one well per cell line was used to
determine the cell density. Next, cells were infected in triplicate with either delNS1
or H5(6)N1 virus at an m.o.i. of 0.01. One hour later cells were washed with PBS
and supplied with 5 ml UltraMDCK medium containing 2 µg/ml trypsin-TPCK
with or without Dox. Supernatant samples were taken 1, 24, 48 and 72 h hpi and
stored at -80°C before determining the virus yield.
The infectious influenza virus titer was measured by determining the tissue culture
infective dose required to infect 50% (TCID50) of MDCK cells. The influenza virus
genome equivalent concentration was derived from the amount of viral RNA
copies determined by M-gene specific qRT-PCR. These two assays were previously
described (171). 
apoptosis measurement
MDCK NS1allBon1, NS1allBon2 and Tet-on Advanced control cells were cultured
for 24 h in the presence (1 µg/ml) or absence of Dox, trypsinized and then allowed
to adhere to the surface of a 96-well plate (Greiner Bio-One) (1 x 104 cells/well) for
1.5 h. To determine inhibition of apoptosis induction by virus infection, cells were
infected with 5 m.o.i. of either delNS1, H5(6)N1 or mock-infected. Dox was sup-
plied to cells which were previously cultured with Dox. To determine apoptosis
induction by host-cell encoded NS1 expression, culture media with or without 1
µg/ml Dox was added to cells that were previously cultured without Dox. 24 h
after infection or NS1 induction caspase-3 and caspase-7 activities were deter-
mined using the Caspase-Glo 3/7 Assay kit (Promega). Briefly, supernatant was
removed and 25 µl Caspase-Glo reagent and 25 µl PBS was added to each well.
After 1 h incubation at room temperature the luminescence of each sample was
measured using a GloMax-Multi luminometer (Promega). Results are given as the
means of triplicate experiments and represent the increase in caspase activity as
compared to control cells (mock infected and non-induced).
Ifn-β quantification by mrna rT-PCr
MDCK NS1allBon1, NS1allBon2 and Tet-on Advanced control cells were incubated
for 24 h in 6-well plates (Greiner Bio-One) (6 x 105 cells/well), with or without 1
µg/ml Dox. Cells were then infected with delNS1 virus (m.o.i. 3) or mock-infected.
After 18 h, RNA was isolated using the RNeasy plus kit (Qiagen). The concentra-
tion of IFN-β mRNA was determined by real-time RT-PCR (Onestep RT-PCR kit,
Qiagen), using canine IFN-β forward (5’-CCAGTTCCAGAAGGAGGACA-3’) and
reverse (5’-CCTGTTGTCCCAGGTGAAGT-3’) primers and Taqman probe (5’-
6FAM-CCTG GAGGACGTCAAAGAGAAGGA-XT-PH). IFN-β mRNA levels
were corrected for the amount of actin mRNA. The concentration of actin mRNA
was determined by real-time RT-PCR using QuantiTect SYBR Green RT-PCR kit
(Roche), using canine actin primers (Section 2.4). A calibration curve was used for
both IFN and actin mRNA by a ten-fold serial dilution (100 to 10-7) of RNA isolated
from delNS1-infected MDCK-SFS cells. 
Ifn-β quantification bioassay
MDCK NS1allBon1, NS1allBon2 and Tet-on Advanced control cells were incubated
for 24 h in 6-well plates (Greiner Bio-One) (6 x 105/well), with (1 µg/ml) or without
Dox. Cells were then infected with delNS1 virus (m.o.i. 3) or mock-infected. After
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25 h, supernatant was harvested and ultra-filtrated (Vivaspin 500, Sartorius, Got-
tingen, Germany) to remove virus. The absence of virus in the filtrate was con-
firmed by incubation of adherent MDCK-SFS cells with the filtrate in an
immunoperoxidase monolayer assay, as previously described (171). To determine
the levels of secreted IFN, MDCK-SFS cells were seeded in 96-well plates (Greiner
Bio-One) (5 x 104/well) and incubated with a serial two-fold dilution series of virus-
free supernatant for 18 h. Cells were then infected (m.o.i. 3) with Newcastle disease
virus (NDV) strain LaSota that was generated by reverse genetics from a Full-
Length NDV cDNA copy (NDFL) that expresses a EGFP reporter gene (NDFL-
tagEGFP) (4) and incubated for a further 48 h. After removal of supernatant, the
fluorescence of each well was measured using a GloMax-Multi fluorimeter
(Promega). The amounts of IFN present in the supernatants were estimated based
on their ability to induce an antiviral state in MDCK-SFS cells and inhibit NDFL-
tag EGFP replication. The supernatant dilution that resulted in the median EGFP
signal was determined for each sample. The reciprocal dilution was used as a rel-
ative concentration of IFN present in the supernatant.
Ifn-β dependent luciferase reporter system
To prepare conditioned medium (CM), MDCK-SFS cells were infected with
delNS1 virus (m.o.i. 0.6) without the addition of trypsin. After 15 h, supernatant
was ultra-filtrated (Amicon Ultra-15 100k, Millipore, Billerica, MA, USA) to remove
virus. This virus-free supernatant was further used to stimulate IFN production
in MDCK cells.
MDCK NS1allBon1, NS1allBon2 and Tet-on Advanced control cells were incubated
for 24 h in 96-well plates (Greiner Bio-One) (1.5 x 104/well), with or without 1 µg/ml
Dox. Next, cells were washed and transiently cotransfected with the reporter plas-
mid carrying the firefly luciferase gene under the control of the IFN-β promoter
(p125Luc, kindly provided by Takashi Fujita, Kyoto University, Japan (193)) and
the Renilla luciferase control plasmid pGL4.73 (Promega), using Fugene HD
(Roche). Cells were then incubated for 7 h, followed by IFN stimulation by addition
of either 10 µg/ml poly-IC or 1% CM, or mock-stimulated. The firefly luciferase
activity was measured after 40 h incubation using the Dual Luciferase Reporter
Assay System (Promega) and normalized to Renilla luciferase activity. All trans-
fection experiments were conducted in duplicate.
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statistical analysis
Data were analyzed for statistical significance by the Students t-test, using the
Minitab software package (Minitab Inc., Coventry, UK). Differences in mean were
assumed significant if p<0.05.
resulTs
Generation of MdCK cells with stable ns1 expression
Transfection of MDCK-SFS cells with the pTet-on Advanced plasmid resulted in
98 stable cell lines. These were screened for transactivator activity by transient
transfection with a luciferase reporter plasmid. A cell line that showed strong lu-
ciferase induction (177-fold) upon Dox addition was selected. Subsequent trans-
fection of this cell line and a commercially available MDCK Tet-off cell line with
either one of the pTRE-tight NS1allA, pTRE-tight NS1allA1-99 or pTRE-tight
NS1allB plasmids yielded 30 stably transformed cell lines. Fifteen of these cell lines
originated from transfection with pTRE-tight NS1allB and ten cell lines from trans-
fection with pTRE-tight NS1allA1-99. Only five (all Tet-off) cell lines were obtained
from transfection with pTRE-tight NS1allA. These 30 cell lines were then screened
for NS1 mRNA expression and increased production of delNS1 virus upon induc-
tion of NS1 expression. Four cell lines, NS1allAoff, NS1allA1-99on, NS1allBon1
and NS1allBon2, that unequivocally showed NS1 mRNA expression and appeared
to support growth of delNS1 virus to higher titers upon NS1 induction (results not
shown) were selected for further studies.
fig. 1. Inducible expression of NS1 genes in stable MDCK cell lines. The NS1 mRNA levels in MDCK NS1allAoﬀ
(A), NS1allA1-99on (B), NS1allBon1 (C) and NS1allBon2 (D) cell lines was determined by qRT-PCR 24, 46 and 70
h after induction with 0, 0.1 or 1.0 µg/ml Dox. The relative NS1 mRNA level as compared to cells infected with
H1N1 virus (panels A and B) or H5N9 virus (panels C and D) are presented.
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ns1 mrna and protein expression
The optimal Dox concentration and induction period leading to high NS1 mRNA
levels was next determined. Figure 1 gives the ratio of NS1 mRNA levels relative
to the NS1 RNA (the sum of mRNA, vRNA and cRNA) levels in cells infected with
the corresponding wild type virus. Note that we used the total amount of NS1
RNA present in infected cells as a reference, which comprises viral mRNA, vRNA
and cRNA. However, in transfected cells only NS1 mRNA is present. The ratio be-
tween NS1 mRNA and total NS1 RNA levels in infected cells is about 0.2 at 24 hpi
(172). Thus, the relative NS1 mRNA levels in our stable MDCK cell lines compared
to NS1 mRNA levels after virus infection are probably 5-fold higher than reported
in Fig. 1.
Each of the four cell lines showed NS1 mRNA expression after 24 h induction,
which did not further increase upon prolonged induction (Fig. 1A-D). The NS1al-
lAoff cell line showed an about 10,000-fold lower NS1 mRNA level than cells in-
fected with H1N1 virus in the non-induced state (with Dox). Furthermore the NS1
mRNA level did not change upon induction by Dox omission (Fig. 1A). Similarly,
the NS1allA1-99on cell line showed no change in NS1 mRNA level upon induction
(with Dox) and an about 100-fold lower NS1 mRNA level than H1N1 virus infected
cells. (Fig. 1B). However, both NS1allBon1 and NS1allBon2 cell lines showed in-
ducible expression of NS1 mRNA that, in the induced (with Dox) state, was about
1000-fold lower than in H5N9 virus infected cells (Fig. 1C and D). For further stud-
ies, NS1 expression was induced by adding 1 µg/ml Dox to Tet-on cell lines or by
Dox omission from Tet-off cell lines, both for a period of 24 h. 
The NS1 protein expression was analyzed by Western blotting using allele-specific
antibodies for detection of allele A NS1 (Fig. 2A) and allele B NS1 (Fig. 2B). Both
Western blots show many faint bands representing aspecific binding to proteins
of MDCK cells that do not produce NS1 (Fig. 2A, lane 11; Fig. 2B, lanes 11-12).
However, a band representing allele A NS1 (Fig. 2A, lane 1-5) and allele B NS1
protein (Fig. 2B, lanes 1-6) is readily observed in samples from MDCK cells 24 hpi
with H1N1 or H5N9 virus. Furthermore, a band representing the truncated allele
A NS1 is visible near the 6 kDa marker(Fig 2A, lane 6), following transient trans-
fection of Dox induced MDCK Tet-on Advanced cells with pTRE-tight-NS1allA1-
99.
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NS1 bands could not be detected in NS1allAoff and NS1allA1-99on cell extracts
(Fig. 2A, lanes 7-10). Both NS1Bon1 and NS1Bon2 cell lines show a strong band at
the expected position after induction of NS1 expression (Fig. 2B, lanes 9 and 11),
which is predominantly absent without induction (Fig. 2B, lanes 8 and 10). The
faint band at this position in non-induced cells is not assumed to represent NS1
since it is also visible in cells that do not express NS1 and were incubated with and
without Dox (Fig. 2B, lanes 11 and 12). A serial dilution of MDCK cells 24 hpi with
H5N9 virus (Fig. 2B, lanes 1-6) was used to quantify the NS1 protein content of
the induced NS1allBon cell lines. Densitometric analysis revealed that the NS1all-
Bon1 and on2 cell lines produced, respectively, 1200- and 500 -fold lower NS1 pro-
tein levels than H5N9 infected cells.
fig. 2. Western blot analysis of NS1 protein expression. MDCK NS1allAoﬀ, NS1allA1-99on, NS1allBon1, NS1all-
Bon2 and Tet-on Advanced  cells were incubated for 24 h in the presence of 1.0 µg/ml Dox or without Dox.
Panels A and B represent Western blot analysis of allele A NS1 and allele B NS1, respectively. Cell extracts of
MDCK-SFS cells infected with H1N1 (allele A NS1) or H5N9 (allele B NS1) inﬂuenza virus at 24 hpi were used as
source of authentic NS1. A serial 5-fold dilution series of cell samples infected with H1N1 (panel A, lanes 1-5) or
H5N9 (panel B, lanes 1-6) virus was included to allow densitometric NS1 quantiﬁcation. As a positive control for
the truncated allele A NS1, Dox induced MDCK Tet-on Advanced cells were transiently transfected with pTRE-
tight-NS1allA1-99 (panel A, lane 6). Non-infected MDCK Tet-on Advanced cells were used as negative control
(panel A lane 11 and panel B lane 11-12). Relevant molecular weight markers (kDa) are indicated on the right of
each panel. 
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effect of ns1 on virus replication
The delNS1 total viral particle yield, as determined by the virus genome equivalent
titer, after infection of induced and non-induced cells was compared (Fig. 3). NS1
expression increased delNS1 virus yield 346-fold in NS1allBon1 cells (p=0.015) and
82-fold in NS1allBon2 cells (p=0.050). The virus yield obtained with both induced
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fig. 3. Eﬀect of NS1 gene induction of four stable MDCK cell lines on production of delNS1 virus. Cells were in-
duced with 1.0 µg/ml Dox (+) or not induced (-) and after 24 h infected with 0.001 m.o.i. delNS1 virus. Three dpi
the virus genome equivalent concentration was measured by qRT-PCR. The two MDCK cell lines expressing only
the transactivator and Vero cells were included as controls. Geometric mean titres and 95% conﬁdence interval
of virus infections performed in triplicate (Vero cells in duplicate) are presented. Diﬀerences were signiﬁcant (*)
when p < 0.05.
fig. 4. Replication of delNS1 and H5(6)N1 virus in NS1allBon1 (panel A) and NS1allBon2 (panel B) cell lines. Cells
were either induced with 1 µg/ml Dox (closed symbols, full line) for 24 h or not-induced (open symbols, dotted
line), followed by infection with 0.01 m.o.i. delNS1 or H5(6)N1 virus. The virus genome equivalent concentration
of delNS1 (squares) and H5(6)N1 (circles) virus was determined by qRT-PCR. The titre of infectious delNS1 virus
was determined by TCID50 (triangles). Geometric mean titres and 95% conﬁdence interval of the mean are pre-
sented of virus infections performed in triplicate.
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NS1allBon cell lines was comparable to the virus yield of Vero cells whereas non-
induced NS1allBon cells yielded virus levels comparable to the Tet-on control cells,
which lack a NS1 gene. However, the virus yield of NS1allA1-99on cells and NS1al-
lAoff cells did not differ upon Dox treatment and was comparable to the virus
yield of the corresponding Tet-on and Tet-off control cells. Infection at a higher
m.o.i. (0.01) resulted in higher maximum titers for all cell lines and a smaller dif-
ference between the delNS1 virus yield obtained with induced and non-induced
NS1allBon cell lines (data not shown). Thus, only the two NS1allBon cell lines, in
which we could demonstrate inducible NS1 expression, showed higher yields of
delNS1 virus upon NS1 expression. Therefore only these cell lines were used in
further studies.
We next determined the kinetics of delNS1 and H5(6)N1 total viral particle pro-
duction by induced and non-induced NS1allBon cells (Fig. 4). The H5(6)N1 virus
contains an intact NS1 gene but is further isogenic to delNS1 virus. Induction of
NS1 expression increased delNS1 total viral particle yield by NS1allBon1 cells at
70 hpi 23-fold (p=0.001; Fig. 4A) and by NS1allBon2 cells 5-fold (p=0.035; Fig. 4B).
The titers at 70 hpi (about 108 TCID50 equivalent/ml) are comparable to those
found after infection with H5(6)N1 virus (Fig. 4A and B), although the H5(6)N1
virus appeared to replicate somewhat faster. Induction of allele B NS1 expression
by both cell lines did not increase the replication speed nor the yield of H5(6)N1
virus. 
Strikingly, the induction of NS1 expression by NS1allBon1 and NS1allBon2 cells
increased the infectious delNS1 virus titer at 70 hpi 244- and 544-fold, respectively
(Fig. 4A and B), which is substantially more than the, respectively, 23- and 5-fold
increase in total viral particle yield.
effect of ns1 on Ifn-β expression
We next determined the effect of NS1 expression by NS1allBon cells on the induc-
tion of IFN-β expression by delNS1 virus infection using three different methods:
quantification of IFN-β mRNA levels (Fig. 5A), quantification of secreted IFN using
a bioassay (Fig. 5B) and the expression of a luciferase reporter gene under control
of the IFN-β promoter (Fig. 5C-E). Production of NS1 by NS1allBon2 cells reduced
the IFN-β mRNA expression after delNS1 virus infection 3.5-fold (p=0.045),
whereas no significant difference was observed for the NS1allBon1 and Tet-on cell
lines (Fig. 5A). Furthermore, IFN-β mRNA was not detectable in mock-infected
cells. The concentration of IFN secreted by delNS1 virus-infected cells was deter-
mined by titration of MDCK-SFS cells with virus-free supernatant, followed by in-
fection of these cells with NDV that expresses EGFP for its quantification. NDV is
known to be highly susceptible to IFN. Thus cells stimulated with IFN produce
less NDV virus as assessed by the level of fluorescence. The production of NDV
viruses was translated to a relative IFN concentration as described in material and
methods. Although NS1 expression by NS1allBon1 cells reduced IFN secretion al-
most 3-fold, this difference was not statistically significant. The IFN expression of
mock-infected NS1allBon1, NS1allBon2 and TET-on cells was below detection lim-
its, since the ultra-filtrated supernatant of these cells did not reduce EGFP expres-
sion after infection with NDFL-tag EGFP.
fig. 5. Eﬀect of NS1 expression on INF-β production determined with three diﬀerent methods. Before each assay,
NS1allBon1, NS1allBon2 and Tet-on Advanced control cells were induced for 24 h with 1.0 µg/ml Dox (+) or not
induced (-). The amount of IFN-β mRNA was determined by qRT-PCR, after infection with delNS1 or mock infec-
tion and normalized for the amount of actin mRNA (Panel A). The relative amount of excreted IFN was deter-
mined after infection of the cells with delNS1, followed by removal of virus from the supernatant 24 h later by
ultra-ﬁltration. The IFN in the supernatant was titrated by stimulating MDCK-SFS cells with a serial dilution of
the supernatant before infection with NDFLtag-EGFP virus. The relative amount of IFN present in the supernatant
was determined by the dilution of the supernatant at 50% EGFP signal (Panel B). Furthermore, the cells were
transfected with an IFN-β dependent ﬁreﬂy luciferase reporter plasmid, followed by stimulation of the IFN-β
production with 1% CM (Panel C), 10 µg/ml poly-IC (Panel D) or mock (Panel E). The luciferase activity was nor-
malised by the Renilla luciferase activity. The mean and 95% conﬁdence interval of the mean of triplicate exper-
iments (luciferase reporter assay in duplicate) are presented for each assay. Diﬀerences were signiﬁcant (*) when
p < 0.05.
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NS1 expression by NS1allBon2 cells reduced IFN secretion to an even lower extent
(Fig. 5B). In the third assay, both NS1allBon cell lines showed slightly lower, al-
though not statistically significant, expression of a reporter gene under control of
an IFN-β promoter when NS1 expression was induced, as compared to non-in-
duced cells upon stimulation of IFN-β production by either CM (Fig. 5C) or poly-
IC (Fig. 5D). These differences were smaller without stimulation of IFN-β
production (Fig. 5E). Although the individual assays mostly do not yield statisti-
cally significant differences, the combined results of these three assays suggest
that induction of NS1 expression by NS1allBon cells slightly reduces IFN produc-
tion. However, this effect is minimal and therefore not likely to be critical in the
process of virus replication.
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fig. 6. Eﬀect of NS1 expression on apop-
tosis and cell growth. NS1allBon1,
NS1allBon2 and pTet-on Advanced con-
trol cells were induced with 1.0 µg/ml
Dox (+), non-induced (-) or infected with
delNS1 virus, followed by measurement
of the combined caspase-3 and -7 activ-
ity 24 h later (panel A). The results show
the relative increase in caspase activity
as compared to the corresponding non-
induced, non-infected cells. The growth
rate of these cells during a 48 h cultiva-
tion period in the presence or absence of
Dox is presented in panel B. Mean and
their 95% conﬁdence interval of triplicate
experiments are given.
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fig. 7. Inhibition of apoptosis by NS1 ex-
pression. Tet-on Advanced control cells
(panel A), NS1allBon1 (panel B) and
NS1allBon2 (panel C) cells were induced
with 1.0 µg/ml Dox (+) or non-induced (-
), followed by infection with delNS1 or
H5(6)N1 virus. The combined caspase-3
and -7 activity was measured 24 hpi. The
relative increase in caspase activity as
compared to the corresponding non-in-
fected cells was then calculated. Mean
and their 95% conﬁdence interval of trip-
licate experiments are given. Diﬀerences
were signiﬁcant (*) when p < 0.05.
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effect of ns1 on apoptosis 
Apoptosis induction was determined by measuring the combined activity of ca-
pase-3 and caspase-7, two proteins involved in the activation of apoptosis (93). Ex-
pression of NS1 in MDCK cells is known to induce apoptosis (81, 145, 195).
Furthermore, Infection of cells with delNS1 virus is known to induce apoptosis
more efficiently than infection with virus containing an NS1 gene (70, 156, 179,
191, 200), indicating that NS1 can inhibit apoptosis during an infection. With re-
spect to the apoptosis induction by NS1 expression, no significant difference in
caspase activity (Fig. 6A) or growth rate (Fig. 6B) was observed between Dox-in-
duced and non-induced NS1allBon1 and NS1allBon2 cell lines, which indicates
that allele B NS1 expression in these cells does not induce apoptosis. As a positive
control, cells were infected with delNS1, which yielded a four to nine-fold increase
in caspase activity (Fig. 6A).
We next analyzed the effect of NS1 expression by NS1allBon cells on apoptosis in-
duction by both delNS1 and H5(6)N1 virus infection. As expected, delNS1 virus
induced about 60% higher caspase activity than H5(6)N1 virus in pTet-on Ad-
vanced control cells and Dox addition did not affect caspase activity (Fig. 7A).
However, expression of NS1 24 h prior to delNS1 virus infection reduced the cas-
pase activity of NS1allBon1 cells 2.1-fold (p=0.017; Fig.7 B) and NS1allBon2 cells
2.0-fold (p=0.018; Fig. 7C). The caspase activity in the induced cells was comparable
to those in cells infected with H5(6)N1 virus. Expression of NS1 prior to infection
with H5(6)N1 virus did not affect caspase activity of NS1allBon2 cells (Fig. 7C) but
did reduce caspase activity of NS1allBon1 cells 1.4-fold (Fig. 7B) which was, how-
ever, not statistically significant (p=0.074). Thus, NS1 expression by NS1allBon
cells reduces apoptosis induction by a virus lacking an NS1 gene to a level that is
comparable with cells that are infected with a virus that contains an intact NS1
gene.
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dIsCussIon
Two stable MDCK cell lines that show inducible expression of allele B NS1 from
the A/turkey/Wisconsin/68 H5N9 influenza strain were established: NS1allBon1
and NS1allBon2. Upon induction, these cell lines showed 500 and 1200-fold lower
allele B NS1 expression levels than virus-infected cells, as assessed by Western blot
analysis. Attempts to generate stable cell lines similarly expressing either the full-
length allele A NS1 or the allele A NS1 N-terminal domain from the A/PR/8/34
H1N1 influenza strain were not successful. A previous attempt by others to estab-
lish a stable MDCK cell line expressing allele A NS1 from A/Ty/Ont/66 was also
not successful, which the authors attributed to apoptosis induction due to leaky
NS1 expression (145). Transient NS1 expression is known to induce apoptosis in
several cell lines, including MDCK (81, 145, 195). However, induction of allele B
NS1 expression in the two NS1allBon cell lines did not induce apoptosis nor did
it affect cellular growth rate. The relatively low NS1 expression level by these cell
lines is likely not the cause of the lack of apoptosis induction, since others previ-
ously found apoptosis induction at comparably low allele A NS1 expression levels
(145). Noticeably, most of the studies into the effect of transient NS1 expression
on apoptosis were done with allele A NS1. There is only one example of an H5N2
strain containing allele B NS1 that does not induce apoptosis in porcine cells (25).
The efficiency of apoptosis induction is also known to vary between allele A NS1
genes from different strains (25, 179, 180, 198). Thus, it is plausible that the suc-
cessful establishment of the NS1allBon cell lines is related to the specific allele B
NS1 gene used. One cell line with stable expression of an NS1-GFP protein was
developed for the production of delNS1 virus, however no further information on
the origin of the NS1 protein, the NS1 expression levels, virus replication efficiency
and cell growth were described (78).
Apart from apoptosis induction by recombinant NS1 expression, NS1 can also
down-regulate the induction of apoptosis due to virus infection. This is suggested
by the lower apoptotic response in cells infected with wild-type influenza virus
than in cells infected with the corresponding isogenic strains lacking a functional
NS1 gene (70, 156, 191, 200). This inhibition of the apoptotic response was attrib-
uted to activation by NS1 of the phosphatidylinositol 3-kinase (PI3K)-Akt signaling
pathway, which is known to result in an anti-apoptotic response (31, 198). We ob-
served that recombinant allele B NS1 expression suppresses the apoptotic response
induced by delNS1 virus to the same level as observed with NS1-expressing virus,
despite the 1000-fold lower NS1 expression level as compared to virus-expressed
NS1. Others similarly observed that low NS1 expression levels are enough to sat-
urate the intracellular Akt signaling pathway, leading to apoptosis suppression
(198). Other methods by which NS1 could have downregulated apoptosis are in-
hibition of PKR, OAS/RNAse L or the JNK/AP-1 stress pathway (59).
NS1 expression in both NS1allBon cell lines increased the delNS1 virus yield com-
parable to those found for Vero cells infected with the same virus. Restoration of
virus production upon recombinant allele B NS1 expression could be related to its
function as an IFN antagonist. Organisms and cells with low or absent IFN re-
sponse, like Vero cells, STAT1 or PKR knock-out mice and young embryonated
eggs, are capable of efficient delNS1 virus replication due to their IFN deficiency
(30). In addition, IFN expression in MDCK cells was reduced 5-fold after transient
expression of allele A NS1 (148). In our studies, however, the NS1 expression by
both NS1allBon cell lines had only a minor effect on IFN production, as was ob-
served in three independent assays. Different assays were used to cover multiple
levels in the IFN cascade, by looking at either activation of the IFN-β promoter,
IFN-β transcription directly or secretion of IFN, and by stimulating IFN induction
with either delNS1 virus, poly-IC or CM. Because allele B NS1 expression only has
a minimal effect on IFN induction, it appears that the increase in virus production
by recombinant NS1 during delNS1 infection is not IFN related. The lack of IFN
inhibition could be connected to the origin of the NS1 gene, since inhibition of IFN
by NS1 is strain dependent (63, 180) and allele B NS1 was found to be less efficient
in the suppression of IFN-β production than allele A NS1 (201). Another possible
cause could be the low expression level. During infection, NS1 is expressed in high
quantities, suggesting that at least one of the many functions of NS1 requires such
a high expression level. This implicates that not all of the NS1 functions, e.g. inhi-
bition of IFN induction, are necessarily complemented by the about 1000-fold
lower NS1 expression level in the NS1allBon cell lines. Another function of NS1
that likely does not occur in the NS1allBon cells upon Dox induction is inhibition
of cellular mRNA preprocessing. Such a function would most likely affect cellular
processes and limit cell division. This was however not observed, as cells grew
with comparable high rates, both induced and non-induced.
The delNS1 virus titers from induced NS1allBon cells were comparable to those
found for non-induced cells infected with H5(6)N1 virus. This indicates that the
NS1 produced by the NS1allBon cells can fully facilitate the viral infection in a
Enhanced delNS1 virus replication in NS1 expressing MDCK cell line.
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similar manner as the allele A NS1 that originates from the wild-type influenza
virus. This is in concordance with the observation that virus replication efficiency
is not dependent on the NS1 allele type (180). Replication of H5(6)N1 strain, which
yielded high titers already in the absence of Dox, was not improved by Dox-in-
duced NS1 expression. Similar observations were made after transient transfection
with NS1, although replication speed of the wild-type strain was somewhat in-
creased (148). Hence there is no significant advantage for NS1 being present at the
start of the infection. The efficiency in infectious delNS1 virus particle production,
as determined by the ratio of infectious virus particles to the number of virus
genome copy equivalent (relative infectious virus titer), is 0.1% for both NS1allBon
cell lines in the absence of Dox. Induction of NS1 expression increased the effi-
ciency 11 to 95-fold, due to the strong increase in infectious virus titer (244 to 544-
fold). This is especially relevant for live attenuated vaccine production, since these
rely on infectious virus particles.
The increased relative infectious titer due to NS1 induction may give a clue to the
mechanism by which recombinant NS1 can complement the replication of delNS1
virus. NS1 regulates viral genome replication and transcription (36), and NS1 ex-
pression reduces viral RNA accumulation in cells transiently transfected with the
influenza polymerase complex genes PB1, PB2, PA and NP, in comparison to cells
that do not express NS1 (180). The lack of regulation of the influenza polymerase
complex by NS1 could result in an altered ratio between the vRNA, cRNA and
mRNA, resulting in lower infectious viral titers while not affecting the number of
virus genome copy equivalent titer, which measures all three RNA types. Thus,
the low yield of delNS1 virus in normal MDCK cells could be due to the loss of
NS1 regulation of viral genome replication and transcription rather than the in-
ability of the virus to interfere with the host cell’s antiviral response. This sugges-
tion is further supported by the observation that IFN expression is not a limiting
factor for influenza replication in MDCK cells (148).
The inducible expression of NS1 allows for further studies into the timing and
level of NS1 expression in relation to its function. Furthermore, these cells are able
to replicate delNS1 virus to high titers required in industrial production. The re-
quirement for Dox in the culture medium may however limit their commercial ap-
plication due to restriction in use of antibiotics in vaccine production. Thus, stable
production cell lines with constitutive expression of allele B NS1 are more suited
for this purpose. The feasibility of establishing such cell lines is suggested by our
Enhanced delNS1 virus replication in NS1 expressing MDCK cell line.
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observation that allele B NS1 expression does not affect cell growth (nor induce
apoptosis). Finally, the use of allele B NS1 may be advantageous for the production
of DIVA vaccines, because of the antigenic difference with the more common allele
A protein.
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absTraCT
Influenza viruses unable to express NS1 protein (delNS1) replicate poorly and in-
duce high amounts of interferon (IFN). They are therefore considered as candidate
viruses for live-attenuated influenza vaccines. Their attenuated replication is ge-
nerally assumed to result from the inability to counter the antiviral host response,
as delNS1 viruses replicate efficiently in Vero cells, which lack IFN expression. In
this study, delNS1 virus was parallel passaged on IFN competent MDCK cells,
which resulted in two strains that were able to replicate to high virus titres in
MDCK cells due to adaptive mutations in especially the M-gene segment, but also
the NP and NS gene segments. Most notable were clustered U-to-C mutations in
the M segment of both strains and clustered A-to-G mutations in the NS segment
of one strain, which presumably resulted from host cell mediated RNA editing.
The M segment mutations in both strains changed the ratio of M1 to M2 expres-
sion, probably by affecting splicing efficiency. In one virus, 2 amino acid substitu-
tions in M1 additionally enhanced virus replication, possibly through changes in
the M1 distribution between the nucleus and the cytoplasm. Both adapted viruses
induced less IFN and less apoptosis compared to delNS1 virus, but still signifi-
cantly more than virus able to express NS1. These results indicate that not only in-
hibition of IFN induction, but also the loss of one or more M1-related functions of
NS1 limit delNS1 virus replication. The mutations identified in this paper may be
used to enhance delNS1 virus replication for vaccine production.
Role of M segment in delNS1 inﬂuenza replication.
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InTroduCTIon
The non-structural (NS1) protein of influenza A virus is an antagonist of the cel-
lular antiviral response. Infection with virus either not encoding NS1 protein
(delNS1) or encoding a truncated NS1 protein results in high levels of type I inter-
ferons (IFN) such as IFN-α or IFN-β. Replication in cell culture of such viruses is
attenuated, indicating that the NS1 protein is not essential for replication in such
hosts (45). In vivo, viruses lacking a fully functional NS1 protein induce IFN in
the absence of detectable virus replication (38), which are favourable conditions
for use as live attenuated vaccines. The local release of IFN and other cytokines
and chemokines appears to be an excellent adjuvant that enhances production of
immunoglobulins and contributes to the activation of dendritic cells required for
antigen presentation (83, 132). DelNS1 candidate vaccines against influenza A and
B have been developed (140, 189) and initial trials in humans showed successful
induction of antibody responses (175). Apart from the use in vaccines, delNS1
viruses also show potential as oncolytic agent (113) and viral expression vector
(187).
NS1 is expressed at high levels directly after infection and facilitates virus replica-
tion in many different ways (reviewed in (59)). Its antiviral properties are focused
on reducing the IFN mediated innate immune response and act at several levels.
Cytoplasmic dsRNA and 5’-triphosphate-containing RNA are produced during
influenza infection and recognized as pathogenic patterns by antiviral proteins
like retinoic-acid inducible gene I (RIG-I), dsRNA-dependent protein kinase R
(PKR) and 2’-5’-oligoadenylatesynthetase (OAS). NS1 binds both dsRNA and RIG-
I, and blocks the activation of PKR and OAS, thereby limiting the onset of several
pathways that lead to IFN induction (132). Other functions of NS1 are inhibition
of cellular pre-mRNA processing (including IFN pre-mRNA) and mRNA nuclear
export (59). Furthermore, NS1 regulates both viral genome replication and trans-
lation (180), splicing of M segment mRNA (134), nuclear export of viral mRNA
(41) and viral ribonucleoprotein (vRNP) (180), and viral protein synthesis (26, 34).
Recently it was found that NS1 binds the human PAF1 transcription elongation
complex (hPAF1C) by a histone-mimicking sequence, thereby inhibiting the role
of hPAF1C in the antiviral response (98). NS1 mRNA is transcribed from the eighth
vRNA segment. It is partially spliced to generate mRNA that encodes the nuclear
export protein (NEP) (59). In the nucleus of infected cells, NEP facilitates the export
of the vRNP complexes containing the viral genome segments to the cytoplasm,
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where assembly of the viral components is completed before virus budding takes
place (2). Independent from vRNP export, NEP also regulates viral genome tran-
scription and replication (135). During development of delNS1 strains it is there-
fore essential to retain the NEP protein.
In cells and animals with a low or absent IFN response, such as Vero cells, STAT1
or PKR knock-out mice, delNS1 virus replicates to high titres (30, 45, 77), whereas
replication is attenuated in MDCK cells and other IFN-competent hosts. When
Vero cells are externally stimulated with IFN-α before infection, delNS1 virus repli-
cation is however also attenuated (38). Moreover, delNS1 only replicated efficiently
in embryonated chicken eggs younger than 8 days, when the host immune re-
sponse is not yet fully developed (161). It is therefore generally assumed that the
inability of delNS1 virus to counter the cellular innate immune response is the
major cause for its attenuated phenotype (132). In addition to the unimpaired IFN
response, the absence of NS1 during influenza virus infection results in enhanced
apoptosis induction (156, 200). Activation of caspases, a group of cysteine proteases
that play an important role in apoptosis, results in cleavage of viral NP protein
and thereby limits the amount of viral protein available for assembly of viral par-
ticles (199). The antiviral effect of apoptosis is therefore believed to contribute to
the attenuated replication of delNS1 virus. Inhibition of the apoptotic response is
attributed to both the activation by NS1 of the phosphatidylinositol 3-kinase
(PI3K)-Akt signalling pathway, which is known to result in an anti-apoptotic re-
sponse (31, 198), as well as the inhibition of IFN. IFN sensitizes cells for apoptosis
(200) through its transcriptional induction of PKR (162) and activation of the
FADD/caspase-8 death signalling pathway (10). The role of apoptosis in influenza
infection is, however, still uncertain as several influenza proteins, including NS1,
also exhibit pro-apoptotic functions. Furthermore, influenza virus replication is
impaired in the presence of caspase inhibitors (190), which appears to be caused
by retention of vRNA complexes in the nucleus, preventing formation of progeny
virus particles. A possible explanation for this double role of NS1 in apoptosis reg-
ulation could be prevention of cell death by inhibition of apoptosis early in the in-
fection, followed by induction at a later stage (198). Ludwig et al. (93) suggested
that caspases enhance vRNP export from the nucleus later in the infection by
widening of the nuclear pores, thereby allowing diffusion of vRNP out of the nu-
cleus. 
Previously we showed that delNS1 virus can efficiently be propagated on a MDCK
cell line showing inducible expression of NS1 from a trans-complementing ge-
nomic gene (170). A 500-fold increase in infectious virus titre was observed, even
though the NS1 level was 1000-fold lower than that in cells infected with wild-
type (WT) virus. Furthermore, apoptosis was reduced to similar levels as found
in WT virus infected cells, whereas the induction of IFN by delNS1 virus was not
significantly reduced in these cells. Because of the limited effect on IFN induction,
we then hypothesized that the low yield of delNS1 virus on normal MDCK cells
could be caused by loss of other NS1 regulatory function rather than the inability
of the virus to interfere with the host cells antiviral response. In this paper we in-
creased the replication efficiency of delNS1 virus by adaptation to IFN competent
MDCK cells during serial passage. Next, we determined if the observed increase
in virus yield was related to decreased IFN and apoptosis induction. Furthermore,
we identified the mutations and partly characterized the mechanism that allowed
the virus to efficiently replicate in the absence of the NS1 protein. 
MaTerIals and MeTHods
Cell culture and virus strains
MDCK-SFS cells (171) were grown in suspension in serum-free SFM4BHK21
medium (Hyclone, Waltham, MA), supplemented with 8 mM glutamine, 5 mg/L
phenol red and 1.5 g/L sodium bicarbonate, or adherent in serum-free UltraMDCK
medium (Lonza Biowhittaker, Basel, Switzerland) supplemented with 4 mM glu-
tamine. Adherent NS1Bon2 MDCK cells (170) were also grown in UltraMDCK
medium, additionally supplemented with 200 µg/ml G418 (Promega, Fitchburg,
WI) and 100 µg/ml hygromycin B (Clontech, Mountain View, CA). G418 and hy-
gromycin were not used during virus infections. Human embryo kidney (293T)
cells were cultured in Glutamax medium (Invitrogen, Carlsbad, CA) supplemented
with 10% FBS. All culture media were provided with 100 units/ml penicillin and
100 µg/ml streptomycin (Gibco). Cells were grown at 37˚C and 5% CO2. Suspen-
sion cells were grown in shaker flasks at 100 rpm. Cell density and viability were
determined with a Countess automated cell counter (Invitrogen).
The influenza delNS1 virus strain (170) used for the adaptation to MDCK-SFS cells
was previously passaged 10 times in 7-day old embryonated chicken eggs and is
referred to as delNS1EA. Note that in the comparison of reassortant virus replica-
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tion, protein expression, apoptosis and IFN-induction, a non-adapted delNS1 virus
strain was used, to which we refer as delNS1. The isogenic H5(6)N1 virus (170)
strain containing the complete NS segment was passaged once in 9-day old em-
bryonated eggs after virus rescue, and is referred to as wild-type (WT) virus. The
infectious influenza virus titre was measured by determining the tissue culture in-
fective dose required to infect 50% (TCID50) of MDCK cells, as previously de-
scribed (171). All virus strains were propagated on the NS1 expressing NS1Bon2
MDCK cell line to generate virus seed stocks with high infectious virus titres (>7
log10 TCID50/ml) prior to further viral characterization. For this purpose, NS1 ex-
pression was induced in this cell line 24 h before infection by addition of 1 µg/ml
doxycycline (Clontech) to the culture medium, followed by infection at multiplicity
of infection (m.o.i.) 0.01 and harvesting at 3 days post-infection (dpi).
Virus adaptation
Two independent adaptation experiments were performed. In the first experiment,
MDCK-SFS cells in suspension were infected with delNS1EA at m.o.i. 0.1. After 2-
3 days the supernatant was collected and used for subsequent infection of fresh
MDCK-SFS cells with unknown m.o.i.. The virus was serially passaged 10 times
in this manner. In the second adaptation experiment 5 serial passages were per-
formed, starting with infection of adherent MDCK-SFS cells with delNS1EA at m.o.i.
0.01. The infectious virus titre was determined daily and the supernatant with the
highest titre was used in subsequent infection of fresh MDCK-SFS cells at m.o.i.
0.01. The two adapted virus strains were cloned 3 times by limiting dilution on
MDCK-SFS cells. Of each adapted strain, eight clones were screened for virus repli-
cation on MDCK-SFS cells and one clone of each strain with high titre was selected
and amplified on NS1Bon2 cells. The resulting strains are referred to as delNS1CA1
and delNS1CA2 respectively.
Plasmids
Ten plasmids containing single or multiple mutations found in delNS1CA1 and
delNS1CA2 (Table 1) were made. Viral RNA of delNS1CA1 and delNS1CA2 was iso-
lated from seed virus and HA and M gene segments were amplified by PCR, using
primers with BsmBI restriction sites (68). The resulting cDNAs were inserted in
plasmid pHW2000 to create pROM33-pROM36. Plasmids containing the mutated
PB1 segments of delNS1CA1 and delNS1CA2 could not be made. pROM16 was made
by cloning a synthetic 675 bp BsrGI-NgoMIV fragment (GenScript Corporation,
Piscataway, NJ) containing mutation A1381G in pHW195 containing the PR8 NP
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Table 1. pHW2000-derived plasmids encoding mutant gene segments from cell-adapted delNS1
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gene (66). Synthetic fragments with suitable BsmBI restriction sites comprising the
complete M segment with one or more of the CA2 mutations or the complete
delNS1 NS segment with all six CA1 mutations were inserted in pHW2000 to con-
struct pROM13 and pROM51-pROM54. All plasmid inserts were sequenced to en-
sure the absence of additional nucleotide substitutions.
rescue of recombinant influenza virus
To generate recombinant influenza virus, a mixture of 1.5 x 106 293T and 5 x 105
MDCK-SFS cells were transfected with equal amounts of the eight plasmids con-
taining the different gene segments, using Fugene HD (Roche Applied Science,
Penzberg, Germany). DelNS1 viruses were made using plasmids pHW191,
pHW192, pHW193, pHW195, pHW197 (66), pPolsabrib H5, pPolsabrib N1 and
pHW NEP (170), whereas WT virus was made by replacing pHW NEP with
pHW198, which contains the full length NS segment. All other recombinant
viruses were made by replacing one or more plasmids with those in Table 1. At 24
h post-transfection (hpt) the transfection mixture was replaced by Glutamax
medium supplemented with 0.3 % bovine serum albumin (Chemie Brunschwig
AG, Basel, Switzerland) and 1 µg/ml TPCK-trypsin (Sigma-Aldrich, St. Louis, MO).
Virus was harvested at 96 hpt. Virus stocks were generated using NS1Bon2 cells
as described above and virus identity was confirmed by sequence analysis. Reas-
sortant delNS1 virus strains are referred to as delNS1, followed by the mutated
gene segment(s) it contains (Table 1) and the adapted virus from which they orig-
inate (e.g. delNS1:[NP M]CA1, which contains the mutated NP and M gene seg-
ments from delNS1CA1). 
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Virus genome sequencing
Viral RNA genomes were isolated using a high pure viral RNA isolation kit (Roche
Applied Science). Universal influenza genome primer uni12 (68) was used for re-
verse transcriptase reactions with the Superscript III first strand synthesis system
(Invitrogen), followed by segment specific PCR reactions with an Expanded high
fidelity PCR system (Roche Applied Science). DNA sequencing was performed at
Baseclear (Leiden, the Netherlands) and sequence analysis was done with Laser-
gene (DNASTAR Inc, WI).
Comparison of virus replication
To study the infection kinetics of the different virus strains, 106 MDCK-SFS cells
per well were incubated in 6-well plates (Greiner Bio-One), in 5 ml UltraMDCK
medium containing 2 µg/ml trypsin-TPCK. Cells were infected in triplicate at m.o.i.
0.01. Supernatant was sampled at the indicated interval and stored at -80°C before
determining the infectious virus titre. The main effect and interactions of the mu-
tated gene segments on the infectious virus titre was analysed by a repeated meas-
ures ANOVA with data from two infection experiments, both performed in
triplicate, using R statistical software package (R Foundation for Statistical Com-
puting, Vienna, Austria). Analysis was performed separately for delNS1CA1 and
delNS1CA2 reassortants datasets, with the mutated gene segments as explanatory
variables, the two infection experiments as random effects and delNS1 virus as the
baseline. Non-significant explanatory variables were excluded from the model.
Ifn reporter assay
MDCK-SFS cells were allowed to attach to the surface of eight 96-well plates
(Greiner Bio-One) for 1 h (4.5 x 104 cells/well) and then transiently cotransfected
with a reporter plasmid carrying a firefly luciferase gene under control of the IFN-
β promoter (p125Luc, kindly provided by Takashi Fujita, Kyoto University, Japan
(193) and a Renilla luciferase control plasmid pGL4.73 (Promega), using Fugene
HD. The next day, supernatant was removed and cells were infected in triplicate
(m.o.i. 5) with WT, delNS1, delNS1CA1 or delNS1CA2, or mock infected. One hour
later, supernatant was replaced with fresh medium. At 8, 10, 14, 16, 18, 20, 22 and
24 hour post-infection (hpi) one plate was stored at -20˚C without supernatant.
The firefly luciferase activity of all plates was measured with a GloMax-Multi lu-
minometer (Promega) using the Dual Luciferase Reporter Assay System (Promega)
and normalized to the Renilla luciferase activity.
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apoptosis assay
MDCK-SFS cells were allowed to attach to the surface of six 96-well plates (Greiner
Bio-One) for 1 h (104 cells/well) and infected in sextuple with WT, delNS1,
delNS1CA1 or delNS1CA2 virus (m.o.i. 5), or mock infected. One hour later, super-
natant was replaced with fresh medium. At 10, 14, 16, 19, 22 and 26 hpi, one plate
was stored at -20˚C without supernatant. Apoptosis was determined by the activity
of caspase-3 and caspase-7 using Caspase-Glo 3/7 Assay (Promega). Caspase-Glo
reagent, diluted 1:1 with PBS, was added to the frozen cells (50 µl/well). After 1.5
h incubation at room temperature, the luminescence was measured with a Glo-
Max-Multi luminometer. 
Western blot analysis of M1 and M2 expression
MDCK-SFS cells were allowed to attach to the surface of 24-well plates (Greiner
Bio-One) for 1 h (3.3 x 105 cells/well) and infected (m.o.i. 5) or mock infected, in
triplicate. HEK293T cells (106 cells/well in 6-well plates) were transiently trans-
fected in triplicate, using Fugene HD with either 2 µg/well pHW195, pROM35,
pROM36, pROM51, pROM52, pROM53, pROM54 (Table 1) or mock transfected.
At 10 hpi or 48 hpt, cells were lysed with reducing NuPAGE sample buffer con-
taining in addition complete EDTA-free protease inhibitor cocktail (Roche). Sam-
ples were sheared with a 21G needle, incubated for 10 min at 75°C and loaded
onto NuPAGE® Novex® 12% Bis-Tris precast gels (Invitrogen). Polypeptides were
transferred to polyvinylidenedifluoride membranes and detected by immunoblot-
ting using monoclonal mouse antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA) against M1 (SC-57881, 0.2 µg/ml) or M2 (SC-32238, 0.4 µg/ml). After subse-
quent incubation with peroxidase-conjugated rabbit anti-mouse immunoglobulins
(0.13 µg/ml; Dako, Glostrup, Denmark), proteins were visualized with ECL plus
(GE Healthcare, Buckinghamshire, UK) and quantified with a Storm840 imaging
system (Molecular Dynamics, GE Healthcare). The M1/M2 band intensity ratio of
each sample was calculated before determining the mean ratio of the triplicate in-
fections or transfections. 
subcellular M1 localization
MDCK-SFS cells were cultured in suspension (6.6 x 105 cells/ml) and infected with
WT, delNS1 or delNS1:MCA2.3 in triplicate (m.o.i. 5). At 6 and 10 hpi, 106 cells were
harvested and cytoplasmic and nuclear extracts were prepared with the NE-PER
nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific, Rockford, IL), ac-
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cording to the manufacturer’s description. However, complete EDTA-free protease
inhibitor cocktail was added to the extraction reagents. Cytoplasmic and nuclear
extractions were subjected to reducing SDS-PAGE and Western blot analysis as
described above. Polypeptides were detected by immunoblotting as described in
the previous section with monoclonal mouse antibodies (Santa Cruz Biotechnol-
ogy) against lamin A/C (SC-7292, 0.2 µg/ml), tubulin (SC-5286, 0.2 µg/ml) or M1
(SC-57881, 0.2 µg/ml). Cytoplasmic and nuclear specific proteins tubulin and lamin
A/C were used to assess the purity of nuclear and cytoplasmic extracts. The
amount of M1 protein was corrected for the extraction efficiency by either tubulin
(cytoplasmic extracts) or lamin A/C (nuclear extracts). The ratio of corrected nu-
clear M1 to corrected cytoplasmic M1 was calculated before determining the mean
ratio of the triplicate infections.
resulTs
delns1 virus adaptation
The egg-adapted influenza virus delNS1EA replicated poorly in MDCK cells, reach-
ing a maximum infectious virus titre that was 104-fold lower than that of WT virus
(Fig. 1A). To investigate whether the virus was able to overcome the negative effect
of the NS1 deletion by acquiring compensating mutations we serially passaged
delNS1EA virus on MDCK-SFS cells in two independent adaptation experiments
(see Materials and Methods). In the first cell adaptation experiment (CA1), virus
was blindly passaged 10 times. In the second experiment (CA2), virus taken from
the time point where the titre was maximal was used to infect cells in the next pas-
sage at a controlled m.o.i. of 0.01. Both adaptation experiments on MDCK-SFS cells
resulted in virus populations with increased replication rate and increased maxi-
mum titres compared to the parent strain. The maximum virus titre of strain
delNS1CA2 increased during the first 3 to 4 passages, but did not increase further
during the fifth passage (Fig. 1B). To obtain clonal virus, the adapted strains were
further cultured during 3 limiting dilution steps on MDCK-SFS cells. The infec-
tious virus titres of the resulting cloned cell-adapted virus strains delNS1CA1 and
delNS1CA2 were about 250-fold higher than the parental delNS1EA virus titre, but
remained 25-fold lower than the WT virus titre (Fig. 1A). 
sequence analysis of adapted virus
All eight gene segments of the delNS1CA1 and delNS1CA2 virus strains and their
parental delNS1EA strain were sequenced (Table 2). No mutations were found in
the PB2, PA and NA segments. The delNS1EA virus contained two mutations in
PB1 and one in HA with all mutations present in approximately 50% of the virus
population. These mutations were silent and must have arisen during the passag-
ing in eggs. Both PB1 mutations were present in both cell adapted viruses, whereas
the HA mutation was only present in delNS1CA2 virus. Due to the presence of mu-
tations in the delNS1EA virus, a non-adapted delNS1 virus was used in the com-
parison of reassortant virus replication, protein expression, apoptosis, and
IFN-induction experiments. We refer to this virus as delNS1.
Compared to delNS1EA virus, delNS1CA1 virus had 13 additional mutations, includ-
ing a silent mutation in PB1, F257L in HA, R446G in NP, four silent U-to-C muta-
tions in M, and six A-to-G mutations in the delNS1 segment. Three of the NS
segment mutations resulted in the amino acid substitutions Y41C, M52V and I76V
in the NEP protein. The first 4 A-to-G mutations in the NSCA1 segment are located
on the part that normally encodes NS1, resulting in two amino acid substitutions
at the NS1 C-terminal. These mutations may be disadvantageous to the WT virus
and removal of the NS1 ORF therefore increased the freedom of this segment to
acquire mutations. DelNS1CA2 virus had 6 additional mutations that were all lo-
fig. 1. Replication of delNS1 virus adapted to growth on MDCK-SFS cells. (A) Replication kinetics of the two
adapted delNS1CA1 and delNS1CA2 virus strains in comparison to WT and parental delNS1EA virus after infection
of MDCK-SFS cells at MOI 0.01. Geometric mean titres and 95% conﬁdence interval of the mean of virus infec-
tions performed in triplicate are presented. (B) Increase in maximum infectious virus titre during each passage
step of the second delNS1 adaptation experiment.
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Table 2. Mutations in egg adapted delNS1EA and cell adapted delNS1CA1 and delNS1CA2 virus strains.
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cated in the M segment. These mutations started to appear simultaneously at pas-
sage 4 and had increased at passage 5 (Fig. 2A). Again, these 6 mutations were all
U-to-C mutations, two of which resulted in amino acid changes V97A and Y100H
in M1. Notably, all mutations on the M and NS segments are clustered in regions
of 50-100 nucleotides. Both M segment mutation clusters are located on a region
of the M1 mRNA that is removed by splicing to generate the M2 mRNA and thus
do not affect M2 mRNA structure (Fig. 2B). Apart from the two silent mutations
in PB1 which were already present in the initial delNS1EA virus, both parallel adap-
tations did not lead to identical mutations.
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fig. 2. Nucleotide substitutions in M-gene segments of adapted delNS1 viruses. (A) Sequence analysis of
delNS1CA2 showing the simultaneous accumulation of six U-to-C substitutions (indicated by arrows) in the M seg-
ment vRNA between position 277-325 from passages 3 to 5 on MDCK-SFS cells. Double peaks are visible at pas-
sage 4 and 5. Note that in the electropherograms, U is shown as T. (B) Schematic overview of the M segment
mRNAs, with the locations of the adaptive MCA1 and MCA2 mutations and splicing products M2 mRNA and mRNA3.
Open reading frames are indicated by thick bars. (C) Nucleotide sequences of the MCA1 and MCA2 regions shown
in panel B, including the amino acid sequence of MCA2, where dots indicate sequence identity of M1CA2 to M1WT.
The square box indicates the location of the NLS in M1, with positively charged (+) amino acids (192). The arrow
indicates the location of the adaptive mutation in inﬂuenza B M protein found earlier (189). The amino acid se-
quence of M1CA1 is not shown since it is identical to M1WT (i.e. all mutations were silent).
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Interferon-β and apoptosis induction by cell adapted delns1 virus
To assess if viral adaptation affected IFN-β expression, cells were transfected with
a firefly luciferase reporter gene under control of an IFN-β promoter and subse-
quently infected with WT, delNS1, delNS1CA1 or delNS1CA2 virus at high m.o.i. (Fig.
3A). The low luciferase activity of cells infected with WT virus as compared to cells
infected with delNS1 virus indicates inhibition of IFN induction by NS1. Both cell-
adapted viruses induced more IFN than the WT virus, but less than delNS1 virus.
Furthermore, IFN induction appeared delayed in comparison to delNS1 virus. 
The induction of apoptosis was determined by measuring the activity of caspase-
3 and caspase-7, two proteases that are induced late in the apoptosis pathway.
Again, the inhibiting effect of NS1 was visible as little caspase activity was seen in
cells infected with the WT virus in comparison to cells infected with delNS1
viruses. Furthermore, both cell-adapted viruses induced more caspase activity
than WT virus but less than delNS1 virus (Fig. 3B).
Infection with delns1 viruses containing mutated gene segments
The effect of each mutated gene segment on the infectious virus titre, and possible
interactions between the gene segments was determined by employing a full-fac-
torial analytical approach. MDCK-SFS cells were infected with reassortant delNS1
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fig. 3. Induction of IFN-β (A) and apoptosis (B) in MDCK-SFS cells infected with either delNS1, WT, delNS1CA1 or
delNS1CA2 virus, or mock infected. IFN induction was measured with an IFN-β dependent luciferase reporter con-
struct and corrected for transfection eﬃciency with Renilla luciferase. Apoptosis induction was assessed by
measuring the activity of caspase 3 and 7. Mean activities and 95% conﬁdence interval of the mean are presented
of experiment performed in triplicate.
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viruses consisting of all 15 possible combinations of delNS1CA1 virus HA, NP, M
and NS gene segments, or the 3 possible combinations of delNS1CA2 virus HA and
M gene segments (Fig. 4A). All reassortant viruses contained the WT PB1 segment,
as we were unable to generate plasmids containing the mutated PB1 segments. In-
fectious virus titres were examined using a repeated measures ANOVA, so as to
determine the relative importance of the gene segments, and possible interactions
between gene segments, on virus replication. Segments with significant effect on
the delNS1CA1 virus titre were NSCA1, MCA1 and NPCA1, with coefficients of respec-
tively 0.68, 0.76 and 0.50 (all p<0.001). These coefficients specify the average in-
Role of M segment in delNS1 inﬂuenza replication.
fig. 4. Comparison of infectious virus titres (3 dpi) after infection of MDCK-SFS cells with the cell-adapted or the
various reassortant virus strains. (A) Titres of delNS1 reassortant viruses made with original delNS1 plasmids
(not-ﬁlled), or plasmids containing single or multiple mutations originating from the adapted virus strains
delNS1CA1 (ﬁlled, marked 1) and delNS1CA2 (ﬁlled, marked 2). (B) Titres of delNS1 reassortant viruses containing
one or more of the delNS1CA2 M segment mutations and of WT reassortant virus containing the MCA2 mutations.
In both panels, geometric mean titres and 95% conﬁdence interval of the mean are presented of triplicate meas-
urements. 
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crease of the virus titre in log10 TCID50/ml, when the mutated segment was in-
cluded in the delNS1 reassortant strain. There was also an interaction effect be-
tween the mutated M and NP segments of -0.36 (p<0.05), which indicated an
average decrease in virus titre when the mutated M and NP segments were com-
bined in the delNS1 virus. Thus, the enhanced delNS1CA1 virus replication was the
effect of these three mutated gene segments together. The enhanced replication of
delNS1CA2 was determined by the mutated M segment alone (Fig. 4A). This obser-
vation was confirmed by statistical analysis, which appointed a coefficient of 2.0
(p<0.001) to MCA2, indicating that the 100-fold increase in virus titre was solely de-
termined by the M segment mutations. Reassortant virus containing all mutated
gene segments (delNS1:[HA NP M NS]CA1 and delNS1:[HA M]CA2) replicated
equally well as the virus from which their segments originated, delNS1CA1 and
delNS1CA2, indicating that the mutated PB1 gene segments did not contribute to
the enhanced virus replication.
Because the M segment plays a major role in increased replication of both adapted
viruses, we further focused on the mechanism by which mutations in this segment
could overcome the decreased replication in the absence of NS1. To determine
which individual MCA2 mutation was responsible for virus titre increase, four ad-
ditional mutant virus strains were made containing either the V97A or Y100H mu-
tation, the combination of V97A and Y100H, or the remaining four silent mutations
(Fig. 4B). When compared to delNS1, the two strains with single amino acid sub-
stitutions did not replicate more efficiently. However, when V97A and Y100H were
combined in delNS1:MCA2.3, a 50-fold increase in virus titre was observed. Further-
more, the four silent mutations increased the virus yield approximately 10-fold,
as indicated by the comparison of delNS1 to delNS1:MCA2.4 and delNS1:MCA2.3 to
delNS1CA2. Interestingly, when introduced into the WT virus, the MCA2 segment
decreased replication (Fig. 4B). 
effect of M segment mutations on M1 and M2 protein expression
To determine if the M segment mutations affected splicing of the M1 mRNA (Fig.
2B) we measured the ratio of M1 and M2 protein expression in cells at 10 hpi by
Western blot analysis (Fig. 5A). The M1 protein of all Y100H mutant viruses
(delNS1:MCA2, delNS1:MCA2.2 and delNS1:MCA2.3) migrated slightly slower in SDS-
PAGE than that of the other virus strains (Fig. 5A, lanes 4, 6 and 7 respectively).
Slight changes in mobility in SDS-PAGE due to amino acid changes that affect pro-
tein charge, such as Y100H, have been observed before (130).
Chapter 5
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fig. 5. Western blot analysis of M1 and M2 protein expression 10 h after infection of MDCK-SFS cells (A) or 48 h
after transient transfection of HEK293T cells (C) with plasmid (Table 1) containing either the WT M segment
(pHW197), the mutated MCA1 or MCA2 segments (pROM36 and pROM35), or the M segment containing one or
more delNS1CA2 mutations (pROM51-54). M1 and M2 protein levels of three independent experiments were
quantiﬁed using densitometry. The M1/M2 ratio for each virus (B) or plasmid (D) is shown as the mean and 95%
conﬁdence interval of the mean. Lanes 1-4 and lanes 5-8 in panel A originated from two diﬀerent blots.
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Cells infected with delNS1 virus (Fig. 5A, lane 2) appeared to express more M2
protein than WT virus infected cells (Fig. 5A, lane 1). This difference was consis-
tently observed in several experiments, even though the difference in M1/M2 ratio
was not statistically significant from that of the WT virus (Fig. 5B). Infection with
virus containing the mutated M segments, delNS1:MCA1 (Fig. 5A, lane 3) and MCA2
(Fig. 5A, lane 4), resulted in an M1/M2 ratio that was 2- and 3-fold higher, respec-
tively, than that of delNS1 (Fig. 5B). Virus containing only the single or double M1
amino acid mutations (delNS1:MCA2.1, MCA2.2 and MCA2.3, Fig. 5A lanes 5, 6 and 7)
showed an M1/M2 ratio similar to delNS1, whereas delNS1:MCA2.4 virus (contain-
ing the 4 silent MCA2 mutations) showed a 2-fold increase (Fig. 5A lane 8 and Fig.
5B). The effect of the mutations on M1 and M2 expression was confirmed by trans-
fection of HEK293T cells with plasmids encoding the different M segments (Fig.
5C). The M1/M2 ratio of cells transfected with WT M segment (0.35; Fig. 5D), is
comparable to that of delNS1 infected cells (0.42; Fig. 5B). The M1/M2 expression
ratio was higher with segments containing the original mutations acquired during
the adaptation (MCA1 and MCA2) and with the MCA2 segment containing the four
silent mutations (MCA2.4 ; Fig. 5C lanes 3, 4 and 8), but not with the MCA2 segments
containing one or both of the non-silent mutations (Fig. 5C lane 5, 6 and 7). Taken
together, these results show that both cell-adapted viruses acquired mutations that
increased the M1/M2 protein ratio in infected cells.
effect of M1 amino acid substitutions on subcellular localization
The M1 mutations V97A and Y100H present in delNS1CA2 are located close to the
NLS at position 101-105 (Fig. 2C). To determine whether they affected the subcel-
lular localization of M1 protein, cells were infected with WT, delNS1 or
Chapter 5
fig. 6. Subcellular localization of M1 protein. MDCK-SFS cells were infected with WT, delNS1 and delNS1:MCA2.3
virus at high MOI in triplicate. Then, cytoplasm and nucleoplasm fractions were prepared at 6 hpi and 10 hpi
and M1 protein was quantiﬁed by Western blot analysis. Tubulin (Tub) and lamin A/C (Lam) were used as cyto-
plasm and nucleoplasm speciﬁc controls, respectively. Panel (A) shows one representative Western blot. (B) M1
protein levels were quantiﬁed by densitometry using tubulin and lamin A/C, respectively, as controls to com-
pensate for the isolation eﬃciency. The ratio of corrected nuclear M1 (M1n) to corrected cytoplasmic M1 (M1c)
was used to determine changes in the distribution of M1 and is shown as the mean and 95% conﬁdence interval
of the mean at 6 hpi (empty bars) and 10 hpi (ﬁlled bars). 
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delNS1:MCA2.3 virus and the nucleoplasm and cytoplasm was isolated early (6 hpi)
and late (10 hpi) in the infection process. The level of M1 present in both compart-
ments was then determined by Western blot analysis and quantified by densito-
metry (Fig. 6A and B).
At 6 hpi, the ratio of nuclear to cytoplasmic M1 was comparable between WT and
delNS1 virus infected cells (Fig. 6B). Four hours later, this ratio remained constant
in WT virus infected cells whereas it was 4-fold lower in delNS1 virus infected
cells, mainly due to a decrease in nuclear M1. Thus, NS1 appears to affect the con-
centration of M1 in the nucleus late but not early in the infection. The mutant virus
containing only M1 amino acid substitutions V97A and Y100H showed a higher
ratio at early stages, although this did not significantly differ from the ratio of the
other two viruses. At 10 hpi nuclear M1 was not detectable anymore, thereby re-
ducing the localization ratio below that of delNS1 infected cells.
dIsCussIon
The low yield of delNS1 virus on MDCK cells is assumed to be caused by the in-
ability of this virus to inhibit the antiviral host response (45). In this study, we ob-
tained two delNS1 influenza virus variants that replicated to 250-fold higher
infectious virus titres (TCID50) after two parallel, serial passages on MDCK cells.
Both adapted delNS1 virus variants induced IFN and apoptosis to a somewhat
lower level than the original delNS1 virus, but still significantly higher than the
WT virus. Apoptosis is linked to IFN induction (10, 162, 200) and early onset of
apoptosis limits virus replication. IFN induction results from activation of the in-
nate immune system by pathogen associated molecular patterns, but is inhibited
by viral factors such as influenza virus NS1. It is unlikely that the lower IFN in-
duction by the adapted viruses results from the appearance of a new IFN inhibitor
and therefore, most probably, results from a lower activation of the IFN response.
Enhanced influenza RNA production increases IFN levels (11) and influenza viral
RNA accumulates in the absence of NS1 (180). It may therefore be possible that
the adapted viruses produce less RNA than the delNS1 virus, resulting in a lower
IFN activation. However, the adapted virus strains still induce a significant amount
of IFN and lower RNA production may therefore not fully explain the considerable
increase in titres. Several recent studies suggest that IFN has a minor effect on in-
fluenza replication in MDCK cells because canine myxovirus resistance proteins
lack anti-influenza activity (148) and secreted IFN is proteolytically degraded by
Chapter 5
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trypsin, which is normally present during influenza production on MDCK cells
(149). Furthermore, delNS1 virus titres could be increased by recombinant NS1
expression, without lowering IFN induction (170), indicating that IFN induction
in MDCK may play a less important role than generally assumed.
The two adapted viruses contained a high frequency of either A-to-G or U-to-C
substitutions (19 out of 22) that occur mostly (16 out of 22) in three clusters in MCA1,
MCA2 and NSCA1 gene segments. Furthermore, all mutations in MCA2 appeared to
be acquired at the same time. Taken together, this suggests that these substitutions
result from hyperediting by adenosine deaminases acting on RNA (ADAR), which
cause A-to-G substitutions in RNA (143). Hyperediting of the influenza genome
by ADAR has previously been reported (158). The occurrence of both A-to-G and
U-to-C substitutions can be explained by hyperediting of the positive sense cRNA
as well as the negative sense vRNA, respectively. Interestingly, ADAR1 is induced
by IFN and is believed to have an antiviral role during influenza infection (143).
Furthermore, NS1 interacts with ADAR1, suggesting that it inhibits ADAR1 func-
tion (116). Possibly, the high level of IFN induction and the absence of NS1 in
delNS1 infected cells resulted in more RNA hyperediting. 
By sequence analysis of the two adapted viruses and subsequent analysis of reas-
sortant viruses generated by reverse genetics, we showed that six substitutions in
the M segment were responsible for the increase in delNS1CA2 virus titres. The in-
crease in delNS1CA1 viral titres was caused by substitutions in the NP, M and NS
segments, where the M segment was most important. Previously, adaptation to
Vero cells yielded an influenza B delNS1 virus with increased titres due to M1
amino acid substitution M86V (189). This is in striking contrast to the many studies
on the adaptation of WT virus originating from eggs or clinical specimens to prop-
agation in mammalian hosts or cell lines, which showed that adaptive mutations
predominantly accumulated in the HA segment or segments encoding the RNA
polymerase (PB1, PB2 and PA), which is assumed to be caused by adaptation to
the different host species (65, 129, 138, 164). This suggests that the preferential iso-
lation of M-segment mutations upon delNS1 virus adaptation compensates for the
absence of the NS1 protein rather than the replication in a different host species.
This conclusion is further supported by our observation that the introduction of
the MCA2 gene segment into a WT virus (that produces NS1) does not enhance, but
even reduces, viral replication.
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Therefore, we focused on the mechanism by which the M segment mutations could
improve replication in the absence of NS1. The M segment encodes the M1 matrix
protein from unspliced M1 mRNA, whereas the M2 ion channel protein is tran-
scribed from a spliced mRNA (Fig. 2B). A second splice product, mRNA3, can arise
from an alternative 5’ splice site and encodes a hypothetical and as yet undiscov-
ered 9 amino acid peptide (82). It was previously shown that NS1 expression limits
splicing, including that of the M segment-derived mRNA (92, 134), resulting in a
higher ratio of M1 to M2 mRNA. Furthermore, M1 expression is reduced in MDCK
cells infected with influenza virus expressing truncated NS1 (30, 34). We therefore
measured M1 and M2 expression in infected cells and calculated the M1/M2 ex-
pression ratio, assuming that this would be dependent on the efficiency of M1
mRNA splicing. Indeed, cells infected with WT virus showed a higher M1/M2 ex-
pression ratio than delNS1 infected cells. The MCA1 and MCA2 segments showed sig-
nificantly increased M1/M2 expression ratios as compared to the WT M segment,
both when expressed using a delNS1 virus backbone and after transfection of cells
with M gene-encoding plasmids. The MCA1 segment contains four silent mutations
whereas the MCA2 segment contains four silent and two non-silent mutations. By
generating novel reassortant viruses we could show that the altered M1/M2 ex-
pression ratio of delNS1CA2 was due to the 4 silent mutations. Furthermore, these
silent MCA2 mutations caused an increase in delNS1 viral titres, although not to the
same extent as a segment that also contains the two non-silent M segment muta-
tions. The silent MCA1 and MCA2 mutations lay in a region that contains the major
determinants for M segment splicing (9). Thus it is likely that both these sets of
mutations lower M1 mRNA splicing efficiency in a similar manner by restoring a
balance that was disturbed due to the absence of NS1. Such a mechanism, aimed
at restoration of M1 splicing efficiency may also explain why introduction of the
MCA2 segment into a backbone of virus that produces NS1 (WT virus) reduces repli-
cation efficiency. Surprisingly, NS1 does not affect the M1/M2 expression ratio in
Vero cells (142). Furthermore, absence of NS1 causes reduced M1 expression in
MDCK but not in Vero cells (30). Taken together with our results this suggests that
the improved replication of delNS1 virus in Vero cells as compared to MDCK cells
is not only determined by the lack of an IFN response, but also by the ability of
Vero cells to retain efficient M segment splicing and M1 expression in the absence
of NS1.
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The major part of the increase in delNS1CA2 virus titre resulted from the combina-
tion of M1 amino acid substitutions V97A and Y100H. As single substitutions these
mutations did not affect replication efficiency. Mutation V97A was previously in-
troduced into the A/WSN/33 [H1N1] strain (which is able to express NS1) and re-
sulted in a 100-fold lower virus yield (16). Residues 97 and 100 are located on the
helix 6 (H6) domain, a positively charged surface region between amino acids 91
to 105 of M1 (150). The influenza B M1 M86V mutation that enhanced delNS1 virus
replication (189) is located near this region. The exact mechanism by which this
mutation affected viral replication was not further investigated. The H6 domain
has multiple functional motifs, including a nuclear localization signal (NLS) be-
tween amino acids 101-105 (Fig. 2C) that binds to cellular importin-α (14). Inside
the nucleus, M1 binds to the vRNP complex, after which NEP can bind to the NLS
of M1 (2). The vRNP-M1-NEP complex can then be exported to the cytoplasm were
virus particles are assembled at the cell membrane (2). The localization of V97A
and Y100H within the H6 domain suggests that they could affect M1 binding to
NEP. Furthermore, Y100H is located immediately next to the NLS and may also
affect importin-α binding, as described earlier for a mutation next to a NLS in PB2
(129). In this manner these mutations could affect M1 (and vRNP) subcellular dis-
tribution. The absence of NS1 during infection resulted in decreased levels of M1
in the nucleus at late stages of the infection. This may result from increased apop-
tosis induction by delNS1 virus as widening of the nuclear pores (37) allows dif-
fusion of vRNPs out of the nucleus (93). Amino acid changes V97A and Y100H
resulted in full depletion of M1 in the nucleus at 10 hpi, thus these mutations do
not restore the M1 localization balance in delNS1 towards infection in the presence
of NS1. It is therefore difficult to speculate how these two mutations can cause a
50-fold increase in virus titre. 
Interestingly, the increased viral titres of delNS1CA1 virus were in part due to six
nucleotide substitutions causing three amino acid substitutions in the NEP protein.
Especially substitution I76V which is located within the domain that binds to M1
(2) could -similarly to the M1 mutations described above- affect vRNP nuclear ex-
port. Similar effects of M1 and NEP mutations that affect their interaction were
observed earlier in WT virus. Mutations of NEP glutamate residues 67, 74 and 75
that bind M1, decreased vRNP content of viral particles and caused morphological
virion changes similar to those that occur in virus particles with mutated positively
charged M1 residues 95, 98, 101 and 102 that bind NEP (3, 16). 
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In this paper we showed that mutations in the M segment can enhance the repli-
cation of delNS1 virus due to both silent mutations that presumably affect the M1
mRNA splicing efficiency and non-silent M1 mutations that presumably affect its
subcellular localization. These findings contradict the previous suggestion that the
restricted replication of this virus is primarily due to the inability to inhibit the
IFN response. The mutations described may have direct applications as they, for
example, allow the development of delNS1 based viruses with improved replica-
tion efficiency, thereby making it possible to produce such a virus in other cell
lines than Vero cells (140) or NS1 expressing MDCK cells (170). Moreover, these
mutations may be combined with the G3A and C8U mutations in HA vRNA,
which increased the HA expression level of a live attenuated NS1 truncated in-
fluenza vaccine strain (95). However, it will be necessary to determine the effect
of these mutations on vaccine safety and efficacy.
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Cell culture based production of avian influenza virus
Vaccines against influenza virus have been produced in embryonated chicken eggs
for over 60 years. Potential difficulties associated with production in eggs include
the intensive planning many months in advance of the vast amounts of eggs
needed which limits flexibility to expand production, the possible loss of the Spe-
cific-Pathogen-Free status of laying flocks during disease outbreak, and sterility
problems that may occur during processing of infected eggs (8). Cell culture based
production offers greater robustness, flexibility and scalability. In comparison to
production in eggs, cell based production is fully contained, thereby reducing the
risk of contamination and offering the possibility to produce HPAI virus strains
in biosafety level 3 production facilities (84). Moreover, cell lines can genetically
be optimized to enhance production and vaccine quality, which is specifically use-
ful for attenuated virus strains. Several commercially available human influenza
vaccines are already produced in cell culture, such as Optaflu® by Novartis vac-
cines (Basel, Switzerland) and Celvapan® and Vepacel® by Baxter vaccines (Vienna,
Austria). Veterinary influenza vaccines may also benefit from the development of
these alternative production systems. The cost price of current veterinary influenza
vaccines is, however, very low and will therefore be a major challenge if the exist-
ing egg-based production process is to be replaced by a cell culture based process.
Furthermore, vaccines need to be available in time during an outbreak. Since stock-
piling of vaccines against the large antigenic diversity of avian influenza strains is
costly, a platform production process is preferred that is able to replicate any sub-
type of avian influenza virus to high enough titers, in a short time period, thereby
allowing custom-produced vaccines. Here we discuss the different aspects of a cell
culture based process for the production of avian influenza vaccines, to be used in
poultry.
Influenza virus cell substrate
In Chapter 2, MDCK, Vero and BHK21 cell lines have been assessed for their ability
to propagate a variety of different AI virus strains (171). Overall, the MDCK cell
line yields the highest virus titers, although the difference with Vero cells is not
very big as MDCK produce on average 3.6-fold more HAU (171). Currently, it is
unclear which cell line is a better substrate for influenza virus and the choice for
either cell line has been based on other aspects than virus yield, such as the histor-
ical use by a specific company (109). Recently, several new cell lines have been de-
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veloped by immortalizing primary cells, including the human PER.C6® (125) and
the avian AGE1.CR® (91) and EB14®/EB66® (104) cell lines, which all showed to be
suitable for vaccine production. The use of avian cell lines above mammalian cell
lines may offer additional benefits for the production of avian influenza virus as
they are the natural host of these strains. However, unlike Vero, MDCK and
BHK21 cells, the use of these proprietary cell lines will add license costs and have
therefore not been evaluated in this thesis. Vero cells are appreciated for their long
term safety record, in the production of polio and rabies vaccines. Furthermore,
Vero cells lack an interferon (IFN) response, due to the absence of the IFN-β gene
(27), which makes them especially useful for growth of immune response sensitive
viruses, such as influenza virus containing deletions in NS1 (45, 170). 
The cells used for vaccine production are often adherent cells (46). At large-scale
production, these cells are grown on micro-carriers, which add additional costs to
the vaccine. Furthermore, during scale-up cells have to be detached with for ex-
ample trypsin and re-attached to new carriers, where it is very important to have
an even distribution of cells over the new carriers. This not only introduces extra
costs, but also extra variation in the process, increases contamination risk and thus
makes the whole process less robust. In addition, cells grown on micro-carriers
are more sensitive to shear caused by agitation and aeration compared to suspen-
sion cells, making scale-up and reaching high cell densities more difficult. There-
fore, suspension growth would be preferred in veterinary AI vaccine production.
Whereas several studies, including ours, have shown the possibility to adapt
MDCK cells to suspension growth (21, 56, 90, 171), only one study showed this to
be possible for Vero cells (121), suggesting a difference in the ability to adapt these
cell lines to suspension growth. Furthermore, the substrate cell line should prefer-
ably be able to grow under serum-free conditions. Not only is serum an expensive
medium component and may be a source of extraneous agents such as viruses,
mycoplasmas and prions, additional washing steps and medium replacement
steps are necessary for serum-dependent cells before infection, as serum compo-
nents inactivate trypsin (47) that is required for high virus yields. Notably, Vero
cells are also known to release a trypsin inhibitor (74), which necessitates repeated
trypsin addition during the infection process. 
Taken together, the serum-free MDCK-SFS suspension cell line (171) appears a
preferred host cell line for commercial, veterinary AI vaccine production, because
it grows serum free in suspension and the virus yield with these cells is high and
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comparable to adherent MDCK cells. However, adaptation to suspension growth
described in this thesis was not performed under GMP conditions and will there-
fore need to be repeated in order to obtain a GMP approved MDCK suspension
cell line. Furthermore, the SFM4BHK21 culture medium is custom made and ex-
pensive, and may have to be replaced by a cheaper, generic medium. Our results
showed that the ability of MDCK-SFS cells to grow in suspension appears to be
linked to the nature of SFM4BHK21 medium, the composition of which is not dis-
closed (171). Therefore, if these cells were to be adapted to alternative media, it is
important to focus on the ability of the cell line to grow in suspension.
In Chapter 3, BHK21 cells were also assessed as a host cell line for AI vaccine pro-
duction (168). BHK21 cells have favorable growth characteristics as they are easily
cultured in suspension, and grow 72% faster and to 3.6-fold higher maximum cell
density than MDCK cells (168, 171). Furthermore, BHK21 cells have a compro-
mised innate immune response, due to a deficiency in the RIG-I pathway, resulting
in a complete lack of IFN production (57). Although most AI virus strains repli-
cated poorly in these cells, a few strains replicate very efficiently and yielded virus
titers that exceeded those of MDCK and Vero cells infected with the same strains
(168, 171). This indicates that BHK21 cells have the potential to efficiently propa-
gate influenza virus. The strict, strain dependent replication in BHK21 cells was
also observed between the two related H1N1 strains PR8 (poor replication) and
WSN (efficient replication). Reassortant viruses in which the HA was exchanged
revealed that HA determined replication in BHK21 cells (168). Reassortant virus
strains with chimeric HA molecules did not reveal, however, which domain of
PR8 HA limits the ability to replicate in BHK21 cells. Nevertheless, the results did
show that BHK21 cells could be used to replicate virus containing a chimeric pro-
tein consisting of the antigenically important HA1 domain of PR8 in combination
with the HA2 domain of WSN. If this approach also allows the production of
viruses containing the HA1 domain of other strains that normally do not replicate
in BHK21 cells, this may offer a novel production platform for influenza vaccines. 
Besides growth, other important aspects for choosing a particular cell line are the
quality and the efficacy of the vaccines resulting from the use of these cells. The
specific host cell line may, for example, change HA glycosylation patterns (46, 138,
139), which may affect down-stream processing (119), and might be relevant for
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the immunogenicity of the resulting vaccine. Before choosing a specific host cell,
it is therefore important to assess the efficacy of the viral vaccines produced using
that particular host cell.
optimization of media and process conditions
A major benefit of cell culture based production over the use of embryonated
chicken eggs is the possibility to monitor, control and optimize process conditions
in order to obtain maximum virus yields and even more important a good quality
of the final product (43). Optimizing process conditions such as m.o.i., trypsin con-
centration and virus harvesting time have shown to increase virus yield (1, 19, 50,
122, 149). Furthermore, optimization of the culture media and process conditions
can improve the cell growth rate and maximal cell density as well as the virus yield
per cell and through these the final virus concentration reached (19, 51, 152). As
stated, even more important than virus yield is the quality of the final produced
vaccine. For example, it is important to optimize the pH of the culture media, as a
low pH during the virus infection in Vero cells is necessary to prevent the occur-
rence of mutant virus with lower stability to acidification and elevated temperature
(114). These mutants showed significantly lower immunogenicity and this pheno-
type was caused by an increased pH threshold of the HA conformational change.
Finally, fed-batch and perfusion bioreactors can be used to further increase the cell
density and final virus concentration (56). In suspension and micro-carrier based
batch cultures, MDCK cell densities are normally around 2 x 106 cells/ml (13, 90,
171), however concentrations up to 11.2 x 106 cells/ml were obtained with MCDK
cells adhered to micro carriers (13) and up to 17.5 x 106 cells/ml for suspension
MDCK cells concentrations (56). However, high cell density may result in a lower
cell-specific virus yield, which is called “cell density effect” (97, 188). The mecha-
nism behind this cell density effect is still unknown. Despite this, Bock et al. (13)
were able to use fed-batch and perfusion bioreactors to obtain very high virus
titers.
Cell line engineering
By resolving factors that limit virus replication in the cell, the cell-specific virus
yield can be further enhanced. A logical first approach would be to knock out the
cellular antiviral response. Recombinant expression of the V protein of the
paramyxovirus simian virus 5 in three human cell lines blocked IFN signaling and
enhanced the titer of a variety of different viruses, including slow-growing wild-
type viruses and attenuated vaccine candidates (194). However, several of the es-
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tablished cell lines used for virus growth, including Vero (27) and BHK21 (57) cells,
already have a defective IFN system and this approach will probably not result in
increased yields. For MDCK cells this may be a feasible approach. Another target
to enhance virus yield may be apoptosis. Influenza virus production starts approx-
imately 4-6 hour post infection (146) with the budding of virus particles from the
cell surface and continues until the cell dies by apoptosis. Delay of apoptosis could
therefore extend the duration in which an infected cell produces new virion par-
ticles and thereby enhance the cell-specific virus yield. Expression of anti-apoptotic
genes has been shown to enhance monoclonal antibody production in Chinese
hamster ovary cells (39), whereas the addition of anti-apoptotic chemicals to the
culture medium can prolong the life of cells infected with a Sindbis virus vector
and enhance recombinant protein production (101). Furthermore, delayed apop-
tosis may also lower the number of lysed cells at the time of harvest, lowering the
DNA and protein content of the culture medium and thereby facilitating down-
stream processing. However, this approach has not yet been successful to enhance
influenza virus production as inhibition of influenza-induced apoptosis, either by
stable expression of BCL2 (118) or addition of a caspase 3 inhibitor to the culture
medium (190), reduced the virus titer. This indicates that apoptosis or parts of the
apoptosis machinery are beneficial for virus replication. It was therefore hypoth-
esized that the influenza virus not only acquired the capability to suppress antivi-
ral and pro-apoptotic responses, but also the ability to misuse the remaining
antiviral activities to support virus replication (93). Although tools such as pro-
teomic analysis (173) and modeling of the influenza virus replication (64, 147, 153)
can hint to what factors limit virus replication, these results demonstrate that our
knowledge of the infection process is still insufficient to predict the outcome of a
rational cell engineering approach. 
Comparison of the transcription profiles of adherent and non-adherent HELA cells
using DNA microarrays revealed the human sialyltransferase ST6GalNac V as an
important factor in cellular adhesion. Recombinant expression of this protein by
inserting the siat7e gene in anchorage-dependent MDCK cells allowed these cells
to grow in suspension (21). Surprisingly, the siat7e-expressing MDCK cells also
showed a 20-fold higher HA production (22). Others have successfully transfected
MDCK, Vero, PER.C6® and CHO cells with the gene for human 2,6-sialyltrans-
ferase (siat1), which increases the amount of receptors containing sialic acid (SA)
with α-2,6 linkage (12, 62, 79, 85, 102). Most of these cell lines not only showed up
to 100-fold increase in virus yield (62), but expression of this gene also resulted in
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an improved ability to isolate human influenza virus strains (79, 117) and an in-
creased sensitivity to neuraminidase inhibitors (62, 102). The siat1 gene was suc-
cessfully introduced in an M2 expressing complementary MDCK cell line, to
enhance replication of an influenza virus strain that is unable to encode M2
(delM2) (174). In order to enhance avian influenza virus production in MDCK cells,
recombinant expression of a sialyltransferase that specifically increases the pres-
ence of SA α-2,3 linkage receptors would probably result in the same increased
virus growth as expression of the SA α-2,6 receptors in these cells do for growth
of human influenza viruses.
Influenza virus strains unable to express NS1 (delNS1) have potential use as DIVA
and live-attenuated vaccines. However, they replicate poorly in most cell lines and
are therefore difficult to produce on commercial scale. In Chapter 4, we developed
two MDCK cell lines able to express NS1 (170). Complementation of NS1 by these
cell lines during infection with delNS1 virus yielded up to 500-fold higher infec-
tious virus titers. Similar complementary cell lines have been described to enhance
replication of influenza virus strains unable to express PB2 (120), NA (69) and M2
(181). Due to the reported toxicity of NS1, we used an inducible expression system
to selectively express NS1 before infection but not during the cell growth phase.
In commercial production systems, however, inducible expression systems are not
preferred due to the addition of the expression inducer doxycycline, which is an
antibiotic, and because the complicated process is less robust. Therefore, a stable
production cell line with constitutive NS1 expression would be preferred. Inter-
estingly, this may be possible as we did not observe apoptosis induction upon NS1
expression in the two developed cell lines, possibly due to the specific NS1 gene
used or the low NS1 expression levels. 
Virus engineering
Wild type human influenza strains do not usually grow well in eggs or cell culture
and are therefore reassorted with a high yielding donor strain (PR8 [A/Puerto
Rico/8/34] or a derivative) resulting in a vaccine strain that contains the HA and
NA of the wild-type virus and all other segments from the donor strain. With the
reverse genetics approach it is now possible to alter the virus more specifically,
such as in the creation of NS1, M2, PB2 and NA deletion mutants. Furthermore,
the introduction of specific mutations allows to specifically engineer the virus to
increase its yield and antigenic quality. Amino acid substitution K58I in HA2 low-
ers the pH that induces the conformational HA change, thereby increasing the re-
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sistance of the virus to acidic pH and high temperature treatment. Live attenuated
vaccines are often applied intranasally and thus must overcome the low pH of the
mucosal surface. Immunization of mice with a live attenuated delNS1 vaccine
strain containing the K58I mutation induced a stronger systemic and local anti-
body response than immunization with a similar virus lacking this mutation (80).
Amino acid substitution E627K in PB2 is a well-known host determining mutation
and is frequently observed during adaptation of an avian influenza strain to a
mammalian host (100, 196). Inserting this mutation in an avian influenza strain
may therefore be used to enhance replication in a mammalian host cell. Further-
more, it will be of great interest to determine if the recently discovered influenza
proteins PB1-F2 (24) and PA-X (71) can be used to enhance virus replication in cell
culture, e.g. by modulating the protein or removing it from the virus.
It was previously shown that influenza viruses encoding a truncated NS1 express
viral proteins such as HA and M1, to lower levels than WT virus (30, 35, 157). HA
is the main influenza antigen and low HA expression levels may therefore lower
the immunological properties of NS1-truncated influenza vaccines. To overcome
this, G3A and C8U “superpromotor” mutations (115) were introduced into the HA
vRNA of a NS1 truncated influenza strain, resulting in enhanced HA expression
(95). Mice that were immunized with this virus showed enhanced protection from
wild-type virus challenge in comparison to mice vaccinated with a similar virus
lacking the promoter mutations. Therefore, these promoter mutations may be use-
ful to enhance HA protein production in other delNS1 based virus strains, and
possibly in other influenza vaccine strains, as well.
A rational approach to cell line and virus engineering does not always give the re-
quired result due to lack of understanding of the complex interplay between the
virus and its host. Recent studies revealed that influenza A virus replication re-
quires 1449 host proteins (182), and 87 virus-host and 21 virus-virus protein inter-
actions (151), of which only a minor part of the binding sites have been revealed.
An example of a failed rational approach are the attempts to enhance virus yield
by inhibition of apoptosis, which resulted in a decrease of virus yield (118, 190).
As obligatory parasites, viruses evolve together with their hosts, as both are in a
continuing struggle for survival. The high mutation rate of the viral RNA poly-
merase and the vast amount of progeny virus particles allow the virus to quickly
adapt to changes in the environment, such as production of antibodies by the host.
In a sense, virology provides us with a window on the mechanism of evolution.
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Transmission, entry, host defenses, tissue diversity and anatomical restrictions all
are serious obstacles to prevent infection and the influenza virus is optimized not
to produce as much infectious virus particles as possible, but to efficiently over-
come all these barriers. The environment in which the influenza virus is commer-
cially produced is however very different, as the virus is generally propagated in
a different cell type and host species than the one from which it was isolated. Fur-
thermore, secondary defenses such as the adaptive immune response and physical
barriers are absent in cell culture. Therefore, vaccine strains often do not replicate
well on the production cell line or eggs and require adaptation to their new host
(46, 137). The viruses resulting from such an adaptation can thus be used to iden-
tify targets for virus engineering to improve virus yield. DelNS1 virus replicates
poorly in MDCK cells, which is generally believed to result from the inability of
the virus to counter the antiviral response of the cell. The restricted replication of
delNS1 introduced a high selective pressure (136) for variants able to replicate ef-
ficiently in the absence of NS1, and in Chapter 5 adaptation resulted in 2 strains
which showed a 250-fold increase in virus yield (169). In both virus strains, muta-
tions were found that significantly increased virus yield, and these could be used
to improve delNS1 virus yield. Interestingly, the mutations appeared not to di-
rectly counter the IFN response of the cell, which would logically have been the
target in a rational approach. Parallel virus adaptation (129) is therefore a valuable
tool to enhance our fundamental understanding of the relationship between the
virus and its host, and to identify targets for virus engineering, which are unlikely
to be found by rational analysis. However, it is important to specifically focus on
the selection mechanism and the resulting mutations. Adaptation of wild-type
virus to embryonated eggs and cell lines could increase virus yield, but may also
reduce immunological properties, due to mutations in the antigenic sites of the
HA protein that were selected during the adaptation process as they enhanced re-
ceptor binding (44), virus entry and HA stability (87). Furthermore, it will be nec-
essary to evaluate the safety aspect of these mutations, especially when they are
used in a live attenuated vaccine.
future perspective
Unlike avian diseases such as Newcastle disease, to which poultry are vaccinated,
outbreaks of avian influenza are generally dealt with by culling birds at the af-
fected farms. Traditional AI vaccines allow limited differentiation between birds
that are vaccinated and birds that carry the virus. Fear for spreading the virus
therefore limits the export of vaccinated birds and with that the application of pre-
ventive vaccination. The large scale application of vaccines against AI in poultry
is therefore determined by political and economical reasons. Development of
cheap and effective DIVA vaccines in combination with the growing societal re-
sistance against large scale culling may pave the way for introduction of vaccina-
tion.
Cell culture based human influenza vaccines can financially compete with vaccines
produced in eggs. The low cost price of vaccines for poultry will, however, require
lower production costs and/or higher yields. Several suggestions have been made
regarding virus yield optimization, including via cell line and virus engineering.
The use of fed-batch and perfusion bioreactors may increase the yield, if the “cell
density effect” can be resolved. Furthermore, the use of a suspension cell line
which grows in a generic, serum-free medium will lower production costs. Finally,
a generic production platform will allow different AI vaccines to be produced in
the same cell line under similar conditions. This will aid the development and reg-
istration of new vaccines, thereby further limiting costs and delivery time to the
market. A financial analysis will be required to determine which steps are neces-
sary in order to obtain a marketable veterinary AI vaccine.
And finally, avian influenza vaccines may benefit from other developments in the
fight against human influenza as well. Current work on universal influenza vac-
cines appears especially promising. Such a vaccine would induce antibodies that
target conserved regions of the influenza virus, such as the M2 protein or the stalk
of the HA protein (35) and would protect against a wide variety of serotypes.
Stockpiling vaccines against different AI subtypes would thus not be necessary.
Furthermore, such universal vaccines could easily be made according to the DIVA
principle. The substrate on which these future vaccines will be produced is, how-
ever, yet to be determined.
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Vaccination of poultry can be used as a tool to control outbreaks of avian influenza,
including that of highly pathogenic H5 and H7 strains. Such outbreaks do not only
cause economical losses in poultry farming, but also pose a serious threat to global
public health. Influenza vaccines are traditionally produced in embryonated chic-
ken eggs. Continuous cell lines have been suggested as an alternative substrate to
produce influenza vaccines in a more robust and flexible manner, as cell culture
based production lacks the long lead time associated with the supply of large
amounts of embryonated eggs. Furthermore, cell culture process conditions can
be optimized and cell line engineering can increase virus yield and improve pro-
duct quality.
Madin-Darby canine kidney (MDCK) and African green monkey kidney (Vero)
cells are the main cell lines used for influenza virus replication. However, both cell
lines normally grow anchorage-dependent. Large-scale virus production with an-
chorage dependent cell lines is complicated as process scale-up will require de-
tachment and reattachment of the cells from and to micro-carriers or roller bottles
between each cultivation step. Furthermore, MDCK and Vero cells require the ad-
dition of serum to the culture medium. Serum is not preferred due to the high
costs, lot-to-lot variation and risk of contamination with extraneous agents. Fur-
thermore, serum addition necessitates medium exchange before infection, as
serum components inhibit trypsin which is required for efficient virus replication.
In Chapter 2 we therefore tried to adapt different cell lines to grow as suspension
cells in serum-free (SF) medium. Using a specific culture medium, we were able
to obtain an MDCK cell line (MDCK-SFS) that grows efficiently in SF medium in
suspension. Vero cells could be adapted to growth in SF medium (Vero-SF), but
not to growth in suspension. Baby hamster kidney cells (BHK21), the third cell line
used in this study already grew in suspension and was adapted to SF growth
(BHK21-SFS).
Next, the production of eight different avian influenza virus strains was compared
between MDCK-SFS, Vero-SF and BHK21-SFS cells. On average, MDCK-SFS cells
produced the highest virus titers, closely followed by Vero-SF cells. Interestingly,
two virus strains replicated to higher titres in BHK21-SFS cells than in MDCK or
Vero cells. However, six further virus strains replicated poorly in BHK21-SFS cells.
Analysis of the influenza virus binding receptors on the cell membrane revealed
that BHK21-SFS cells consists of two populations, with one population lacking the
avian influenza virus preferred sialic acid α-2,3 receptors. This could however not
Summary
- 119 -
explain the strain dependent influenza virus replication. MDCK-SFS was the only
cell line able to grow SF in suspension and replicate a wide variety of influenza
strains to high titers and was therefore selected for further studies in Chapters 4
and 5.
BHK21 is a fast growing suspension cell line that can reach high cell densities in
batch culture and is currently used in the production of veterinary vaccines against
foot-and-mouth disease and rabies. However, the selective replication of particular
influenza virus strains limits their potential use in influenza vaccine production.
The molecular basis of this selective virus replication was further investigated in
Chapter 3. Model strain A/PR/8/34 [H1N1] (PR8) was found to replicate poorly,
whereas the related strain A/WSN/33 [H1N1] (WSN) replicates efficiently in
BHK21-SFS cells. This difference is determined by the hemagglutinin (HA) protein
since reciprocal reassortant viruses with swapped HA gene segments grow on
BHK21-SFS cells to comparable titres as the parental virus from which their HA
gene is derived. Furthermore, the ability of several other influenza virus strains to
grow on BHK21-SFS cells also appears to depend on the HA gene. To determine
which part of the HA protein determines virus replication in BHK21-SFS cells, PR8
based reverse genetics viruses that encode PR8-WSN chimeric HAs (cHAs) were
generated. This approach did, however,  not allow us to identify a single specific
region of HA that determines the ability to replicate in BHK21-SFS cells, as virus
containing the WSN HA1 domain and the PR8 HA2 domain replicated equally
well as the reciprocal strain containing the WSN HA2 and PR8 HA1. Viruses ex-
pressing two other reciprocal cHAs also replicated equally efficient. However,
these results do show that it is possible to replicate a virus encoding the PR8 HA1
domain to high titers by fusion to the WSN HA2 domain. The HA1 domain con-
tains most antigenic sites and is therefore important for vaccine efficacy. This me-
thod of producing the HA1 domain as fusion to a heterologous HA2 domain could
therefore potentially be used to produce HA1 domains of other viruses, and enable
the use of BHK21-SFS cells as a generic platform for veterinary influenza vaccine
production.
Influenza viruses that are unable to express the NS1 protein (delNS1) replicate
poorly on cells and induce high amounts of interferon (IFN). Their attenuated re-
plication is generally assumed to result from the inability to counter the antiviral
host response. DelNS1 virus strains are currently considered as candidate viruses
for live-attenuated influenza vaccines and veterinary vaccines that allow differen-
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tiation of infected from vaccinated animals (DIVA). However, their attenuated
growth limits large scale virus production on MDCK cells. To develop a high yiel-
ding delNS1 virus production system, we made two MDCK cell lines that are able
to express NS1 (Chapter 4). Since heterologous NS1 expression can cause apopto-
sis, we used an inducible expression system. Upon induction, both cell lines repli-
cated delNS1 virus to equally high titers as were obtained with an isogenic virus
strain able to express NS1, to which we refer as wild-type (WT) virus. Notably,
the NS1 expression by both cell lines was about 1000-fold lower than in influenza
virus infected cells. Furthermore, NS1 expression inhibited delNS1 virus-induced
apoptosis, but did not significantly lower IFN production. Thus, the enhanced
virus replication appeared not to be due to decreased IFN production. In contrast
to previous findings, recombinant NS1 expression by itself did not induce apop-
tosis, nor did it affect cell growth. This may be due to the specific allele B NS1 gene
used. As a consequence, it may therefore be possible to develop a stable cell line
with constitutive expression of allele B NS1, which can be used to enhance delNS1
yield in large-scale vaccine production.
Another approach to enhance virus replication is virus adaptation to the cell sub-
strate. In Chapter 5, the delNS1 virus was adapted in two parallel experiments,
which resulted in two virus strains with 250-fold higher infectious virus titers in
IFN competent MDCK cells. By sequence analysis of the adapted viruses and sub-
sequent analysis of reassortant viruses generated by reverse genetics, we showed
that mutations in the M gene segment of one virus (delNS1CA2), and in the M, NP
and NS segments of the other virus (delNS1CA1), caused the significant increase in
virus replication. The most notable ones were clustered U-to-C mutations in the
M segment of both strains and clustered A-to-G mutations in the NS segment of
delNS1CA1. Presumably these mutations resulted from host cell mediated RNA edi-
ting. NS1 is known to limit splicing of the M segment mRNA, resulting in a higher
M1/M2 mRNA ratio. Interestingly, the silent mutations in the M segment of both
adapted virus strains increased the ratio of M1 to M2 expression, probably by af-
fecting splicing efficiency, towards the ratio observed in the WT virus. Further-
more, two amino acid substitutions in the M1 of delNS1CA2 virus additionally
enhanced virus replication, possibly through changes in the subcellular localiza-
tion of M1. Both adapted viruses induced less IFN and less apoptosis compared
to the delNS1 virus, but still significantly more than the WT virus. It appears that
the restricted replication of delNS1 virus is not only caused by the inability to coun-
ter the host cell antiviral response, as suggested in the literature, but also by the
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loss of one or more M1-related functions of NS1. The mutations identified may
have direct applications as they can be used to enhance delNS1 virus replication
for vaccine production.
Cell culture based human influenza vaccines can financially compete with vaccines
produced in eggs. The low cost price of vaccines for poultry will make it necessary
to lower the production costs of a cell culture based production process, for exam-
ple by increasing the yield of virus per liter medium. In Chapter 6, several sugge-
stions have been made regarding virus yield optimization, including engineering
of the vaccine virus and substrate cell line. However, large-scale implementation
of poultry vaccination is not only determined by the price of the vaccines, but also
by macro-economical and political factors. Future developments in veterinary in-
fluenza vaccines, such as broadly protecting influenza DIVA vaccines, may further
help to implement emergency vaccination as a tool to control and possibly also to
prevent outbreaks of avian influenza.
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Vogelgriep (of aviaire inﬂuenza) is een besmettelijke vogelziekte die veroorzaakt
wordt door het inﬂuenza A virus. Tot deze virusgroep behoren ook virussen die
griep veroorzaken in andere soorten, zoals mensen, varkens, paarden en zee-
zoogdieren. Over het algemeen zijn griepvirussen vrij gastheer speciﬁek, wat
betekend dat humane virusstammen alleen mensen infecteren en vogel-
griepvirussen alleen vogels. Echter, in sommige gevallen kan het virus van de ene
op de andere soort overspringen. Watervogels, zoals eenden en ganzen, zijn de
hoofdgastheer het inﬂuenza A virus maar vertonen zelf weinig tot geen ziektev-
erschijnselen. Zij kunnen het virus overbrengen op andere vogelsoorten, zoals kip-
pen en kalkoenen, die wel ziek worden. Een uitbraak van vogelgriep kan daardoor
economische schade veroorzaken voor de pluimvee industrie. Er bestaat echter
ook de mogelijkheid dat vogelgriepvirussen van het H5 en H7 subtype muteren
in dodelijke virusvarianten. In het recente verleden is gebleken dat deze virussen
ook mensen kunnen besmetten, met veelal ernstige gevolgen. Om de volksgezond-
heid te beschermen is het daarom noodzakelijk om uitbraken van vogelgriep te
voorkomen of te beheersen. Hiervoor zijn een aantal maatregels beschikbaar,
waaronder vaccinatie van pluimvee. 
Inﬂuenza vaccins worden traditioneel geproduceerd in bevruchte kippeneieren.
Deze methode is echter vrij omslachtig omdat zeer grote hoeveelheden bevruchte
eieren vele maanden van te voren besteld dienen te worden. Vaccinproductie op
basis van dierlijke celkweek is robuuster en ﬂexibeler, en is daarom als alternatief
voorgesteld. Voor inﬂuenza vaccin productie worden voornamelijk MDCK en Ver
cellen gebruikt (respectievelijk honde- en apeniercellen). Echter, beide cellijnen
groeien alleen wanneer zij gehecht zijn aan een oppervlak. Voor grootschalige
virusproductie is dus een zeer groot oppervlak nodig, in de vorm van rollerbottles
of micro-carriers. Daarnaast dienen gehechte cellen gedurende de groei her-
haaldelijk losgehaald te worden van het oppervlak. Ook vereisen beide cellijnen
toevoeging van serum aan het groeimedium. Serumgebruik heeft echter een aantal
nadelen, waaronder hoge kosten, de variatie tussen productiebatches en de kans
op besmetting van het vaccin door aanwezigheid van virussen of prionen in het
serum. Verder is bij gebruik van serum een wasstap noodzakelijk, omdat serum-
componenten interfereren met de trypsine die nodig is voor infectie. In Hoofdstuk
2 is daarom geprobeerd om verschillende cellijnen te adapteren naar groei in sus-
pensie in serumvrij medium. Door gebruik te maken van een speciﬁek medium is
het gelukt om een MDCK cellijn te ontwikkelen (MDCK-SFS) die onder deze con-
dities groeit. Vero cellen konden aan serum-vrij condities geadapteerd worden,
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maar niet aan groei in suspensie (Vero-SF). Een derde cellijn, BHK21 (hamstern-
iercellen), groeide al in suspensie en werd geadapteerd naar serumvrije condities.
Vervolgens werden deze drie cellijnen vergeleken in hun vermogen om acht ver-
schillende inﬂuenza virusstammen te produceren. MDCK-SFS cellen hadden de
hoogste virusproductie voor de meeste virusstammen, hoewel de productiviteit
van Vero-SF cellen niet veel lager lag. De productie in BHK21-SFS cellen was op-
merkelijk omdat zes van de acht virusstammen slecht repliceerde in deze cellijn,
terwijl de overige twee virusstammen beter repliceerde dan in MDCK en Vero
cellen. Humane en vogelgriepvirussen binden bij voorkeur aan celmembraanre-
ceptoren met, respectievelijk, α-2,6 en α-2,3 siaalzuurreceptoren. Receptor analyse
toonde aan dat de BHK21-SFS cellijn bestaat uit twee cel populaties waarvan er
één geen α-2,3 siaalzuurreceptoren bezit. De uitkomst van deze analyse kon daar-
door niet de virusstamafhankelijke replicatie van inﬂuenza in BHK21 cellen verk-
laren. MDCK-SFS was de enige cellijn die onder serumvrije condities in suspensie
kan groeien en tegelijk van verschillende virusstammen grote hoeveelheden virus
kan produceren. Deze cellijn is daarom gebruik voor verdere studies in Hoofdstuk
4 en 5.
BHK21 cellen worden gebruikt voor de productie van veterinaire vaccins tegen
mond-en-klauwzeer en hondsdolheid, en hebben als voordeel dat ze snel groeien
en een hoge celdichtheid kunnen bereiken in batchkweek. Door de virusstam
afhankelijke replicatie lijken BHK21 cellen niet geschikt voor de productie van in-
ﬂuenza vaccins. De moleculaire basis voor deze selectieve replicatie is onderzocht
in Hoofdstuk 3. De inﬂuenza stam A/PR/8/34 [H1N1] (PR8) repliceert slecht terwijl
de verwante A/WSN/33 [H1N1] stam (WSN) zeer goed repliceert in BHK21 cellen.
Het verschil blijkt te worden veroorzaakt door het hemagglutinine (HA) eiwit van
het inﬂuenza virus, want wanneer het HA van het PR8 virus vervangen wordt
door het HA van WSN, dan repliceert het virus goed, terwijl een WSN virus
waarin het HA vervangen is door het HA van PR8 juist slecht repliceert. Het HA
lijkt verder ook de oorzaak te zijn voor de gelimiteerde replicatie van andere in-
ﬂuenza virusstammen in BHK21 cellen. Verschillende virussen werden ontwikkeld
waarin delen van het HA eiwit zijn uitgewisseld tussen PR8 en WSN. Met behulp
van deze chimeren konden we echter niet één speciﬁek gebied aanwijzen dat de
replicatie in BHK21 cellen bepaald, virussen met het HA1 van PR8 en het HA2 van
WSN repliceerde namelijk net zo goed als virus met het HA1 van WSN en het HA2
van PR8. Echter, de resultaten lieten wel zien dat het mogelijk is om het PR8 virus
eﬃciënt in BHK21 cellen te produceren door alleen het HA2 eiwit deel te vervan-
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gen door dat van WSN. Het HA1 domein bevat de voornaamste antigenen en is
daarom van belang voor het vaccin. Deze methode zou het dus potentieel mogelijk
maken om het HA1 deel van andere inﬂuenza virusstammen, die normaal niet
repliceren in BHK21 cellen, te fuseren met het HA2 van WSN. Hierdoor zou de
BHK21 cellijn gebruikt kunnen worden als een platform productiesysteem voor
veterinaire inﬂuenza vaccins.
Inﬂuenza virussen die niet in staat zijn om het NS1 eiwit tot expressie te brengen
(delNS1) repliceren slecht in de meeste cellijnen en induceren de productie van
veel interferon (IFN). IFN is een signaal voor cellen om zich te verdedigen tegen
een virusinfectie. Een belangrijke functie van NS1 is om de productie van IFN te
remmen. De verzwakte delNS1 virusreplicatie wordt daarom toegewezen aan het
feit dat het delNS1 virus niet in staat is deze antivirale reactie te voorkomen.
DelNS1 virussen zijn door deze eigenschappen interessant om als basis voor een
levend-verzwakt vaccin te dienen. Verder zouden ze ook als DIVA vaccin gebruikt
kunnen worden. Dit zijn veterinaire vaccins waarbij gevaccineerde dieren te on-
derscheiden zijn van geïnfecteerde dieren. Echter, door de verzwakte replicatie is
grootschalige vaccin productie moeilijk. Om toch hoge virusproductie te behalen
hebben we twee MDCK cellijnen ontwikkeld in Hoofdstuk 4, die in staat zijn om
het virale NS1 eiwit te maken. Beide cellijnen produceerden delNS1 virus tot hoge
concentraties, vergelijkbaar met normale MDCK cellen die geïnfecteerd waren met
een wild-type (WT) virus dat wel een functioneel gen voor NS1 bezat. Opmerkelijk
genoeg produceerden de twee cellijnen ongeveer 1000 keer minder NS1 dan nor-
male MDCK cellen die geïnfecteerd waren met het WT virus. Verder beschermde
de heterogene NS1 expressie de cellen tegen delNS1 virus geïnduceerde celdood
(apoptose). Er is was echter geen signiﬁcant eﬀect op de IFN expressie, wat erop
wijst dat de verhoogde virusreplicatie niet veroorzaakt werd door een verlaging
van de cellulaire antivirale reactie. Omdat uit eerder onderzoek was gebleken dat
NS1 expressie in cellen tot apoptose kan leiden, hebben we een induceerbaar ex-
pressiesysteem gebruikt. Echter, in tegenstelling tot deze eerdere vindingen, had
de NS1 expressie in beide cellijnen geen eﬀect op celgroei en veroorzaakt het geen
apoptose. Dit houdt mogelijk verband met het speciﬁeke NS1 allel dat gebruikt is,
en maakt het potentieel mogelijk om een cellijn te ontwikkelen die NS1 constitutief
tot expressie brengt. Een dergelijke cellijn zou potentieel gebruikt kunnen worden
voor grootschalige inﬂuenza vaccin productie op basis van het delNS1 virus.
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Adaptatie van een virus aan een cellijn is een bekende methode om de replicatie
eﬃciëntie te verhogen. In Hoofdstuk 5 hebben we het delNS1 virus in twee par-
allelle experimenten geadapteerd aan MDCK cellen. Dit resulteerde in twee
virusstammen die tot 250 keer meer infectieuze virusdeeltjes produceerden. Door
analyse van het virale genoom en het maken van reverse genetics virussen hebben
we vervolgens aangetoond dat mutaties in het M segment (beide virussen) en in
het NP en NS segment (een virus) verantwoordelijk zijn voor de toename in virus
replicatie. Opmerkelijk waren de geclusterde U-naar-C mutaties in de M seg-
menten van beide virussen en de A-naar-G mutaties in het NS segment. Deze mu-
taties zijn waarschijnlijk het gevolg van RNA editing door het cellulaire ADAR
eiwit. Mutaties in het M segment bleken het belangrijkste te zijn voor de toename
in virus replicatie in afwezigheid van NS1. Het is bekend dat NS1 een remmend
eﬀect heeft op de splicing van het M segment mRNA, waardoor de verhouding
M1/M2 mRNA stijgt. De stille mutaties die werden gevonden in het M segment
van beide virussen verhoogden het M1/M2 mRNA ratio. Hierdoor lijkt de ratio
van de geadapteerde virussen meer op de ratio van het WT virus en dit komt
waarschijnlijk doordat deze mutaties de splicing eﬃciëntie van het M1 mRNA
beïnvloeden. Twee additionele M1 eiwit aminozuur mutaties bleken ook een sig-
niﬁcant eﬀect te hebben op de virusreplicatie en mogelijk houdt dit verband met
de lokalisatie van het M1 eiwit in de cel. Beide geadapteerde virussen induceerden
minder IFN en minder apoptose dan het oorspronkelijke delNS1 virus, maar nog
altijd meer dan het WT virus. Het lijkt daarom dat de lagere delNS1 virusreplicatie
niet alleen veroorzaakt wordt doordat het virus niet in staat is om de IFN expressie
te onderdrukken, zoals gesuggereerd in de literatuur, maar ook door het gebrek
aan 1 of meer M segment gerelateerde functies van NS1. De gevonden mutaties
bieden meer inzicht in de werking van het NS1 eiwit en zouden verder gebruikt
kunnen worden om delNS1 virusproductie te verhogen in een commercieel vaccin
productie proces.
De productie van inﬂuenza vaccins op basis van celkweek kan ﬁnancieel com-
peteren met vaccins die geproduceerd zijn op de klassieke manier in bevruchte
eieren. Door de lage prijs van vaccins voor pluimvee is het noodzakelijk om de
productiekosten van een celkweek proces zo laag mogelijk te krijgen, bijvoorbeeld
door het verhogen van de opbrengst per liter medium. In Hoofdstuk 6 worden
verschillende suggesties gegeven om de virusproductie te verbeteren, waaronder
het aanpassen van de vaccin virus stam en de substraat cellijn. Echter, het
grootschalig vaccineren van pluimvee tegen vogelgriep wordt niet alleen bepaald
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door de prijs van vaccins, maar ook door macro-economische en politieke factoren.
Toekomstige ontwikkelingen in veterinaire inﬂuenza vaccins, zoals een breed
beschermend DIVA vaccin moet het mogelijk maken om vaccins vaker toe te
passen als methode om uitbraken van vogelgriep te beheersen en mogelijk ook te
voorkomen.
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禽流感的爆发不仅仅会为家禽养殖造成经济损失，同时也会严重威胁全球公
众的健康。因此为家禽接种疫苗，由此抵御病毒的传播，包括预防高致病性H5、
H7菌株，是当前控制疫情的发生和传播的有效手段之一。传统的禽流感疫苗是在
鸡胚胎蛋中繁殖和培育的。然而由于鸡胚胎蛋的局限性：例如等待胚胎蛋生产和
供应的时间过长，繁琐的操作；使病毒的培育以及疫苗的制作过程变得复杂。因
此，另一种培育方式：在可连续传代的细胞系中繁殖禽流感病毒，从而制作禽流
感疫苗，已经被建议作为一种可以代替传统工艺的方式。相比于鸡胚胎蛋，细胞
培养更易于操作，并且细胞培养的工艺条件可以被尽可能的优化，从而提高病毒
的产量和产品的质量。
犬肾传代细胞（MDCK）和非洲绿猴肾细胞（Vero细胞）是当前主要用于禽流
感病毒复制的细胞系列。然而，这两种细胞株生长的局限性和依赖性使病毒的生
产过程复过于复杂。在生产病毒的过程中，细胞对于微载体的附属和分离要在不
同的步骤之间转换。而相对于细胞自身来讲，这两种细胞在繁殖的过程中都需要
在培养基中额外添加血清。血清具有成本高，生产批量存在差异的缺点，并且血
清极易被外界因素污染。以上种种都为成功生产病毒从而制作疫苗带来不可预知
的风险。此外，众所周知，血清有抑制胰蛋白酶的作用。而胰蛋白酶却是病毒有
效复制的关键因素之一，因此在病毒感染细胞前加入血清会在一定程度上影响病
毒的复制和繁殖。为了有效解决这个问题，在本论文的第二章中，我们尝试培养
适应无血清培养基、并且能够在悬浮状态中繁殖的细胞。使用特殊的培养基，我
们得到可以在无血清培养基的悬浮介质中有效增长的MDCK细胞（MDCK-SFS）。虽
然Vero细胞也可以适应无血清培养基（Vero-SF）,但是Vero细胞无法在悬浮介质
中增长。此外，我们也成功培养了仓鼠崽肾细胞（BHK21）适应无血清培养基并以
悬浮状态生长（BHK21-SFS）。
在获得可用于病毒繁殖且不需要血清参与的细胞的基础上，八个不同的禽流
感病毒株被分别培养在MDCK-SFS，Vero-SF和BHK21-SFS细胞上进行比较。平均而
言，MDCK-SFS细胞产生的病毒浓度最高，其次是Vero-SF细胞。有趣的是，在
BHK21-SFS细胞上，两种病毒株各自复制后的浓度要远远大于这两种病毒株在
MDCK-SFS或是Vero-SF细胞上复制后的浓度。然而，其余六种病毒株在BHK-21SFS
细胞上复制的结果却不理想。针对于这个现象，我们对细胞膜表层的流感病毒的
结合受体进行了分析。分析后我们发现，BHK21-SFS细胞包含两种群体，其中一种
缺少禽流感病毒倾向于结合的sialic acid α-2,3受体。然而这个发现并不足以
解释为什么部分病毒株可以繁殖而另一部分不能。
MDCK-SFS是目前所测试的细胞中唯一可以在无血清培养基中悬浮生长、且适
合大多数禽流感病毒株的复制和高效繁殖的细胞。因此，MDCK-SFS细胞被选择进
摘要
- 131 -
行进一步研究。详情请见第四章和第五章。
BHK21细胞可快速的以悬浮状态增长并且在分批培养中达到需求的细胞密度。
因此，具有这种特性的BHK21细胞当前被用来生产对抗口蹄疫的兽用疫苗。然而，
禽流感病毒不同病毒株在BHK21细胞上的选择性复制局限了这种细胞在禽流感疫苗
生产上的应用。因此，在第三章中，我们详细讨论了在分子水平上我们对于这种
病毒选择性复制特性的研究。我们选择A/PR/8/34[H1N1](PR8)和A/WSN/33[H1N1]
（WSN）作为研究的模板。结果指出，前者不能在BHK21-SFS细胞上进行正常的复
制，后者却可以在该细胞上完成有效的复制。由于在病毒复制过程中，子代所携
带的血凝素（HA）基因片段是来自于父代和母代的HA基因交换以及重组，而HA蛋
白质是复制的关键因素之一，因此这两种病毒株复制能力上的差异取决于血凝素
（HA）蛋白质。
为了证实HA蛋白质是决定因素之一，我们用另外几种流感病毒株做了实验，
结果指出，其他几种流感病毒株在BHK21-SFS细胞上的繁殖能力似乎也取决于HA基
因。为了确定具体哪一部分的HA蛋白质决定了病毒的复制能力，我们在PR8的基础
上合成了携带反向遗传因子的病毒。虽然这种病毒可以编码并复制PR8-WSN嵌合
HAs，由此为我们提供大量的可用信息; 然而根据这些信息，却不足以让我们识别
与鉴定具体是哪个HA上的单一区间在以BHK21-SFS细胞为载体的病毒复制上起了决
定性的作用。这是由于包含WSN HA1域的病毒与包含PR8 HA1的病毒所表现出来相
近的复制能力，以及当病毒表达另外两种cHAs时，复制能力几乎没有变化。虽然
如此，结果依旧指出，倘若将PR8 HA1域与WSN HA2域相融合，病毒就可以增强复
制能力。这是由于HA1域中包含了大量的抗原位点，大量的抗原位点对于疫苗的有
效性起到了至关重要的作用。虽然携带HA1域的流感病毒在BHK21-SFS上并没有非
常显著的复制与繁殖能力，但是携带HA2域的流感病毒却可以在该细胞上进行非常
高效的繁殖与复制。于是我们提出，将HA1域融合入杂合HA2域，并依赖于携带HA2
域的病毒在BHK21-SFS细胞上高效复制繁殖的特性，使得融合后的HA1域同时进行
了复制和繁殖。这样的方式，可以提高病毒的复制能力，疫苗的有效性，并且可
以将BHK21-SFS细胞引入流感疫苗的制作基底细胞之一。
不表达NS1蛋白（delNS1）的流感病毒在细胞上的复制率会降低，同时会诱导
产生大量的干扰素（IFN）。降低的复制率通常由于这类病毒无法抵抗具有抗病毒
能力的宿主。基于这些特性，目前DelNS1病毒株正在被考虑作为制作减毒流感活
疫苗和兽用疫苗的候选病毒。然而，在MDCK细胞上，病毒减活的生长限制了大规
模的病毒生产。为了研制高收益的delNS1病毒生产系统，我们合成了两种可以表
达NS1蛋白的MDCK细胞（第四章）。由于异源性NS1表达可以导致细胞凋亡，因此
我们使用诱导表达系统。诱导后，delNS1病毒在两种合成细胞上的复制和繁殖产
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量显著增高并且与同源病毒株（WT病毒，自身表达NS1蛋白）的生产浓度几近持平
。同时值得注意的是，这两种合成表达NS1蛋白的细胞，NS1的表达量是普通流感
病毒感染后细胞的千分之一。此外，NS1蛋白表达抑制delNS1病毒诱导的细胞凋亡
，但没有显著降低干扰素的产生。因此，增强病毒复制并不是由降低IFN的产量而
造成的。与先前研究结果相反，重组后的NS1蛋白表达本身并不诱导细胞凋亡，也
不影响细胞的生长。这可能是由于特定的等位基因B NS1基因。因此，若细胞可以
稳定表达等位基因B的NS1蛋白，那么他就可以被用来大规模生产delNS1病毒，并
且由此生产减活高效流感疫苗。
另一种加强病毒复制能力的方式是让病毒适应细胞基底。第五章中，两个并
列实验同时测量适应后的delNS1病毒。结果显示，当感染干扰素主导的MDCK细胞
时，两个实验中病毒分别感染细胞的感染率为普通MDCK细胞感染率的250倍。通过
分析改编后的病毒序列以及随后产生的基因重组，我们发现，显著增长的病毒复
制是由一个病毒中M基因片段上的突变（delNS1 CA2）和其他病毒中M,NP,NS片段
上的突变（delNS1 CA1）造成的。其中最显著的是同时在两个病毒株的M片段上发
现了U到C的突变和在delNS1 CA1病毒株中NS片段上A到G的突变。据推测，这些突
变导致宿主细胞被感染到修改后的RNA。NS1蛋白通常限制M片段中mRNA的剪接，从
而使M1/M2的mRNA的比值增大。有趣的是，两个适应后病毒中的M片段中的无表达
突变使得M1/M2表达的比值增大，这个可能是由于剪接的效率造成的。此外，通过
改变M1的亚细胞定位，两个delNS1 CA2 M1中置换的氨基酸也同时增强病毒的复制
能力。和delNS1病毒比较，两种适应后的病毒都具有较低的IFN的诱导和细胞凋亡
率，但是依旧明显高出WT病毒。通过这样的比较得出，限制delNS1病毒的复制不
只由于病毒本身对宿主抗病毒反应的不耐，也由于病毒丧失一个或多个NS1中有关
M1蛋白的功能。相关的突变也因而可以直接应用于加强delNS1的病毒复制能力，
从而应用于疫苗的生产。
细胞培养的流感疫苗在经济效益上比鸡胚胎卵生产的疫苗更有竞争力。由于
本身禽流感疫苗的价格并不高，于是对于成本造价的要求就更为突出。因此基于
细胞培养的流感病毒在降低成本上体现出来了更多的优势。例如，用细胞培养流
感病毒可以方便的提升每升培养基中病毒的产量。第六章介绍了几种优化病毒产
量的建议，其中包括疫苗病毒工程和基底细胞工程。然而，若实施大规模的家禽
接种疫苗，将不仅仅取决于疫苗的价格，同时也取决于宏观的经济和政治因素。
兽用流感疫苗未来的研究和发展，例如使用广谱流感疫苗DIVA，会进一步帮助落
实紧急防御接种的必要性，并将作为一种常规方案来控制甚至预防禽流感疫情的
发生和扩散。
实际内容以英文版本为准。中文翻译仅作为参考。
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Mooi boekje he?! Ik zal je iets verklappen. Ik heb het niet alleen gedaan. Mijn naam
staat dan wel op de voorkant, maar zonder de directe of indirecte hulp van veel
mensen was ik nooit zo ver gekomen. En al die mensen wil ik hierbij graag be-
danken….. Vinaka vaka levu!
In het bijzonder waardeer ik de inzet van de mensen die mij gedurende mijn pro-
motieonderzoek hebben begeleid. Michiel, Dirk, Ben, Rob, René en Jose, samen
hebben we een aantal zeer leuke onderzoeken gedaan die op de scheidslijn lagen
tussen fundamentele, virale en cellulaire processen en de toegepaste procestech-
nologie. Behalve begeleiders waren jullie ook mijn sparringpartners, en door jullie
werden de onderwerpen vanuit verschillende disciplines scherp uitgelicht.
Michiel, als dagelijkse begeleider hebben wij het meeste samengewerkt. Enthou-
siast stond je altijd klaar voor een uitleg, discussie of het supersnel reviewen van
een tekst. Soms dacht ik zelfs dat jij het nog leuker vond dan ikzelf. Jou integere
en kritische blik weerspiegelt zich in dit proefschrift, en in de experimenten die ik
in de toekomst uit zal denken. Dirk, ten eerste respect voor de minstens 14.000
km die je in totaal afgelegd moet hebben om elke 2 weken te praten in Lelystad.
Als procestechnologen spraken wij dezelfde taal en daardoor begreep je dus vaak
als eerste een nieuw idee dat ik had bedacht, dat je daarna ook een stuk beter ver-
woordde. Dank voor je vertrouwen en je support. Ben, jij bracht een sterke mole-
culaire kennis in onze groep, dat duidelijk z’n weerklank had zowel in ons leukste
onderzoek, als in mijn begrip en enthousiasme voor dit vakgebied. Jose, helaas is
jouw enthousiaste inbreng in het project van korte duur geweest. Gelukkig bleef
je wel altijd bereikbaar voor een gesprek en industriële adviezen. Rob, jouw er-
varing was een stabiele factor in onze groep en zorgde voor een continue focus.
Het was een genoegen om samen met jou en Michiel af te reizen naar Malta voor
een leerzaam, inspirerend en gezellig inﬂuenza congres. Bedankt voor je
vertrouwen en je adviezen. René, onze besprekingen waren minder frequent, maar
je vertrouwen, kritische blik, sturing en hulp gedurende lastige momenten waren
echter niet minder. Dank.
Op het lab vond ik de tweede, onontbeerlijke groep, mijn collega’s. Jet, het was
jammer dat je zo snel van het project werd gehaald. Toch heeft jouw initiële werk
uiteindelijk de basis gelegd van veel van mijn verdere werk. Sandra D en Sandra
V, dank de fantastische faciliteiten op het lab en alle hulp bij de kleine labzaken
die uiteindelijk toch veel tijd innamen. Diana en Els, dank voor al jullie assay hulp
en assay adviezen, en jullie inzet om onze laatste artikel op tijd aan te passen.
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Gerjanne, Jos, René v G en Mirriam, bedankt voor jullie hulp en vooral het
uitleggen van alle sequence, transfectie en Western blot zaken. Olav, dank voor je
adviezen en je hulp bij het maken van de constructen. Achteraf gezien is
moleculaire biologie best wel heel gaaf! Sylvia en Rene H, dank voor jullie PCR
adviezen en het zo makkelijk beschikbaar stellen van die vele virusstammen die
ik kon gebruiken. Bernie en Rob voor de hulp met de FACS. Marloes, mijn enige
studente, ondanks al je inzet heeft je voornaamste werk helaas geen doorgang
kunnen vinden tot een publicatie. Echter… dat kleine zijprojectje wat je vol
enthousiasme oppakte terwijl ik op vakantie was, leidde tot een van de leukste
resultaten in dit proefschrift (Hoofdstuk 5). Aldo, dank voor al je hulp op het
gebied van statistiek, en Bart voor je hulp bij het opzetten van mijn privé ML II
labje. Akis, Carla, Jose, it took a little while, but ﬁnally we had ourselves a proper,
gezellige PhD group. En als laatste natuurlijk al die andere mensen van service,
onderhoud, diagnostiek, etc. Bedankt voor de schroevendraaiers, de pakketjes, de
eieren, de ery’s, de antilichamen, etc.
D., you did truly amazing work designing the cover. 非常感谢
Timo, Antje and all others from the MPI in Magdeburg. I regret we were not able
to share a publication. Thanks for being inspiring colleagues from afar. Martin
Listner, hoewel het maar 4 letters waren (ADAR), bewees je dat congressen niet
alleen leuk maar ook noodzakelijk zijn. During my daily commute I was enter-
tained by the scientists of the “This week in virology” podcast (www.TWIV.net).
Many of my ideas may have originated from their lively and enthusiastic discus-
sions, for which I am thankful.
Douwe, dank voor je altijd-beschikbare-steun en je creatieve inspiraties, ik heb er
veel aan gehad. Erik en Diederik, samen wisten we belachelijk veel avontuur te
stoppen in onze jaarlijkse uitje. Het was steeds een welkome afwisseling op het
labwerk. Ik kijk uit naar volgend jaar! Stevan, Joost, Bernard en Guido, met jullie
was er altijd wel een goed moment om een biertje te drinken, een ﬁlmpje te pakken,
voor een festival, een bordspel of een kanotochtje over de Amsterdamse grachten.
Klaas, werken, borrelen of vakantie, het is allemaal leuk met jou. Winny, your
assay suggestion was valuable. How great is it to talk with friends about your
work. Hinco, je hebt een aanstekelijk enthousiasme voor wetenschap, ik kijk uit
naar je terugkomst. Eelse en Marloes, hoewel de etentjes wat minder frequent
worden, worden ze wel gezelliger. Matthijs, de buurman die helaas een verre
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vriend werd. Jij verwoordt de fun en de noodzaak van wetenschap beter dan welke
scientist dan ook. Op eentje na dan, maar die telt niet meer mee. Dank voor het
uitvinden van de anti-procrastination laptop. Zonder welke ik dit proefschrift niet
zo snel af had kunnen maken.
Lieve ouders. Jullie zijn de belangrijkste reden waarom ik zover ben gekomen. Jul-
lie gaven mij onvoorwaardelijke steun en de vrijheid om mijn nieuwsgierigheid
en creativiteit te ontplooien. Wat volgens Oma begon met bolletjes wol in de
vriezer, ontwikkelde zich tot amﬁbieën die ik van vakantie mee naar huis mocht
nemen, vele andere huisdieren, lego waarmee in Indiana Jones tempels nabouwde,
een scheikundedoos, mijn eerste computers, etc. Ik dacht serieus bakker te willen
worden, maar jullie adviseerde toch om door te gaan en een zwaardere uitdaging
aan te gaan. Het resultaat van die uitdaging heb je nu vast. (Ironisch genoeg heb
ik wel tijdens het schrijven van dit proefschrift thuis ﬂink zitten experimenteren,
op zoek naar de beste manier om brood te bakken). Lieve Oma, het is zo jammer
dat je dit niet meer hebt kunnen lezen. We missen je! Daphne en Maureen, ik hoop
dat jullie een beetje trots zijn op je broer(tje). Dank voor jullie steun en interesse,
en excuses voor all my science rants. Dit geldt natuurlijk ook voor de rest van mijn
familie.
En… als laatste…. Kunnie, thank you for completing me and teaching me the im-
portant things that I didn’t focus on. Your support made this possible, while your
humor, cuteness and intellect enlighten my life. And of course, your stickers, al-
ways, everywhere. 我愛你
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Curriculum vitae

My life started on the 22th of June 1976 in Amsterdam. I was a curious child, in-
terested in everything that was related to nature or technology. In 1994, the year
that I received my VWO diploma, I heard for the ﬁrst time about DNA and biotech-
nology, which made me decide to study Biology at the University of Amsterdam.
However, after one year I realised I wanted a more technical study and therefore
changed to the Wageningen University to study Bioprocess Engineering. During
this study, I performed two thesis research projects at the department of Bioprocess
Engineering. Under the supervision of Dr. R. Osinga I assessed the potential use
of marine sponges as biocatalysts by growing their cells as aggregates (prim-
morphs). Following this project, I worked on a dynamic model of the glycolysis
in lactic acid bacteria, under supervision of Dr. M. Hoefnagel. Around this time, I
also grew an appetite for travel and therefore grabbed the opportunity to live in
Australia for a half year, where I performed a research project at the Royal Mel-
bourne Institute of Technology, on the optimization of the production of a veteri-
nary mycoplasma-vaccine, under guidance of Dr. J Power.
After obtaining my Master degree in the beginning of 2002, I worked at the bio-
pharmaceutical company Centocor in Leiden (now Janssen biologics), initially as
a Trainee at the Upstream and Downstream Production departments and at the
Quality Assurance department. After 2 years, I started as Technical Specialist at
the DSP Process Development department on the improvement of large-scale chro-
matography column packing. In 2005, I had another opportunity to work abroad,
now as Marine Project Oﬃcer for Coral Cay Conservations (Puttenham, UK) in
Fiji. While experiencing a tropical half year, I assisted and coached a local, gov-
ernment endorsed team in setting-up marine protected reserves around the island
of Kandavu, with the aim to protect the marine ecosystem.
After return to the Netherlands in 2006, I started as an Assistant Researcher at the
Animal Science Group Products Division (now Merial Lelystad) of the Wagenin-
gen University and Research Centre (WUR). Here, I characterized and optimized
both cell culture and virus propagation of the foot-and-mouth disease vaccine pro-
duction process. In 2008 I decided to further develop my scientiﬁc skills by apply-
ing for the PhD position, of which this thesis is the ﬁnal result. In October 2012, I
will start as Scientist Process Development at UniQure, an Amsterdam-based
biotech company that develops viral vectors for gene therapy.
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Discipline speciﬁc courses and activities
Bioreactor design and operation, Wageningen, 2008
Statistics for life science, Wageningen, 2009
Waters Millenium/empower fundamentals, 2008
BD FACS operation course, 2010
Bird ﬂu congress, Oxford, UK, 2008
Minisymposium MPI2, Magdeburg, DE, 2008
European Society for Animal Cell Technology meeting2, Vienna, AT, 2011
ACTIP fellowship2, Glasgow, UK, 2011
ESWI Inﬂuenza conference1, Malta, 2011
NBC workgroup day2, Ede, 2011
European Network on Viral Vaccine Processes2, Frankfurt, DE, 2011
Dutch Annual Virological Symposium, Amsterdam, 2012
Netherlands Biotechnological Congress2, Ede, 2012
General courses
Project and time management, Wageningen, 2008
PhD competence assessment, Wageningen, 2009
Writing for academic publications, Lelystad, 2009
Teaching and supervising thesis students, Wageningen, 2010
Career assessment, Wageningen, 2012
Optional courses and activities
PhD excursion MSD animal health & Synthon 2008,2012
PhD study trip USA, 2010
Brainstormday Process Engineering, 2012
1 Poster
2 Presentation
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